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Abstract 
 
This research describes the scope of 1,3-dipolar cycloaddition between selected 1,3-
dipoles  (nitrile  oxide/nitrone)  and  dipolarophiles  (PFP  ethenesulfonate/PFP-1-
bromoethenesulfonate).  Nitrile  oxide  cycloaddition  with  PFP-1-
bromoethenesulfonate  furnished  3,5-isoxazoles  in  a  regiospecific  fashion;  where 
solvent polarity, reaction temperature and the amount of base are the determining 
factors for efficient cycloaddition. Subsequent aminolysis with various amines were 
also  carried  out.  Aminolysis  with  secondary  and  aromatic  amines  produced  low 
yields,  nevertheless  a  wide  range  of  the  corresponding  sulfonamides  were 
synthesized. 
 
A  collection  of  the  isoxazolidinyl  PFP  sulfonate  esters,  and  the  corresponding 
sulfonamides,  were  found  to  exhibit  anti  HIV-1  activity  in  micromolar  scale. 
Synthesis  of  the  isoxazolidinyl  sulfonamides  was  also  diversified  in  order  to 
investigate  the  structure-activity  relationships.  Furthermore,  synthesis  of  the 
candidate for immobilized medium for affinity chromatography was established, via 
a multi-step reaction sequence.  
 
Biological  testing  of  the  synthesized  isoxazolidinyl  PFP  sulfonate  esters,  and 
sulfonamides show that the candidate molecules act on the host factors required for 
viral infection, rather than the virus itself. Furthermore, they show specific activity 
toward viral targets and do not exhibit toxicity toward live cells. 
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1  Introduction 
1.1  Introduction to sulfonamides 
Sulfonamides have been used as therapeutic agents for over fifty years. They were 
first used as antibacterial/antibiotic agents, but their applications have been extended 
to treat other diseases since. In 1935, Sulfonilamide was identified by Domagk et al. 
as the active metabolite of the red azo dye known as Prontosil 1. Prontosil 1 does not 
possess any activity in vitro; however it metabolizes in vivo to give the active agent 
sulfanilamide 2; where it can interfere with the process of bacterial DNA synthesis 
and act as potent antibacterial agent.
1  
 
Scheme 1 In vivo metabolism of Prontosil 
Apart from the commercialized application as antibacterial/antibiotic agents, various 
sulfonamides are also known to inhibit several enzymes such as carbonic anhydrase, 
cysteine  protease,  HIV  protease  and  cyclooxygenase.
2  Moreover,  the  widespread 
potential  value  of  sulfonamides,  have  led  to  the  discovery  of  various  other 
therapeutic applications, in cancer chemotherapy, diuretics, hypoglyceamia and the 
anti-impotence agent Viagra.
3 
 
Due to the inability of bacteria to acquire dihydrofolic acid from their environment, 
as part of bacteria’s DNA biosynthesis, inhibition of dihydrofolic acid synthase poses 
a desirable target for bacteriostatic agents (Scheme 2).
4 Inhibition of these enzymes 
has been achieved with early sulfonamides such as sulfanilamide 2. The formation of 
dihydrofolic  acid  is  initiated  by  coupling  pteridine  diphosphate  3  with  para-
aminobenzoic acid 4, which can then undergo amide coupling with glutamic acid to 
form dihydrofolic acid 5. Sulfonilamide 2 displays similar core structure to that of p-
aminobenzoic acid 4 and act as a competitive inhibitor. Dihydrofolic acid formation 
is interrupted during the second step; due to a lack of acidic terminal available to 
couple with glutamic acid, hence dihydrofolic acid 5 formation is interrupted.
4 11 
 
 
Scheme 2 Inhibition of DHF formation by sulfanilamide 
Later steps involve reduction to tetrahydrofolic acid using dihydrofolate reductase; 
however this step can also be inhibited using methotrexate 6 or trimethoprim 7 to 
enhance antibacterial activity, and it is commonly taken in conjunction to increase 
inhibitory activity and reduced dosage. 
 
Figure 1 Structures of methotrexate and trimethoprim 
1.1.1  Sulfonamides as therapeutic agents 
1.1.1.1  Sulfonamides as cysteine protease inhibitors 
Cysteine proteases are a class of biologically important enzymes, which are involved 
in inflammation, cell apoptosis and protein degradation.
5-7 These enzymes are also 
implicated  in  several  disease  states  such  as  arthritis,  osteoporosis,  Alzheimer’s 
disease, cancer and malaria. 
 
Examples of cysteine protease enzymes include caspase, a cysteine protease which 
cleaves  at  the Ala-Asp  residue  (hence  caspase),  and  is  strongly  associated  with 12 
 
apoptosis,  necrosis  and  inflammation.  There  are  11  caspases  now  know,  namely 
caspase 1-10 and 13. Not all caspases are directly involved in apoptosis; where the 
initiator caspases (CASP-2, CASP-8 and CASP-9) are responsible for activating the 
effector  (executioner)  caspases  (CASP-3,  CASP-6  and  CASP-7)  before  the 
apoptosis. Therefore, apoptosis occurs through a network cascade of caspases instead 
of an individual enzymatic reaction.
5, 7  
 
Another example is the interleukins illustrated by interleukin-1β (IL-1β), a cytokine 
implicated  in  various  neurodegenerative  diseases  such  as  Alzheimer’s  disease. 
However,  IL-1β  is  normally  present  in  its  inactive  pro-form  and  needs  to  be 
converted into the active cytokine by an IL-1β converting enzyme (ICE), now known 
as  caspase-1.  Early  studies  from  various  groups  have  found  that  deficiency  of 
caspase-1  on  animal  model  (transgenic  mice)  were  associated  with  decreased 
neuronal apoptosis, suggesting an indirect association of caspase-1 with neuronal cell 
death.
 Therefore if caspase-1 level can be moderated, this will then be possible to 
treat Alzheimer’s disease. 
8-10 
 
It is clear that inhibition/interference with caspases offers a number of therapeutic 
opportunities and this motivated Shahripour et al. to develop an approach toward a  
library of diphenyl ether sulfonamides 8 and these were shown to exhibit micromolar 
inhibition against caspase-1.
11 However an SAR study by Harter et al. suggested that, 
by  increasing  the  number  of  H-bonding  on  a  known  peptide-based  caspase-1 
inhibitor 9, increases the rigidity of the molecule as well as potency (Figure 2). In 
addition, KI and IC50 are further decreased by introducing a sulfonamide group and a 
C2H4Ph side arm  in 10 and 11.
12 Thus  improvements  in potency can be achieved 
rendering sulfonamides potentially therapeutically useful.
 13 
 
 
Figure 2 Structures and biological activity of Caspase-1 inhibitors 
A high-throughput screen at GSK identified two 5-nitroisatin based compounds 12 
and 13 as potent caspase-3 inhibitor (Figure 3). Caspase-3 is an effector caspase that 
directly  linked  to  apoptosis.  Lee  et  al.  have  synthesized  several  analogues  with 
different substituents on the 5-C position, and found that replacing a nitro group with 
a sulfonamide group can improve the potency to low-nanomolar range, for example 
the  pyrrolidine  sulfonamide  14  exhibited  potent  caspase-3  and  caspase-7 
inhibition.
13, 14 
 
Figure 3 Structures and biological activity of Caspase-3 inhibitors 
Cysteine proteases are also important to the life cycle of pathogenic protozoa such as 
Trypanosoma Curzi, which was found to be the cause of Chagas’ disease in South 
America. Cruzain, a form of cysteine protease in T. Cruzi, was found to be a potential 
therapeutic target  for treatment of Chagas’ disease. Roush et al. have synthesized 
several vinyl sulfones, sulfonates and sulfonamides and these were screened against 
Cruzain. It was found that several of these compounds were very potent inhibitors 
(Figure 4),
15 especially vinyl sulfonamide 15 and vinyl sulfonate 16. Furthermore, 
the second generation of the vinylsulfonamides 17 and 18 are found to be active in 
vitro and in vivo.
16 14 
 
 
Figure 4 Structures of Cruzain inhibitiors 
1.1.1.2  Sulfonamides as HIV inhibitors 
Sulfonamides also possess activity against HIV proteases. HIV protease consists of a 
homodimer with aspartyl active sites (Asp
25 and Asp
125), which have the ability to 
cleave difficult bonds, such as Tyr-Pro and Phe-Pro
2. Thus far, several HIV protease 
inhibitors  are clinically  available, and are often  used  in conjunction  with reverse 
transcriptase  inhibitors  to  deliver  the  multi-drug  treatment  known  as  the  Highly 
Active Anti-Retroviral Therapy (HAART, see section 2.3.3). It was found that non-
peptidic protease inhibitors display higher bioavailability as well as slower excretion 
rate compared to the  conventional peptide-base protease  inhibitors. Among  those 
protease inhibitors Amprenavir 19 and Tipranavir 20 are sulfonamide derived drugs.
2, 
17, 18  15 
 
 
Figure 5 Structures of HIV protease inhibitors 
Most  drugs  achieved  their  high  potency  due  to  their  ability  to  bind  rigidly  and 
optimally into an active site. However, high mutation rates within HIV viral particles 
renders many anti HIV drugs inactive, furthermore it poses tremendous challenge on 
antiretroviral therapy. A more recent idea of overcoming this problem is to synthesize 
a drug that, instead of binding tightly to the protease active site, binds tightly with the 
protein backbone since the protein backbone are only  minimally deformed during 
mutation.
19  An  example  of  this  approach  can  be  seen  in  the  investigations  of 
derivatives of Amprenavir 19 which are currently being investigated; these include 
TMC-114 (a.k.a Darunavir) 21 and TMC-126 22 (Figure 5). X-ray crystallography of 
TMC-114 21 bound to HIV protease showed that the bis-THF moiety of TMC-114 
21 forms strong H-bonds with Asp
29 and Asp
30 amides within the protein backbone, 
and  showed  10-fold  higher  potency  than Amprenavir  19  and  Tipranavir  20.
2,  19 
Ohtaka et al. also showed that TMC-126 22 displays 13-fold higher potency than that 
for Amprenavir  19.
2,  20  Meanwhile,  another  class  of  arylsulfonamide  23  and  24, 
which are structurally  related to TMC-114 21 and TMC-126 22, also display  low 
nanomolar concentration during a QSAR study.
21 
 
Apart from the numerous studies as HIV protease inhibitors, sulfonamides in recent 
years, are also found to inhibit HIV reverse transcriptase
22 and cell entry.
23 Tucker et 16 
 
al.  have  modified a previously known  viral  fusion  inhibitor BMS806
24,  25 25 by 
replacing  the  α-ketoamide  with  a  sulfonamide  and  a  biaryl  moiety  26  to  further 
improve the potency (Figure 6).
23 
 
Figure 6 Structures and biological activity of HIV cell entry inhibitors 
1.1.1.3  Sulfonamides as carbonic anhydrase inhibitors 
Carbonic anhydrases catalyze the interconversion of carbon dioxide and bicarbonate. 
The active site of the enzymes consist of a zinc ion coordinating to 3 histidine (His
94, 
His
96 and His
119) side chains, with the fourth site occupied by a water molecule. The 
water  molecule  is deprotonated by  the  fourth histidine  imidazole before attacking 
carbon  dioxide  to  form  bicarbonate  molecule.  The  main  function  of  carbonic 
anhydrases is to modulate physiological pH, respiration, CO2 transport, electrolyte 
excretion, regulation and homeostasis. Sixteen CA isozymes have been identified in 
humans, CA I to CA XV, with different sub-cellular localization.
26-28 
 
Carbonic anhydrase IX  and XII (as secondary tumor related CA) are found to be 
over-expressed  in  cervical,  breast,  bladder  and  non-small  cell  lung  cancers  by 
instigating hypoxia, causing acidification in the extracellular region, which leads to 
metastatic  spread  of  these  tumor  cells.  Furthermore,  the  acidification  can  render 
classical  cancer  treatments  ineffective, particularly  those  utilizing basic antitumor 
drugs and  radiotherapy.  It  is  therefore believed that  inhibition of CA IX/CA  XII 
could be an attractive alternative option for anticancer therapy. Supuran et al. have 
reported that a range of sulfonamides 27-30 have anti-carbonic anhydrase activity in 
nanomolar concentration (Figure 7).
26, 28 However, due to their low selectivity, these 
CA inhibitors show good inhibitory activity against several isozymes including CA I, 
CA II, CA IX, and to some extent, CA XII. 17 
 
 
Figure 7 Structures and biological activity of CA I/CA II/CA IX inhibitors 
Supuran et al. later synthesized another class of sulfonamides 31-33 and carried out 
an investigation of their potency against CA I, CA II and CA IX. It was found that 
even though the compounds were ineffective against CA I they were very effective 
against both CA II and CA IX (Figure 8). Furthermore, a docking study of 33 within 
CA II and CA IX, by the same group, indicates that the binding pockets of the two 
isozymes (CA II and CA IX) are very similar; if this is the case then it will make it 
difficult to target one isozyme over the other. 
29 
 
Figure 8 Non-selective inhibition of CA I/CA II/CA IX 
Supuran et al. more recently reported that, by introducing a pyridinium moiety to the 
CA  II/CA  IX  inhibitor  34,  tumor  acidification  can  be  reduced  by  specifically 
inhibiting CA IX. 35 were reported and display good inhibition of CA IX over CA 
II.
30 
 
Figure 9 Specific inhibitors for CA IX 
Acetazolamide 36 (AZA, anti-glaucoma), Zonisamide 37 (ZNS, anti-convulsant) and 18 
 
Topiramate 38 (TPM, anti-convulsant) are known for their ability to inhibit CAs, and 
their X-ray crystal structures have been determined,
31, 32 which show tight binding of 
the  inhibitors to CA II, CA VA and CA VB.  Interestingly  it  has been  noted  that, 
during clinical studies, obese patients  experienced dramatic weight  loss as  a side 
effect.
33 Therefore inhibiting CA II, VA and VB can reduce the rate of lypogenesis, 
and in turn, can be used as anti-obesity drugs.
33, 34 
 
Figure 10 Commercially available inhibitors of CA V 
Supuran et al. and Vullo et al., have synthesized a wide range of sulfonamides such 
as 39 and 40 for anti-CA V activity, and it was found that several aminobenzolamides 
display low-nanomolar potency compare to registered CA inhibitors (Figure 11).
33-35 
 
Figure 11 Structures and biological activity of CA V inhibitors 
1.1.1.4  Sulfonamides as COX-II specific inhibitors 
Cyclooxygenase  (COX)  is  involved  in  the  synthesis  of  prostaglandins  and 
thromboxane from arachidonic acid. Cyclooxygenase exist in three isoforms: COX(I-
III). Cyclooxygenase-I is expressed in platelet aggregation and mucosal protection by 
prostaglandin production, thus an undesirable side effect of COX-I inhibition can be 
gastric damage. Cyclooxygenase-II is induced and expressed during inflammation, 
cell  proliferation  and  oncogenesis.  Cyclooxygenase-III  is  identified  as  a  COX-I 
variant, and it’s known to be inhibited by paracetamol.
36-38  
 
Traditional COX inhibitors such as ibuprofen are known to have low selectivity and 
hence  may  induce  ulcer, bleeding and  gastroduodenal erosion.  However, COX-II 
specific inhibitors can relieve symptoms such as pain, caused by inflammation, but  19 
 
without the undesirable side effects of traditional COX inhibitors.
39 Celecoxib 41 and 
Valdecoxib  42  (Figure  12)  have  been  developed  by  Pfizer  as  COX-II  specific 
inhibitors for the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA).
40, 
41  
 
Figure 12 Commercially available COX-II inhibitors 
Normally, prostacyclin (PGI2) and thromboxane (TxA2) are both produced, but the 
traditional COX-II specific inhibitors may disrupt the optimum balance of the two 
species  and  an  increase  in  the  amount  of  thromboxane,  can  elevate  the  risk  of 
cardiovascular disease, heart attack and stroke; which it is the case for Valdecoxib 
42. Recently a new approach has been to utilize an inhibitor which is mainly COX-II 
selective but with mild COX-I inhibitory properties. Yang et al. have synthesized a 
range of iminium benzenesulfonamides 43 (Figure 13), based on the natural product 
Resveratrol 44, that have 7-80 fold selectivity for COX-II over COX-I.
42 
 
Figure 13 COX-II selective inhibitors with mild COX-I inhibitory properties 
1.1.1.5  Other applications of sulfonamides 
A  large  number of sulfonamides  have been  used  for  therapeutic  intervention and 
more recently a very well known example is that of as Sildenafil 45 (Viagra
®, Figure 
14) for the treatment of erectile dysfunction. Erection is caused by binding of nitric 
oxide NO (released  from the brain) to  guanylate cyclase, causing the build-up of 
cyclic guanosine monophosphate (cGMP) resulting in smooth muscle relaxation and 
increase blood flow to the male organ. Viagra works by inhibiting phosphodiesterase-
5; which is responsible for metabolizing cGMP, resulting in prolonged erection.
43  20 
 
 
Figure 14 Commercially available anti-impotence agent Sildenafil 
1.1.1.6  PFP sulfonate esters as bacterial DDAH and ADI inhibitors 
Nitric oxide (NO) is an endogenous signaling agonist, which may be implicated in 
several  disease  states  upon  a  rise  in  NO  levels;
44  therefore  partial  inhibition  of 
enzymes  responsible  for  NO  production  can  be  useful  in  developing  effective 
therapeutic  agents.  An  indirect  approach  has  been  described  which  involves  the 
inhibition  of  dimethylarginine  dimethylamino  hydrolase  (DDAH)  which  is 
responsible for controlling levels of N-methyl-L-arginine (MMA) and asymmetric N-
,N-dimethyl-L-arginine (ADMA) which are both inhibitors of nitric oxide synthase 
(NOS). Recent studies reported by the groups of Vallance and Caddick have shown 
that small molecules such as functionalized PFP sulfonates display activity against 
DDAH and, the  structural related arginine  deiminase (ADI).  Various  heterocyclic 
PFP sulfonates were screened against DDAH and ADI, and it was reported that  46 
and 47 have significant activity against DDAH and ADI (Figure 15).
45  
 
Figure 15 Isoxazolidines as  modulators of  nitric oxide synthesis  via  inhibition of 
DDAH and ADI 
1.2  Isoxazoles as therapeutic agents 
Although  there  are  numerous  active  heterocyclic  aromatic  compounds,  there  are 
reatively few drugs that contain the isoxazole moiety, however it would appear that 
there  is  a  growing  interest  in  the development of biologically active  compounds 
based on isoxazoles.
46 21 
 
 
An  example  is  Sulfamethoxazole  48,  an  antibacterial  agent  which  contains  both 
isoxazole and sulfonamide moiety (Figure 16). The mode of action is the same as 
described in Section 1.1 Sulfamethoxazole 48 has mainly been used in conjunction 
with  trimethoprim  for treatment  in  many bacterial-linked diseases such as  urinary 
tract infection and E.Coli-induced sickness. 
 
Figure 16 Structure of sulfamethoxazole 
1.2.1  Isoxazoles as enzyme inhibitors 
1.2.1.1  Isoxazoles as anti-inflammatory agents 
Dihydroorotate dehydrogenase (DHODH)  is an enzyme catalyzing the conversion 
from  dihydroorotate  49  to  orotate  50  which  is  required  for  pyrimidine  synthesis 
(Scheme 3). The proliferative and inflammatory effects of DHODH suggest that it 
could  be  implicated  in  rheumatoid  arthritis  and  hence  a  potential  target  for 
therapeutic intervention. The enzyme consist of 2 domains- a large C-terminal and a 
smaller N-terminal domain, with the smaller N-terminal domain containing a binding 
site for the cofactor ubiquinone.
47 
 
Scheme 3 Formation of orotate 50 from dihydroorotate 49 
Leflunomide  51,  developed  by  Sanofi-Aventis,  is  used  in  the  treatment  for 
rheumatoid arthritis. The isoxazole moiety of leflunomide is quickly converted to an 
enol-nitrile  active  metabolite  A771726  52  in  vivo  (Figure  17)  and  acts  as  a 
competitive inhibitor of ubiquinone. Albert et al. have reported that lefluonomide 51, 
its active metabolite 52, and its thioamide analogue display micromolar inhibition 
against DHODH.
48, 49 22 
 
 
Figure 17 Structures of leflunomide and its active metabolite 
Another example of an isoxazole containing drug is valdecoxib 42 , which is a COX-
II inhibitor for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA).
50-52 In 
a recent study it was shown that the specific COX-II selectivity of Valdecoxib 42 is 
due to the presence of p-phenylsulfonamide moiety. The removal of the sulfonamide 
moiety is associated with reversal of COX-II selectivity.
40 
1.2.1.2  Isoxazoles as anti-convulsion agents 
Epilepsy is caused by a sudden excitation of neurons in the brain, which is found to 
be  associated  with  high  abundance  of  carbonic  anhydrase  (described  in  1.1.1.3) 
isoform II, VII and XIV within the neuron cells, in such CA inhibitors can be used as 
anti-convulsant.
32,  53,  54  Recently,  the  anti-epileptic  agent  Zonisamide  53  (ZNS, 
Figure  18)  was  reported  as  a  weak  CA  II  and  CA V  inhibitor  with  micromolar 
inhibition. However in contrast, Supuran et al. reported that a long period of in vitro 
incubation, of  Zonisamide 53  led  to  very potent  inhibition of CA II (KI =  35.2 
nM).
32 As follow up Uno et al. described the synthesis and biological activity of a 
range of Zonisamide analogues and explored the SAR where they observed that the 
presence of a halide in the 5- position increases potency as anti-convulsant.
55 
 
 
Figure 18 Structure of Zonisamide 
1.2.1.3  Isoxazoles as antiviral agents 
Human rhinovirus (HRV) is one of the most common infectious viral diseases, which 
is responsible for 50% of all human fevers. Its capsid consists of 4 types of proteins 
(VP1-VP4).
56, 57 Two extensively studied HRV inhibitors WIN51711 54 (Figure 19) 23 
 
and WIN52084 55 contain one oxazoline and one isoxazole ring. They inhibit HRV 
by binding to the VP1 Asn
219 residue on the nitrogen atom of the oxazoline ring, 
which results in a conformational change in the VP1 protein. The seven-carbon chain 
and the isoxazole ring is extended into the binding site’s side pocket ensuring tight 
binding, and subsequently inhibit the function of the viral capsid.
58  
 
Figure 19 Structures of HRV inhibitors 
Other anti-viral agents based on sulfonamides include Amprenavir 19 and Tipranavir 
20  which  are  active  against  human  immunodeficiency  viruses  (HIV).  However, 
isoxazole-containing  anti  HIV  agents  are  considerably  less  common  than 
sulfonamides. A range of isoxazole based nucleosides 56 and 57, synthesized by Kim 
et al. were found to have anti-poliovirus activity (Figure 20) and were also tested 
against HIV and HSV.
59 
 
Figure 20 Potential anti-poliovirus agents 
1.2.1.4  Isoxazoles as anti cancer agents 
Cancer is defined as an uncontrolled cell growth, which has deregulated from normal 
cell apoptosis. Several anti-tumor agents operate purely through latent cytotoxicity; 
however the induced side effects are normally irreversible. Other agents have been 
focused on the inhibitory activity during cancer cell cycle, i.e cell phosphorylation 
and angiogenesis.
4, 60 
 
Combretastatin A-4 58 is a natural product isolated from the South African willow 
tree, which shows an ability to shut down cancer cell vasculature and successfully 
inhibit cancer cell angiogenesis. To successfully replicate the cis-diaryl moieties and 
the effect of Combretastatin A-4 58, several derivatives have been synthesized by 
Carrez et al., where the rigid olefin linker has been replaced by a five-membered 24 
 
heterocyclic ring.
61, 62 Several isoxazoline and isoxazole derivatives show antitubulin 
activity, and 59 shows higher antitubulin activity than Combretastatin A-4 58 (Figure 
21)
61  Another  diaryl  isoxazole  compound  60,  developed  by  Oh  et  al.  displays 
nanomolar inhibition against cancer metastasis and angiogenesis (Figure 21).
63 
 
Figure 21 Anti cancer agents derived from combretastatin A-4 
1.3  Synthetic approaches to sulfonamides 
Due to the broad applicability of sulfonamides,  it  is desirable to  find  general and 
effective methods for their synthesis. Although a comprehensive review of this is not 
provided  the  following section provides several of the  most common and  recent 
methods of sulfonamide synthesis. 
1.3.1  Sulfonamides from sulfonyl chlorides and sulfonic acids 
The traditional and general method for preparing sulfonamides 62 is via coupling of 
sulfonyl chloride 61 with primary or  secondary  amine (Scheme 4). The sulfonyl 
chloride  is  normally  prepared  from  the  corresponding  sulfonic/sulfinic  acid  with 
SOCl2, PCl5 or POCl3,
64-67 or from bubbling chlorine gas through thiols in aqueous 
acid.
68 However, this method requires excess oxidant and aqueous acid, and is not 
compatable with acid sensitive substrates.
69 
 
Scheme 4 Formation of sulfonamides from sulfonyl chlorides 
Wright  et  al.  reported  a  method  for  the  formation  of  sulfonamides  from  thiols, 
requiring  the  in  situ  synthesis  of  a  sulfonyl  chloride  using  sodium  hypochlorite 
(commercial  bleach)  mediated  oxidation  of  thiol.  This  methodology  introduces 
several advantages, such as readily availability of the reagents as well as controlled 
amount of the oxidant used. The resulting sulfonyl chlorides 63 were then trapped 
with benzylamine in the subsequent reaction to produce sulfonamides 64 up to 98% 25 
 
yield (Scheme 5).
68 
 
Scheme 5 Formation of sulfonyl chloride using sodium hypochlorite 
Bonk et al. have developed a methodology of using trichlorocyanuric acid (TCCA) 
and benzyltrimethyl ammonium chloride in water to generate a controlled amount of 
chlorine into aprotic solvent (MeCN). The use of TCCA introduces the advantage of 
high-purity chlorine production compare to that of hypochlorite. In order to optimize 
the reaction conditions, the group then further modified the methodology by adding 
the subsequent amine into a one-pot reaction, generating sulfonyl chloride 65 in situ, 
and furnishing sulfonamides 66 under 1 hour (Scheme 6).
70 
 
Scheme 6 Formation of sulfonyl chlorides using trichlorocyanuric acid 
Even though a wide variety of sulfonamides can be generated from these procedures, 
several steps are required. Furthermore, the conditions are fairly harsh and therefore 
restrict the functional group compatibility. In an alternative, Barrett et al. reported the 
use of Grignard reagent 67 to increase diversity on sulfur in a one-pot sulfonamide 
synthesis (Scheme 7). Aromatic halides are mixed with magnesium to form Grignard 
reagent  67,  which  can  then  attack  sulfur  dioxide  to  form  sulfinic  acid  salt  68. 
Subsequent  chlorination  using  sulfuryl  chloride  generates  sulfonyl  chloride,  and 
aminolysis  furnishes sulfonamides  69  in one-pot. A wide range of organohalides 
were  studied,  but  only  aromatic  and  heteroaromatic  halides  produced  desirable 
results.
71 
 
Scheme 7 Sulfonamides formation via Grignard reagents 
It  would  appear  that  some  general  limitations  to  sulfonamide  synthesis  exist 26 
 
including (1): excessive amount of highly toxic chlorinating agents (SO2Cl2, PCl5 
and  POCl3)  and  (2):  organolithium  and  Grignard  reagents  are  incompatible  with 
several functional groups (-OH, -SH and -COOH) 
 
Charasiri et al. reported the use of trichloroacetonitrile-triphenylphosphine complex 
(Cl3CCN/PPh3)  for sulfonamide  formation.  It  was  found  that  the optimal  yield  is 
reached  when  3:3:1  (Cl3CCN:PPh3:sulfonic  acid)  ratio  and  dichloromethane  are 
used, however the yields are not reproducible in other solvents and ratios (Scheme 
8), One of the notable advantages of this  methodology  is that  it  is  not  limited to 
aromatic sulfonyl chlorides, and can be applied to heterocyclic and aliphatic sulfonyl 
chlorides.
72 
 
Scheme 8 Sulfonamide formation from sulfonic acids using Cl3CCN:PPh3 
Shaabani  et  al.  recently  developed  a  novel  approach  to  sulfonamide  synthesis 
utilizing sulfonic acids and isonitriles under aqueous conditions (Scheme 9). Their 
preliminary  study  showed  that  aromatic  and  camphor  sulfonic  acids  70  were 
converted into sulfonamides 71 in high yield (86-93%). Even though the mechanism 
has not yet been verified experimentally, a working model has been suggested and is 
given in Scheme 10.
73 
 
Scheme 9 Sulfonamides formation from sulfonic acids using isonitrile 27 
 
 
Scheme 10 Postulated mechanism by Shaabani
73 
1.3.2  Sulfonamides from sulfenamides 
Another innovative example of sulfonamides synthesis is illustrated in the synthesis 
of 6-uracilsulfonamide (an antagonist of orotic acid) by Greenbaum  et al. In  this 
approach  the  sulfonamide  is  reasonably  effectively  oxidized  from  6-
uracilsulfenamide using KMnO4 with 64% yield.
74 Schwam et al. also used similar 
methodology  for  the  synthesis  of  6-hydroxybenzothiazole-2-sulfonamide  72  as  a 
potential carbonic anhydrase inhibitor in 80% yield (Scheme 11).
75 
 
Scheme 11 KMnO4 oxidation of sulfonamide to sulfonamide 
Alternative mild and selective oxidants have also been used for the conversion of 
sulfenamides into sulfonamides.
76  For example Revankar et al. reported that, during 
their synthesis of pyrimidine-4-sulfonamide 73 as potential antitumor drug, oxidation 
of  sulfenamide  74  using  one  equivalent  of  m-CPBA  produced  48%  of  the 
corresponding sulfonamide 73, this could be increased to 58% using four equivalents 
of m-CPBA in ethanol (Scheme 12).
77-79 
 
Scheme 12 m-CPBA oxidation of sulfenamide to sulfonamide 28 
 
1.3.3  Sulfonamides from N-arylation 
The aforementioned methods do have some limitations in as much as they do not 
allow diversification of substituents on sulfur or nitrogen. An alternative approach is 
to  carry  out  synthetic  modification  of  a  primary  sulfonamide.
80  Transition-metal 
catalyzed C-N bond formation has been studied extensively, where the most well-
known,  palladium  catalyzed  N-arylation  is  the  Buchwald-Hartwig  reaction.
81-83 
However there are  few reports of  N-arylation on sulfonamides. The  first example 
used  cupric  acetate  and  arylboronic  acid  to  give  N-arylsulfonamide.  Lam  et  al. 
described an effective protocol using 0.1 equivalent of copper(II) acetate in air, to 
give near-quantitative yield (Scheme 13).
84, 85  
 
Scheme 13 N-arylation of sulfonamides using Chan-Lam reaction 
More recently, Guo et al. have synthesized a range of sulfonamides using copper (I) 
catalysed coupling using aryl bromide/iodide (Scheme 14). During the optimization 
process,  they  found  that  using  an  amino  acid  as  a  ligand  introduces  several 
advantages such as easy removal after the reaction. After screening several amino 
acids,  they  found  that  N-methylglycine  and  N,  N-dimethylglycine  are  the  most 
effective  with Cu(I). Together  with K3PO4 as base, and  DMF as the solvent, all 
desired N-arylsulfonamides 75-78 can be generated in up to 99% yield (Figure 22).
86 
 
Scheme 14 Copper mediated N-arylation using amino acids as ligand 29 
 
 
Figure 22 Isolated yield obtained from copper catalyzed N-arylation 
Despite  the  advances  in  transition  metal  catalysis,  few  applications  have  been 
reported for sulfonamide synthesis,
87, 88 and even fewer under microwave heating.
89 
Cao  et  al.  reported  the  palladium  catalysed  N-arylation  of  sulfonamides  under 
microwave  irradiation.  In  their  report  they  describe  the  effect  of  modifying  the 
ligands,  bases  and  solvents,  and  identified  optimal  reaction  conditions  under 
microwave heating at 180 °C for 10 minutes (Scheme 15). Unfortunately this method 
led to only modest yield of N-arylsulfonamides.
80 
 
Scheme  15  Palladium  mediated  N-arylation  of  sulfonamides  under  microwave 
conditions 
1.3.4  Sulfonamides from sulfonate esters 
Pentafluorophenyl (PFP) sulfonate esters have been recently introduced to replace 
sulfonyl chlorides for sulfonamide preparation. The use of PFP sulfonate esters 79 
may introduce several advantages such as reduced toxicity, enhanced shelf stability, 
makes  them  desirable  as  precursors.
69  Caddick  et  al.  have  reported  that  the 
aminolysis of sulfonates in refluxing THF can be used as an effective method for the 
synthesis of sulfonamides 80 in good to excellent yield. It was further shown that a 
range of amines (primary, secondary, aromatic, and aliphatic) could undergo reaction 30 
 
with  PFP  sulfonate  esters  79  to  produce  a  wide  range  of  sulfonamides  (Scheme 
16).
90, 91 
 
Scheme  16  Aminolysis  of  pentafluorophenyl  sulfonate  esters  to  generate 
sulfonamides 
Caddick et al. have postulated a sulfene mechanism for amine substitution for alkyl 
PFP sulfonates based on deuterium  incorporation (Scheme 17).
90-92 However, aryl 
PFP sulfonates do not have α-proton available for deprotonation therefore aminolysis 
proceed through the classic direct displacement, resulting in a slower reaction rate 
than that for alkyl sulfonates. 
 
Scheme 17 Postulated sulfene mechanism by Caddick
90-92 
Caddick et al.  have also reported the  relative stability/reactivity of PFP sulfonate 
esters in comparison to sulfonyl chlorides. Thus p-tolylpentafluorophenyl sulfonate 
81 is mixed with benzenesulfonyl chloride 82 and subjected to aminolysis with 4-
methylbenzylamine  83  at  0  °C.  In  the  product  mixture,  90%  of  the  p-
tolylpentafluorophenyl sulfonate ester 81 was recovered, thereby showing  that PFP 
sulfonates are not as reactive as sulfonyl chlorides (Scheme 18). Another advantage 
of PFP sulfonate esters over sulfonyl chlorides is that they can readily be employed 
under aqueous conditions.
90 31 
 
 
Scheme 18 Reactivity between PFP sulfonate esters and sulfonyl chlorides 
Caddick et al. have also reported aminolysis of PFP sulfonate esters with various 
amines  under  microwave  heating.  All  desired  sulfonamides  were  generated  in 
moderate  to  high  yield  (Figure  23)  while  the  reaction  times  were  significantly 
reduced (5 min).
69, 93 
 
Figure 23 Yield reported from aminolysis under microwave irradiation 
So far, all the above examples are focused on intermolecular aminolysis; however an 
intramolecular aminolysis was also reported by Caddick et al. in the formation of β-
sultams 84 (cyclic sulfonamides), which are potential serine lactamase inhibitors in 
bacterial  developed  resistance  to  penicillin.  Caddick  et  al.  reported  the  use  of 
Mo(CO)6 to catalyse N-O bond cleavage  in  isoxazolidine PFP sulfonate esters  85 
(Scheme  19),  this  was  then  followed  by  direct  displacement  of  PFP  by  the 32 
 
intramolecular amine to give pure cis β-sultams, which were characterized by x-ray 
crystallography.
94 
 
Scheme 19 Formation of β-sultams via N-O bond cleavage using MO(CO)6 
Due to the high cost of pentafluorophenol, a cheaper and even less toxic alternative 
was sought. Trichlorophenol (TCPOH), a household antiseptic, was employed in the 
formation  of  sulfonate  esters,  and  found  to  be  a  good  leaving  group  during 
subsequent  aminolysis.  Aminolysis  of  TCP  sulfonate  esters  86  later  furnished 
sulfonamides 87  in  up to 94%  yield. However due  to  high stability of  TCP, the 
reactivity is noticeably reduced in comparison with that of PFP, therefore an increase 
in reaction time  is needed as well as more forcing condition (Scheme 20).
95 
 
Scheme 20 Aminolysis from TCP sulfonate esters 
1.4  Introduction to 1,3-dipolar cycloaddition 
The history of 1,3-dipolar cycloaddition dates back to 1888, when Buchner studied 
the reaction between diazoacetic ester  and  α,β-unsaturated esters.
96 However, the 
potential value of cycloadditions were not realized until the discovery of the Diels-
Alder  reaction  in 1928.
97 Since then 1,3-dipolar cycloadditions  have  evolved and 
become  more  widely  utilized  due  to  thier  applicability  to  synthesize  various 
heterocycles,  while  generating  up  to three stereocenters  in a single  step  (Scheme 
21).
98 
 
Scheme 21 Generation of three stereo-centers from cycloaddition 
Mechanism of 1,3-Dipolar cycloaddition involves overlap between three pz orbitals 
of a dipole and two pz orbitals of a dipolarophile e.g. alkenes, alkynes or carbon-33 
 
heteroatom  multiple  bonds. That  suggests  the  cycloaddition  could  proceed  via  a 
concerted process  (Scheme 22) or a step-wise procedure. However  the concerted 
mechanism  is  generally  accepted  because  the  reaction  retains  the  relative 
stereochemistry of the dipolarophile. In the cycloaddition between benzonitrile oxide 
and  trans-dideuterated  ethene,  the  product  isolated  was  exclusively  the  trans-
dideuterated isoxazoline (Scheme 23).
98, 99 
 
Scheme 22 Cycloaddition via a concerted process 
 
Scheme 23 Concerted  reaction between benzonitrile oxide and  trans-dideuterated 
ethene 
There are two principal types of 1,3-dipoles: the allyl anion type and the propargyl 
anion type. The allyl anion type dipoles are characterized by a bent structure, where 
the central atom can be nitrogen, oxygen or sulfur e.g. nitrones, azomethine imines, 
azomethine  ylides,  carbonyl  ylides,  thiocarbonyl  ylides,  carbonyl  imines  and 
carbonyl oxides. The propargyl anion type dipoles are linear, and the central atom 
can  only  be  nitrogen  e.g.  nitrile  oxides,  nitrile  imines,  diazoalkanes  and  azides 
(Figure 24).
98, 100 34 
 
 
Figure 24 Structure of various allyl and propargyl anion dipoles 
1.4.1  Properties of 1,3 dipoles 
This thesis is concerned principally with the reactivity of 1,3-dipoles in cycloaddition 
reactions. The widely-studied 1,3-dipoles nitrones and nitrile oxides have become the 
species of interest, therefore only the chemical properties, preparations and reactions 
of these dipoles are discussed. 
1.4.1.1  Preparation and reaction of nitrile oxides 
The  first  nitrile oxide,  fuminic acid (R = H,  Scheme 25) was discovered  in early 
1800s, and one of its most used analogues benzonitrile oxide, was first generated in 
1886.
101 Despite of the  long  history of  nitrile oxides, their chemical and physical 
properties  are  little  understood  due  to  their  inherent  instablity.
102  At  ambient 
temperature, most nitrile oxides 88 readily dimerize to furoxan-2-oxides 89 in the 
absence of a dipolarophiles. However with bulky nitrile oxides, dimerization is less 
likely and rearrangement to isocyanates 90 predominates at elevated temperature.
102 
Dimerization to 1,2,4-oxadiazole-4-oxides 91 in the presence of triethylamine and 
1,4,2,5-dioxadiazines  92  in  the  presence  of  excess  BF3  has  also  been  reported 
(Scheme 24).
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Scheme 24 Decomposition of nitrile oxides 
The most common literature preparations of nitrile oxides are:  
(1)  dehydrohalogenation  of  hydroximoyl  chlorides  93  using  triethylamine  in  a 
biphasic solution, Scheme 25 (i),
104,  105 where the preparation of the  hydroximoyl 
chloride  from  oxime  have  been  reported  using  DMF/N-chlorosuccinimide,
102,  104 
DMF/HCl/ozone
106 or trichlorocyanuric acid/pyridine/dichloromethane;
102, 105  
(2)  dehydration  of  nitroalkane  94  using  phenylisocyanate  in  the  presence  of 
triethylamine, Scheme 25 (ii),
107 (nitrile oxides generated from primary nitroalkanes 
are  usually  unstable,  and  are  normally  employed  in  a  one-pot  1,3-dipolar 
cycloaddition);
102 and  
(3) cycloreversion from furoxan-2-oxide 95, Scheme 25 (iii), where dimerization of 
nitrile oxide becomes reversible at elevated temperature,
102 the latter procedure is far 
less common than (i) and (ii). 
 
Scheme  25  Preparation  of  nitrile  oxide  from  (i)  hydroximoyl  chloride,  (ii) 
nitroalkane, and (iii) cycloreversion from from furoxan-2-oxide 
In  the presence of other reagents,  nitrile oxides can undergo a range of reactions 
including  deoxygenation,  condensation  with  an  appropriate  nucleophile  and  1,3-36 
 
dipolar cycloaddition. Synthetically, the most important reaction of nitrile oxide is 
the 1,3-dipolar cycloaddition; where cycloaddition with an alkene, alkyne or oxime 
generates an isoxazoline 96, an isoxazole 97 or an oxadiazoline-oxide 98 (Scheme 
26).
102, 108 
 
Scheme 26 1,3-Dipolar cycloadditions of nitrile oxide 
Sandhu et al. for example have reported that when chromone-3-carbonitrile oxide 99 
underwent  cycloaddition  with  a  terminal  alkene  such  as  allyl  bromide,  a  single 
isomer  of  isoxazoline  100  was  formed.  If  the  same  nitrile  oxide  underwent 
cycloaddition  with  phenylacetylene,  the  fully  oxidized  ring,  isoxazole  101,  was 
formed (Scheme 27).
109 
 
Scheme 27 Nitrile oxide cycloaddition with an alkene and an alkyne 
1.4.1.2  Preparations and reactions of nitrones 
Nitrones were first discovered by Beckmann in 1890.
98 Since then nitrones have been 
extensively  studied  due  to  their  relative  stability  compared  to  nitrile  oxides.
102 
Preparation of nitrones are generally divided into two categories: oxidative and non-
oxidative methods. Oxidative methods include:  
(1) oxidation of imines using peracid or H2O2 to generate oxaziridines, which can 37 
 
then rearrange to nitrones, Scheme 28 (i);
110  
(2)  oxidation  of  amines  using  various  oxidants  such  as  peracids,
111  H2O2  or 
DMDO,
112 Scheme 28 (ii). (oxidation of primary amines leads to a mixture of nitro-, 
nitroso-  and  oxime  compounds,  whereas  direct  oxidation  of  secondary  amines 
furnishes nitrones as a sole product
102); and  
(3) oxidation of secondary hydroxylamines (with an α-proton) using peracid, H2O2 or 
various  metal  oxides,  provides  mild  condition  for  generating  the  corresponding 
nitrones, Scheme 28 (iii). Non-oxidative  methods  include condensation of  mono-
substituted  hydroxylamine  with  a  carbonyl  group,  which  proceeds  under  mild 
condition, Scheme 28 (iv); this is compatible with various functional groups that are 
sensitive to oxidation, and thus used extensively in nitrone preparation.
102 
 
Scheme  28  Nitrone  formation  through  oxidative  (i-iii)  and  non-oxidative  (iv) 
methods 
Nitrones  can  undergo  a  range  of  reactions  include  rearrangement,  oxidation, 
reduction,  nucleophilic/electrophilic  substitution  and  1,3-dipolar  cycloaddition. 
Nitrone cycloaddition with alkenes and alkynes have been extensively studied, and 
have been shown to  generate  isoxazolidines and  isoxazolines  in  good regio- and 
diastereocontrol. In addition, nitriles, isocyanates, ketenes and porphyrins have also 
been reported as dipolarophiles.
102 However, only cycloadditions  with alkenes are 
discussed here due to the relevance to our work.  
1.4.2  Selectivity in 1,3-dipolar cycloadditions 
The  outcome  of  1,3-Dipolar  cycloaddition  is  influenced  by  frontier  orbital 38 
 
interactions, which can be approximated  using Frontier Molecular Orbital (FMO) 
theory. Sustman has categorized 1,3-dipolar cycloaddition  into three types (Figure 
25). In type I, HOMOdipole-LUMOdipolarophile predominates. In type III, LUMOdipole-
HOMOdipolarophile predominates; however in type II, the HOMO and LUMO energy of 
dipole  and  dipolarophile  are  similar,  therefore  HOMOdipole-LUMOdipolarophile  and 
LUMOdipole-HOMOdipolarophile interactions are equally possible. Substituents that raise 
the  HOMOdipole  or  lower  the  LUMOdipolarophile  favour  type  I  interaction,  whereas 
substituents that raise the HOMOdipolarophile or lower the LUMOdipole favour type III 
interaction.
98, 113 
 
Figure 25 Classification of 1,3-dipolar cycloaddition using FMO theory 
Nitrones are normally classified as type II; whereas nitrile oxides are at the border 
line of type II and type III, due to their low lying HOMO. The characterized low-
lying  HOMO  of  nitrile  oxides  make  HOMOdipole-LUMOdipolarophile  interaction  less 
likely,  which  in  turn  bias  towards  LUMOdipole-HOMOdipolarophiles  interaction.  In 
addition,  energy  overlap  of  each  counterparts  to  generate  isoxazol(in)es  are 
essentially  regiospecific,  forming  the  3,5-isoxazol(in)es  (Figure  26).  However, 
reversal  of  regiochemistry  in  nitrile  oxide  cycloaddition  has  been  reported  when 
highly electron deficient dipolarophile is used (Scheme 29),
114 or substituents on both 
nitrile oxides and alkenes are sterically demanding.
115, 116  39 
 
 
Figure 26 Type III interaction between nitrile oxides and monosubstituted alkenes 
 
Scheme  29  Generation  of  4-substituted  isoxazole  using  electron  deficient 
dipolarophile 
1.4.2.1  Regioselectivity in nitrone cycloadditions 
Nitrone cycloaddition are generally categorized as type II; they could be bias towards 
either type I or type III interaction depending on the electronic and steric factors of 
nitrone or alkene.
98, 113 
 
In  early  studies,  cycloaddition  of  nitrones  with  alkenes  was  considered  to  be 
dominated by the LUMOdipole-HOMOdipolarophile interaction (type III) generating the 
3,5-isoxazolidine; however Houk et al. reported the use of strong electron deficient 
dipolarophiles  to  generate  predominantly  the  3,4-substituted  isoxazoli(di)ne  102 
(entries 1, 3 & 5) as the major regioisomer (Table 1). However, as the steric bulk of 
the  nitrone  increases  (entries  2,  4  &  6),  the  3,5-substituted  isoxazoli(di)ne  103 
increases inspite even with these highly electron deficient dipolarophiles.
117,118 Such 
electron  deficient  alkenes  possess  a  low-lying  LUMO,  and  favors  HOMOdipole-
LUMOdipolarophile interaction (type I) leading to the 3,4-isoxazolidines. However, the 
steric  factors will overwrite the orbital overlap consider when either  nitrone and 
alkene become sterically demanding.
117, 119 40 
 
 
Entry  R=  R’=  Dipolarophile  102  103 
1  Ph  Me    100  0 
2  H 
tBu    50  50 
3  Ph  Me    100  0 
4  H 
tBu    0  100 
5  Ph  Me 
 
68  32 
6  H 
tBu 
 
30  70 
Table 1 Cycloaddition using highly electron deficient dipolarophiles 
1.4.2.2  Diastereoselectivity in nitrone cycloadditions 
A nitrone can interact with an alkene in either an endo- or an exo- orientation, where 
endo- orientation  is characterized by secondary π  interaction during the transition 
state  (Figure 27). The  favourability of each transition state  is dependent on  three 
factors:  (1) orientation of alkene,  (2) orientation of  nitrone, and  (3)  geometry of 
nitrone. Therefore upon cycloaddition, these factors determine the ratio of the regio- 
and  distereoisomers  amongst  all  possible  outcomes  (Scheme  30).  Therefore 
stereoselectivity and enantioselectivity have become the major issue in 1,3-dipolar 
cycloaddition.
98, 100 
 
Figure 27 Endo- and exo- orientation in nitrone-alkene cycloaddition 41 
 
 
Scheme  30  Regio-  and  stereo-chemical  outcomes  of  nitrone  cycloaddition  to  an 
alkene 
In order to achieve enantioselectivity, either chiral alkenes or chiral nitrones could be 
used.  Saito  et  al.  developed  a  chiral  nitrone  104  based  on  tartaric  acid  which 
undergoes cycloaddition with methyl crotonate 105. The transition state is formed 
from a unidirectional endo- approach of the chiral nitrone 104, generating the 3,4-
anti isoxazolidine 106 in 95% de.
120 The same group also developed a tartaric acid 
derived chiral alkene  107 which undergoes cycloaddition with cyclic nitrone  108. 
The endo- approach  furnishes the 3,4-anti  isoxazolidine  109  in  high de  (Scheme 
31).
121 
 
Scheme 31 Asymmetric 1,3-dipolar cycloaddition with chiral nitrone/alkene  
In  conclusion,  through  early  work  of  Houk  et  al.  it  is  apparent  that  the 
regioselectivity  is  influenced by the energy  levels of  the  reacting orbitals of the 
dipolarophile.  Diastereoselectivity  and  enantioselectivity  have  also  been  achieved 
through the usage of chiral nitrones, chiral alkenes and catalysts such as TiCl(O
iPr)3 
and ZnCl2. However, cycloadditions with vinyl sulfonates and vinyl sulfonamides are 
less common.
122 Therefore, guided by previous work conducted within the group, the 
present studies were directed toward expanding the scope of cycloaddition with vinyl 
sulfonates and vinyl sulfonamides. 42 
 
2  Results and Discussion 
2.1  Aim 
The aim of this research was to study the 1,3-dipolar cycloaddition reactions of PFP 
ethenesulfonate with dipoles such as nitrones and nitrile oxides. The concept of 1,3-
dipolar  cycloadditions  have  been  introduced  since  1950s.  However  PFP 
ethenesulfonate has only been introduced recently as a dipolarophile. Therefore an 
in-depth study of cycloaddition reaction with PFP ethenesulfonate is of great interest 
in expanding this area.
113, 122 
 
Formation of isoxazolyl PFP sulfonates and isoxazolyl sulfonamides have been the 
focus of  this project as  isoxazolidines  made  in previous  work showed biological 
activity  against  DDAH,  ADI  and  HIV-1,  and  hence  being  able  to  synthesize  a 
collection of related compounds is of interest as well as the potential opportunities 
for using isoxazoles as a reasonably new class of biologically active agent for drug 
discovery.
123 
 
Cycloaddition between nitrile oxides and an alkyne equivalent furnished a collection 
of isoxazoles in mild conditions (2.5 eq NEt3, RT, 1 h, Figure 28). Isoxazolyl PFP 
sulfonates were then able to undergo subsequent aminolysis to produce isoxazolyl 
sulfonamides that can be screened against HIV-1. 
 
Figure 28 1,3-dipolar cycloaddition between a nitrile oxide and an alkyne equivalent 
As  a  continuation  to  the  previous  work  within  the  group,
113  isoxazolidinyl  PFP 
sulfonates and sulfonamides were also synthesized via 1,3-dipolar cycloaddition to 
provide suitable candidates  for testing against HIV-1. Further study  is required  in 
order  to  investigate  the  structure–activity  relationship  of  the  isoxazolidinyl  PFP 
sulfonates and  sulfonamides. At  the same time, diastereoselectivity of aminolysis 
also needed to be addressed in order to synthesize each diastereomer of sulfonamide 
more efficiently (Scheme 32). 43 
 
 
Scheme 32 Various outcomes of nitrone cycloaddition and aminolysis 
2.2  Synthesis of isoxazoles 
Preparation  of  isoxazoles  described  in  the  literature  often  involve  the  use  of 
alkynes,
76  bromoalkenes
124  and  1,3  dicarbonyls  (Scheme  33).
82  However,  we 
envisaged an alternative based on the oxidation of the isoxazolidine PFP sulfonates. 
 
Scheme 33 Literature preparation of isoxazoles 
2.2.1  Preparation of pentafluorophenyl (PFP) ethenesulfonate 
Pentafluorophenyl ethenesulfonate 110 was prepared using a procedure developed by 
Wilden  from  2-chloroethane-1-sulfonyl  chloride  111  (Scheme  34)
125  Due  to  the 
exothermic  reaction  upon  addition  of  pentafluorophenoxide  to  2-chloroethane-1-
sulfonyl chloride 111, the reaction temperature must be kept below 0 °C to minimize 
decomposition. Furthermore, by  introducing a dry ice-acetone bath to the reaction, 
this allows faster addition of pentafluorophenoxide solution to the reaction mixture.  
 
Scheme 34 Preparation of PFP ethenesulfonate 44 
 
2.2.2  Nitrone cycloaddition and isoxazolidine oxidation 
Preparation of  nitrones  reported  in  the  literature  include  oxidation of  imines
110 or 
more commonly condensation of a  hydroxylamine  with an aldehyde.
126 With our 
desired dipolarophile 110  in  hand, the required  nitrone had to be synthesized. N-
tbutyl-C-phenyl was initially chosen due to its acid labile nature of the 
tbutyl group 
which  can  be  easily  removed.  To  synthesize  the  desired  nitrone, 
tbutyl 
hydroxylamine 112 was condensed with benzaldehyde to generate the desired nitrone 
113;  which  then  underwent  cycloaddition  with  PFP  ethenesulfonate  110  to  form 
isoxazolidine 114 in moderate yield (Scheme 35). The structure of the 3,4-substituted 
isoxazolidine  was  determined  by  NMR,  which  compared  favourably  with  the 
literature.
92 With  isoxazolidine  114  in  hand,  we envisaged the removal of the  N-
protecting  group  followed  by  ring  oxidation  to  give  the  corresponding  isoxazole 
(Scheme 36). 
 
Scheme 35 Synthesis of N-
tbutyl isoxazolidine 
However, after 48 hours of refluxing 114 in TFA, 65% of the starting material 114 
was  recovered  with  no  evidence  of  desired  isoxazoline  and  isoxazole  formation. 
Therefore it was suspected that prolonged heating was required in order to partially 
oxidize the heterocycle to isoxazoline, and subsequent DDQ oxidation would furnish 
our desired isoxazoles. However upon reluxing for 5 days in TFA, only 24% of the 
starting material 114 was recovered, and the rest of the reagents were decomposed. 
 
Scheme 36 Initial proposed route to form isoxazole 
Due to the lack of success in ring oxidation via 
tbutyl deprotection, this approach was 
disgarded, and an alternative approach  to  isoxazolyl PFP sulfonate synthesis  was 
sought. 
 45 
 
2.2.3  1,3-Dipolar  cycloaddition  of  nitrile  oxide  with  PFP-1-
bromoethenesulfonate 
The classical approach to isoxazoles is the condensation of hydroxylamine with a 1,3 
dicarbonyl compounds.
82 Our  next route towards  isoxazole synthesis involves the 
1,3-dipolar cycloaddition of nitrile oxide with an alkyne (Scheme 37).
76, 127  
 
Scheme 37 Cycloaddition between nitrile oxide and alkyne 
In  order  to  incorporate  the  PFP  sulfonyl  moiety  into  this  cycloaddition,  it  was 
proposed to use the acetylenic PFP sulfonate ester as dipolarophile (Scheme 38). 
 
Scheme 38 Cycloaddition between nitrile oxide and acetylenic PFP sulfonate ester 
Acetylenic sulfonate ester synthesis has only been seldom reported,
128,  129 and with 
several unsuccessful attempts (pyridine/NEt3/LDA + AgOTf, Scheme 39) within the 
group,  this  problem  still  remains  to  be  overcome.  However,  a  synthon  to  the 
acetylenic sulfonate ester-, the 1-bromo ethenesulfonate ester,  has been successful 
synthesized using radical chemistry,
130 and this dipolarophile was used in place of 
acetylenic  sulfonate  ester  in  our  synthesis.  Pentafluorophenyl-1-
bromoethenesulfonate  115  was  readily  generated  by  radical  bromination  of  PFP 
ethenesulfonate  110  followed  by  dehydrobromination  to  furnish  the  PFP-1-
bromoethenesulfonate 115 in excellent yield, 97%, over two steps (Scheme 39).
130 
 
Scheme 39 Preparation of PFP-1-bromoethenesulfonate 
 46 
 
2.2.3.1  Preparation of nitrile oxide 
Nitrile oxides, as described in 1.4.1.1, are very reactive 1,3-dipoles, and can readily 
dimerize  to  form  furoxan,
131 thus in-situ  formation  from  hydroximoyl chloride  is 
required, nitrile oxide is then rapidly trapped by a suitable dipolarophile in a one-pot 
cycloaddition. Preparation of hydroximoyl chlorides 116a-p was easily achieved by 
chlorination of oximes 117a-p using N-chlorosuccinimide (Scheme 40).
104 In order to 
obtain uniformly high yield it was crucial to keep the temperature below 40 °C. Most 
of the desired hydroximoyl chlorides were then obtained in moderate to high yield, 
with the exception of 116n. It was observed that 116n chlorinated on the furyl ring 
instead of on the oxime α-carbon, to give a mixture of chlorinated compounds that 
were  inseparable by  flash chromatography.  Therefore  furyl  substrates were  not a 
suitable for this methodology.  
 
Scheme 40 Preparation and yield of hydroximoyl chlorides from oximes using N-
chlorosuccinimide 
2.2.3.2  Cycloaddition of hydroxymoyl chlorides with PFP-1-bromoethenesulfonate 
With both  hydroximoyl chlorides  116a-p and PFP-1-bromoethenesulfonate 115  in 
hand, cycloadditions were carried out in dichloromethane using Touaux’s method.
127 
The reaction was refluxed in dichloromethane for 15 hours. However, poor yields 
were obtained upon purification (Table 2). Therefore it was suspected that the nitrile 
oxides  could  have  dimerized  readily  to  produce  furoxan-2-oxide  (as  described 
earlier) as a competing reaction to cycloaddition, resulting in the poor yield obtained. 
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Entry  R  Yield/ % 
a 
 
24% 
b  Ph  42% 
c 
 
0% 
d 
 
44% 
e 
 
0% 
f 
 
0% 
g 
 
0% 
Table 2 Isoxazolyl PFP sulfonates obtained using Touaux’s method 
2.2.3.3  NMR study and structure determination 
Selectivity  in  nitrile oxide cycloaddition, as discussed  in  1.4.2, suggest  that  most 
nitrile oxides cycloaddition with  monosubstituted  alkenes should be regiospecific, 
forming  the  3,5-substituted  isoxazole.  However,  in  a  few  cases,  highly  electron 
deficient dipolarophiles were used and the reverse regioisomer was observed.  
 
The structure of the product isoxazoles was confirmed to be 3,5 substituted by NMR 
experiments and X-Ray crystallography. Proton, carbon and fluorine NMR spectra 
were consistent with the structure in Figure 29. In addition, 
1J C-H coupling on the 
isoxazole 4-C position has a value of 189 Hz; which is consistent with the literature 
data; whereas 
1J C-H coupling on the isoxazole 5-C position would have a value of 
>200  Hz.
132  Therefore  the  structural  analysis  confirmed  that  the  3,5-substituted 
isoxazole is formed despite of the electron deficient nature of the dipolarophile. This 
led  to  the  conclusion  that  even  though  the  dipolarophile  contains  an  electron 
deficient  PFP  sulfonyl  group,  this  does  not  overwrite  the  steric  factors  of  both 48 
 
counterparts. Therefore steric factors still remain the determining issue of this regio- 
outcome.  
 
Figure 29 Structure of cycloadduct determined by NMR and X-ray crystallography 
2.2.3.4  Optimization of reaction condition 
As discussed in 2.2.3.2, cycloaddition using Touaux’s conditions (2 eq NEt3, DCM, 
45 °C) resulted in low yields. However, Hamme et al. reported that most of their 
cycloadducts were isolated in high yield (Scheme 41), using only slightly different 
condition.
124 
 
Scheme 41 Hamme’s cycloaddition using 1-bromophenylvinylsulfone 
Hamme’s  conditions  (1.2  eq  NEt3,  DCM,  RT)  were  then  employed  for  our 
cycloaddition (Table 3 entry b). However it was found that the majority of PFP-1-
bromoethenesulfonate 115 was still present by TLC (not isolated) even after 72 hours 
and  no product was produced; which suggests that Hamme’s conditions  were  not 
optimal for our cycloaddition.  
During optimization,  varying  temperature (Table 3 entry  c) and solvent  (Table 3 
entry d) were also investigated with no success. However, with an increase in the 
amount of triethylamine, the reaction time was observed to be significantly reduced 
(Table  3  entry  e).  It  is  believed  that  an  excess  amount  of  triethylamine  may  be 
catalyzing the reaction by either addition to the dipolarophile in a Baylis-Hillman 
fashion,
82 which triggers cycloaddition with the nitrile oxide; or by addition to the 
nitrile  oxide  to  form  amidoxime.
102 Therefore  a  mechanistic  study  was  required, 
which is discussed at the end of this section. 49 
 
Entry 
 
/ eq. 
 
/ eq. 
NEt
3/ 
eq. 
Solvent  Temp/ 
°C 
Time/ 
h 
Yield/ 
% 
a  1   2   2   DCM  45   15   30% 
b  1   1   1.2   DCM  21  72   0% 
c  1   1   1.2   DCM  45   12   0% 
d  1   1   1.2   Toluene  110   12   <5% 
e  1   1.5   2.5   Toluene  110   1   60% 
Table 3 Initial optimization of nitrile oxide cycloaddition 
The initial optimized conditions (Table 3 entry e) were then applied to synthesize a 
collection of  isoxazolyl PFP sulfonates and  was pleasing to observe significantly 
improved yields (Table 4).  
 
Due  to  the  recent  advances  in  microwave  chemistry,  microwave  assisted 
cycloadditions  were  also  attempted.  In  an  initial  attempt  using  a  microwave 
conditions developed by Mok,
113 all starting materials were decomposed, therefore 
reaction  conditions  were  modified  to  be  less  forcing.  The  reaction  time  and  the 
temperature  were  varied,  and  it  was  found  that  the  optimal  condition  for 
cycloaddition  was  100  °C,  4  minutes.  Even  though  the  reaction  time  was 
significantly  reduced  compared  to  conventional  thermal  heating,  the  product 
obtained from conventional thermal heating was much cleaner (Table 4).  
 
Only aromatic  hydroximoyl chlorides were employed, because cycloaddition with 
aliphatic hydroximoyl chlorides appeared to be unsuccessful, this is believed due to 
that aliphatic hydroximoyl chlorides are unstable upon addition of triethylamine, and 
were prone to be deprotonated at the α-proton instead of forming nitrile oxide. 
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Compound  R  Yield/% 
(Δ) 
Yield/%  
(MW) 
118a 
 
92%  85% 
118b  Ph  86%  54% 
118c 
 
88%  52% 
118d 
 
75%  24% 
118e 
 
87%  84% 
118f 
 
87%  75% 
118g 
 
69%  63% 
118h 
 
86%  61% 
118i 
 
90%  70% 
118j 
 
52%  30% 
118k 
 
82%  46% 
118l 
 
50%  --- 
Table 4 Comparison between thermal and microwave irradiation conditions in nitrile 
oxide cycloaddition 
It was observed that all electron rich isoxazoles (118a, 118c, 118e, 118f and 118h) 
were  generated  in  higher  yield than  the electron poor  isoxazoles  (118j), and  was 
observed  that  halides  on  ortho-  and  para-  position  (118c,  118e,  118f  and  118h) 51 
 
produces higher yield than on meta-position (118d and 118g), which is in congruent 
with  the  aromatic  mesomeric  affect.  The  iodo-  compound  118l  was  isolated  in 
moderate yield, and was believed that this  is due to the steric demand of  iodide; 
contrastingly the fluoro- compound 118i was isolated in high yield. Therefore it is 
concluded that the electron donating effect of the aryl group and the steric hinderance 
are directly related to the yield. 
 
Several new conditions were also investigated for these cycloaddition. Temperature, 
quantity  of  triethylamine  and  solvent  were  varied  in  order  to  compare  with  our 
previously best condition (Table 5 entry a). It was observed that an increase in the 
amount of triethylamine had led to an increase in the rate of reaction, and on the 
reaction with 2.5 eq NEt3 performing at room temperature (Table 5 entries b, c, f and 
g) it was found that all reactions reached completion within 2 hours. This suggests 
that triethylamine could be catalyzing the reaction. Furthermore, an investigation of 
the solvent effect between toluene and DCM has also been carried out, and it was 
found that the reaction proceed faster in  less polar solvent (toluene) than in more 
polar solvent (DCM), as well as in higher yield. DMF (Table 5 entry h) was also 
introduced to investigate whether increasing solvent polarity would affect the rate of 
reaction, but it was found that the reaction in DMF led to low yields.
123 
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Entry 
R N
OH
Cl
R=4-OMePh 
/ eq. 
NEt3 
/ eq. 
Solvent  Temp/ °C  Time/ 
min 
 
Yield/ % 
a*  1.5   2.5   Toluene  110   30  60% 
b  1.5   2.5   DCM  21  120  52% 
c  1.5   2.5   Toluene  21  100   87% 
d*  1.5   5   DCM  45   20  50% 
e*  1.5   5   Toluene  110   10  81% 
f  1.5   5   DCM  21  90  48% 
g  1.5   5   Toluene  21  60  92% 
h  1.5   5   DMF  21  20  43% 
Table 5 Optimization of nitrile oxide cycloaddition. * = reflux 
With the optimized conditions in hand (Table 5 entries c and g), our interest was to 
study the mechanistic pathway of this cycloaddition. In entries b, c and d, reactions 
were  monitored  by  TLC  every  10  minutes,  and  all  showed  that  the  immediate 
consumption of hydroximoyl chloride after the addition of triethylamine, suggesting 
as expected that the cycloaddition does not proceed via hydroximoyl chloride, but 
through an intermediate nitrile oxide. On the other hand, excess triethylamine seems 
to  catalyze  the  reaction  (comparing  entries  c  and  g),  suggesting  that  excess 
triethylamine participated in our cycloaddition. It has been reported that nitrile oxide 
is susceptible to nucleophilic attack by amine to form amidoxime.
102,  133 Therefore 
we suspect that the excess triethylamine underwent nucleophilic attack on the nitrile 
oxide prior to cycloaddition, and subsequent dehydrobromination to furnish the 3,5 
isoxazolyl PFP sulfonate as a sole product (Scheme 42). 53 
 
 
Scheme 42 Proposed mechanism of nitrile oxide cycloaddition 
2.2.4  Aminolysis of isoxazolyl PFP sulfonate 
With the desired isoxazolyl PFP sulfonates in hand, subsequent aminolysis was then 
carried  out  using  4-methylbenzylamine  and  allylamine  to  generate  isoxazolyl 
sulfonamides  119a-120k.  Displacement  of  the  pentafluorophenol  with  an  amine 
generated isoxazolyl sulfonamides in good yield. However, this reaction (1-3 h) did 
not proceed as fast as the analogous aminolysis of isoxazolidinyl PFP sulfonate (1 h) 
that  had  previously  been  reported  by  the  group. Aminolysis  of  alkyl  sulfonates 
generally proceeds via the sulfene intermediate, however,  isoxazolyl PFP sulfonate 
does  not  contain  an  α-proton  available  for  deprotonation;  therefore  direct 
displacement has to occur, resulting in prolonged reaction time. Despite the longer 
reaction time required for aminolysis, all isoxazolyl sulfonamides were isolated in 
high yield, and no general trend in yield was observed relating to the electronics of 
the  isoxazolyl  PFP  sulfonates  (Table  6).  Therefore  it  was  believed  that  all  the 
isoxazolyl  PFP  sulfonates  are  sufficiently  electron  deficient  to  be  susceptible  to 
substitution by primary amines. 
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Compound  R  Yield/ %  Compound  R  Yield/ % 
119a 
 
71%  120a 
 
66% 
119b  Ph  95%  120b  Ph  64% 
119c 
 
83%  120c 
 
60% 
119d 
 
72%  120d 
 
53% 
119e 
 
82%  120e 
 
64% 
119f 
 
73%  120f 
 
67% 
119g 
 
84%  120g 
 
67% 
119h 
 
90%  120h 
 
68% 
119i 
 
84%  120i 
 
77% 
119j 
 
72%  120j 
 
69% 
119k 
 
83%  120k 
 
69% 
119l 
 
71%       
Table  6  Aminolysis  of  isoxazolyl  PFP  sulfonate  using  4-methylbenzylamine  or 
allylamine 
Other primary amines were also chosen for this reaction, namely tert-butylamine and 
isopropylamine.  However,  due  to  their  bulky  nature,  aminolysis  did  not  proceed 
efficiently as detailed  in  Table 6  (Scheme 43) and  therefore tetrabutylammonium 55 
 
chloride (TBAC) was then introduced as a nucleophilic catalyst. The primary action 
of TBAC is to generate sulfonyl chloride in-situ from the PFP sulfonate ester in order 
to  enhance  reactivity  for  aminolysis.
134  It  was  found  that  the  reaction  time  was 
significantly reduced, from 24 hours to 3 hours upon TBAC addition, along with an 
increase in yield. Again, there was no general trend of the yield that corresponded to 
the electronic nature of substituent, however, tert-butylsulfonamides 121a-121k were 
isolated in lower yield than isopropylsulfonamides 122a-122k due to the increased 
steric demand of the tert-butylamine. 
 
Scheme 43 Aminolysis using t-butylamine and isopropylamine 
The  scope  of  aminolysis  was  also  extended  to  secondary  and  aromatic  amines. 
Initially, when the previous aminolysis conditions (Table 7 entry a) were applied, 
sulfonamides were isolated in poor yield, therefore in order to optimize this reaction, 
temperature, amount of triethylamine and TBAC were then varied. It was observed 
that a lower yield was obtained when using LHMDS (Table 7 entries d and e), and it 
was suspected that LHMDS was too harsh a base. Optimal conditions were identfied 
that prolonged heating of the reaction mixture was required (Table 7 entry c), where 
upon yields obtained were markedly improved (Scheme 44). 
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Entry 
 
/ eq. 
Base
  Heating  Temp/ 
°C 
Time/ 
min 
Yield/ 
% 
a  3  
With TBAC 
NEt3  Δ  65  180  47% 
b  3  
With TBAC 
NEt3  MW  100  5   44% 
c  3  
With TBAC 
NEt3  Δ  65  24 h  62% 
d  3  
 
LHMDS  Δ  65  240  0% 
e  3  
With TBAC 
LHMDS  Δ  65  240  37% 
Table 7 Optimization of aminolysis using N-methylbenzylamine 
 
Scheme 44 Optimized condition from Table 7 entry c 
Next,  aminolysis  with  an  aromatic  amine,  aniline  was  studied.  Due  to  the 
participation of the nitrogen lone pair within the aromatic system, it is known to be 
less nucleophilic compared to other amines. Previous aminolysis conditions (Table 7 
entry c) were then employed  for the  following reactions. However, sulfonamides 
were only obtained in up to 50% yield. It was suspected  that the aniline used was 
slowly oxidized; therefore aniline  was distilled prior to  aminolysis  to  investigate 
whether the purity of aniline affects the yield (Table 8). It was observed that upon 
using freshly distilled aniline, yields improved slightly by about 10-15%; therefore 
concluding that the purity of aniline does affect the yield. 
 
Over the course of consecutive aminolyses, yields decreased dramatically (Table 8). 
Aniline was then suspected to oxidize steadily to produce lower yield, therefore all 
reactions were then repeated in carousel using a batch of freshly distilled aniline. No 
distinctive  pattern  was  shown  on  the  Carousel  reactions.  However,  with  para- 57 
 
substituted electron donating  ligands (124a, 124c and 124f) the yields tend to be 
higher. 
Compound  R  Yield/ % 
 
Yield/ % 
(carousel) 
124a 
 
60 %  93 % 
124b  Ph  68 %  46 % 
124c 
 
67 %  68 % 
124d 
 
50 %  62 % 
124e 
 
43 %  42 % 
124f 
 
46 %  80 % 
124g 
 
42 %  32 % 
124h 
 
37 %  47 % 
124i 
 
17 %  10% 
124j 
 
9 %  44 % 
124k 
 
6 %  46 % 
Table 8 Comparison in yields between consecutive aminolysis and carousel 
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2.3  Introduction to HIV 
Human  immunodeficiency  virus  (HIV)  is  a  lentivirus  (a  class  of  retrovirus)  that 
causes the delayed onset immune system failure in human, and eventually leads to 
the Acquired Immunodeficiency Syndrome (AIDS) and opportunistic diseases such 
as meningitis, bronchitis, eruption of  Herpes Simplex virus (HSV) and Hodgkin’s 
lymphoma.
135  
 
The  origin  of  HIV  is  believed  to  be  the  cross-species  variant  of  the  Simian 
Immunodeficiency Virus  in chimpanzees (SIVcpz), after various  minor  mutations, 
the  modern HIV  virion  was born.
136,  137 It was  first discovered  in 1970s  when a 
patient displays the signs of  lymphadenopathy, but remain  un-named  until  it  was 
isolated from lymph nodes of a patient suffering lymphadenopthy in 1983.
138  
 
HIV  infects  cells  in  the  immune  system  such  as  the  CD4
+  helper  T-cells, 
macrophages and dendritic cells. It reduces CD4
+ count through three mechanisms: 
(1) direct killing of the infected cells by the virus, (2) increased apoptosis of infected 
cells  and  (3)  recognition  and  killing  of  the  infected  CD4
+  Th-cells  by  the  CD8 
cytotoxic T-cells.  Reduced  level of CD4
+ count  leads to  immunedysfunction, and 
increases the risk of contracting opportunistic diseases.
138 
2.3.1  Structure and genomic organization of HIV 
The structure of HIV is approximately 120nm in diameter; which consists of a core 
capsid, viral matrix and protein membrane (Figure 30). The core capsid comprises of 
two  single stranded  RNA  molecules, which are  in close association  with reverse 
transcriptase,  integrase,  protease,  ribonuclease  and  nucleocapsid  proteins.  The 
surrounding matrix maintains and ensures the integrity of the viral structure; which is 
all encased in a viral envelope constructed from two phospholipid layers. There are 
two embedded surface proteins:  gp120, a cap trimer that  is responsible  for  initial 
binding  to  CD4
+  Th-cell,  and  the  transmembrane  gp41,  which  consists  of 
homodimeric  trimer  helix (total  six  helix)  that  support  the extracellular  nature of 
gp120. 
139, 140 
 
There are two types of HIV: HIV-1 and HIV-2. HIV-1 is more virulent and possesses 59 
 
higher transmissibility and  mortality rate than  HIV-2. While HIV-1  is  globalized, 
HIV-2  is  localized within West Africa.  Both subtypes of HIVs contain  the  same 
genome (apart from Vpr and Vpx), but are different in their genome mapping, where 
HIV-2 is closer resembled to SIVcpz than HIV-1.
141 
 
Figure 30 Schematic of HIV virion from Behera
142 
Each viral RNA encodes for nine genes within the HIV viral particle (Gag, Pol, Env, 
Vif, Vpr/Vpx, Rev, Tat, Vpu and Nef), five of the genes (Gag, Pol and Env, Tat and 
Rev) encode for proteins that are vital to infection and life cycle: Gag codes for the 
structural  matrix protein, capsid protein and  nucleocapsid proteins;  Pol codes  for 
enzymes within the capsid, such as protease, reverse transcriptase, and integrase; Env 
(envelope protein) codes for the gp160 glycoprotein, which is later broken down to 
gp41 and gp120; Tat and Rev are essential during the viral transcription as they are 
the transcription activator and RNA transporter/stabilizer. Absence or mutation of Tat 
and Rev genes inactivate the virus.
143, 144 The remaining four genes regulate the viral 
replication cycle. The start/end region of the HIV genome is occupied by a structural 
landmark called viral Long Terminal Repeats (LTRs), which contain sequences that 
repeat up to several hundred times. After the viral RNA is reverse-transcribed into a 
double helix vDNA, LTR is used for mediating insertion of vDNA into host DNA 
during  integration.  LTRs  are  specific  to  retrovirus,  therefore  it  can  be  used  to 
determined the degree of HIV infection by counting the number of LTRs.
140, 141 60 
 
2.3.2  HIV life cycle 
The life cycle of HIV can be divided into 3 stages: (1) cell entry, (2) replication and 
transcription, and (3) resemble and release.  
2.3.2.1  Cell entry 
The life cycle of HIV begins with binding of the gp120 glycoprotein with the CD4
+ 
receptors and macrophages; which allows a structural change in the gp120, exposing 
a secondary binding  ligand. The secondary binding  ligand  is then able to  interact 
with  the  chemokine  co-receptors  on  the  host  cell  surface  (α-chemokine  receptor 
CCR5 or β-chemokine receptor CXCR4).  Secondary interaction between gp120 and 
chemokine  co-receptor  ensures  further  conformational  changes  within  the  viral 
particle, and allows exposure of gp41 glycoprotein to penetrate into the hydrophobic 
cell membrane. The HR1 domain of the gp41 stabilizes cell penetration, and the HR2 
domain begins to coil up, bringing viral particle closer to the cell membrane, known 
as the “HR2  zipping”. This triggers  fusion between  viral phospholipid  layers and 
host cell membrane, and subsequent delivery of the viral capsid into the cell (Figure 
31).
139, 145 
2.3.2.2  Replication and transcription 
The uncoated viral RNA is reverse transcribed into single stranded complementary 
DNA, then into the double stranded vDNA by its reverse transcriptase. vDNA is now 
in  close  association  with  reverse  transcriptase,  matrix  protein,  integrase  and  Tat 
protein, forming a pre-integration complex (PIC), which can then be imported into 
the nucleus with the aid of viral protein R (Vpr).
141, 145, 146 It is believed that matrix 
protein and Vpr contains nuclear localization signal that can interact with Importin (a 
nucleocytoplasmic shuttling receptor) in order to achieve nuclear import.
147, 148 
 
Within the nucleus, vDNA is integrated into the chromosomal DNA, generating a 
provirus.  This provirus DNA can  lay dormant, or become active when  Tat (HIV 
transcription transactivator) protein activates the host transcription factor NF-kB, and 
the  cellular  transcription  then  copies  the  integrated  DNA  into  mRNA  by  RNA 
polymerase.
144, 149, 150 It has been reported that the transcription factor NF-kB could 
be  activated  in  the  infected  cell,  and  that  this  has  antiapoptotic  property.  This 
antiapoptotic property acts as a defence mechanism to limit replication, and leads to 
direct cytotoxic killing (by other cytotoxic cells) of the infected cells.
151 HIV exploit 61 
 
the antiapoptotic property of NF-kB by triggering cytotoxic killing of the infected 
Th-cell, or conversely  by  increasing apoptosis to  increase  viral spread.
151,  152 Post 
transcription,  mRNA  is exported to  cytoplasm (by  Rev protein),  where  it can be 
spliced  into  smaller  fragments  of  mRNA  to  provide  essential  structural  proteins 
during translation. As Rev level increases, RNA splicing is inhibited, furthermore it 
provides stabilization of the RNA in cytosplam.
141  
 
 
Figure 31 HIV replication cycle from Nisole
145 
2.3.2.3  Assembly and release 
During translation, glycoprotein gp160 is produced, which is further broken down to 
provide surface glycoproteins gp41 and gp120. At the same time, gag and gag-pol 
polyproteins  are  synthesized  in  the  cytoplasm,  and  then  transported  to  the  cell 
membrane. The immature virus starts to bud from the host cell, but maturation only 
occurs when protease cleaves the polyproteins into smaller essential and regulatory 
proteins. The mature viral particle can then be released from the infected host cell, 
which can then proceed to infect more cells.
141  
2.3.3  Treatment of HIV 
Through a better understanding of the HIV replication cycle, it has been possible to 
develop  various  anti-retroviral  agents.  Each  of  them  had  been  synthesized  to 62 
 
specifically target different enzymes during the replication cycle. Key stages include 
reverse transcriptase, protease, integrase and viral fusion. However, due to the error-
prone nature of the reverse transcriptase, viral RNA is can mutate rapidly; and results 
in mutated viral proteins, renders most antiretroviral agents inactive. Highly Active 
Anti-Retroviral Therapy (HAART) is a multi-drug treatment that was first introduced 
in  1996,  which  comprises  of  three  or  more  antiretroviral  agents  working  in 
conjunction with one another. Clinical success of HAART is due to the simultaneous 
inhibition during different stages of replication cycle, and has significantly reduced 
the  mortality  rate  of  viral  infection.  However,  life-long  treatment  is  required  to 
suppress viral spread, where disruption or termination of treatment may resume viral 
activity.
153 
2.3.3.1  Reverse transcriptase inhibitors 
The first identified target for anti HIV treatment is reverse transcriptase. There are 
two known types of reverse transcriptase inhibitors: nucleoside reverse transcriptase 
inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).  
 
Reverse transcriptase comprises of two enzymes: nuclease and polymerase, where 
the initial reverse transcription occurs at the polymerase. In order for the polymerase 
to  form  the  complementary  single  stranded  DNA,  it  requires  deoxynucleotide 
triphosphate (dNTP) as a building blocks and these must be phosphorylated into a 
triphosphate  to allow subsequent chain elongation  to occur.
139 Nucleotide reverse 
transcriptase inhibitors (NRTIs) resemble the structure of the building block, and act 
as competitive inhibitors. However, NRTIs lack 3’-OH group, which is required for 
chain elongation. Once the NRTI is incorporated into the cDNA, there is no 3’-OH 
available  for  chain  elongation.  Therefore  chain  elongation  terminates  and  viral 
replication ceased (Scheme 45).
139  63 
 
 
Scheme 45 Inhibition of reverse transcription using NRTIs 
Another class of reverse transcriptase inhibitor NNRTI: do not competitively bind to 
the polymerase active  sites;  instead  they  interacts  with  the  hydrophobic allosteric 
binding  pocket  near  the  active  site,  creating  a  conformational  change  within  the 
active site of the reverse transcriptase and this in turns leads to lost of function of 
reverse transcriptase.
139, 154 Current available reverse transcriptase inhibitors include 
Zidovudine  125,  Stavudine  126  and  Lamivudine  127  as  NRTIs;  Enfavirenz  128, 
Delavirdine 129, Nevirapine 130 and TIBO 131 as NNRTIs (Figure 32).
139, 154 
 
Figure 32 Commercially available NRTIs and NNRTIs 
2.3.3.2  Protease inhibitors 
Another type of HIV inhibitor, also a constituent part of HAART, is the HIV protease 64 
 
inhibitors.  HIV protease  inhibitors act on the  later stage of  the replication  cycle, 
where the Gag and Gag-Pol polyproteins are being processed  into essential  viral 
proteins  by  the  enzyme  protease.  HIV  protease  is  a  homodimeric  enzyme  that 
consists  of  two  active  sites  (Asp
25  and Asp
125).  Both  aspartic  residues  work  in 
conjunction, using water as nucleophile to hydrolyze the peptide bond.
155, 156 
 
HIV  protease  inhibitors  mimic  the structure of a  natural substrate  (biomimetics), 
therefore acting as a competitive  inhibitor;  however  most of them contain a  non-
hydrolysable  hydroxyethylamine  moiety  in  place  of  a  peptide  bond  (Figure  33). 
Therefore,  subsequent  binding  of  HIVPIs  terminates  the  action  of  protease,  and 
protease  function  is  lost.
156  Several  HIVPIs  are  currently  available,  such  as 
Amprenavir  19,  Atazanavir  132,  Tipranavir,  Indinavir,  Ritonavir  and  Darunavir; 
however some are more active than another due to development of drug resistance 
within the protease. 
 
Figure 33 Commercially available HIV protease inhibitors 
2.3.3.3  Fusion inhibitors 
HIV entry inhibition has also been a subject of interest; where if HIV fusion can be 
inhibited,  subsequent  HAART  treatment  could  pose  a  significant  advantage  in 
combating HIV. There are  several  fusion  inhibitors available, such as  Enfuvirtide 
(gp41 inhibitor)
157and the recombinant protein CD4-IgG2 (gp120 inhibitor), which 
acts on HIV virion.
158 However, several other inhibitors are designed to act on the 
host cell  instead, such  as AD101  133, PSC-RANTES and Maraviroc  134 (CCR5 
inhibitors).
159, 160  
It has been reported that with 50% of HIV infected people, the virus switches its 
entry pathway from CCR5 predominant pathway to CXCR4 predominant pathway. 
These  strains  are  known  as  the  syncytium-inducing  virus.
161,  162  Therefore  it  is 65 
 
desirable to develop an inhibitor that acts on both CCR5 and CXCR4. Schols et al. 
have developed a dual CCR5/CXCR4 antagonist AMD3451,that block R5 (HIV that 
uses only CCR5), X4 (HIV that uses only CXCR4) and R5/X4 HIV.
163 
 
Figure 34 Entry inhibitors 
Through a better understanding of the structure and replication cycle of HIV, various 
treatments have been employed to significantly reduce the threat of viral infection. 
Although there still  remains  no cure,  numerous  more potent,  less  toxic anti-HIV 
drugs are being developed at  the  meantime,  including several  sulfonamide-based 
drugs,  therefore  our  synthesized  sulfonamides  and  PFP  sulfonates  are  potential 
interest for activity against HIV. 
2.4  Synthesis of isoxazolidines 
Previous  work  conducted  within  the  group  has  been  focused  on  1,3-dipolar 
cycloadditions  of  PFP  ethenesulfonate  and  nitrones  to  generate  3,4-anti 
isoxazolidines  as  the  products  (Scheme  46).
113,  122  In  addition,  several  of  the 
isoxazolidinyl  PFP  sulfonates  prepared  and  the  corresponding  isoxazolidinyl 
sulfonamides  have  been  evaluated  for  their  inhibitory  activity  against  HIV-1. 
Therefore, as a continuation of this work, the following studies were conducted (1) 
synthesis of different analogues of isoxazolidinyl sulfonamide for SAR study, and (2) 
development of reagents for the target identification. 
 
Scheme 46 Formation of isoxazolidine via nitrone cycloaddition 
2.4.1  Initial screening and SAR study 
Previous  work  by  Mok  examined  the  cycloaddition  of  nitrones  with  PFP 
ethenesulfonate  and  N-(4-methylbenzyl)ethenesulfonamide.
113  This  library  of 66 
 
isoxazolidines was then  screened  against HIV-1 vector. It  was  found that several 
small  molecules 135-139 exhibit  micromolar  inhibition against  HIV,  furthermore, 
sulfonamides 138 and 139 appeared to exhibit the highest potency. Therefore several 
sulfonamides were then synthesized  in order to try and establish some structure-
activity relationship.
113 
 
Figure 35 Percentage of HIV inhibition at 150-250 µM concentration 
From the initial screening it was observed that the potency is determined on several 
factors:  The  4-methylbenzyl  sulfonamide  group  is  essential  for  HIV  inhibition. 
Substitution to other sulfonamide leads to loss in potency (Figure 36). 
 
Figure 36 A selected initial screening at 150-250 µM 
Substituents on the phenyl ring also shows fluctuation in inhibition activity. The o-
halide  compounds  were  found  to  be  the  most  potent,  and  potency  was  closely 
followed by the  p-halide compounds.  Thus  the  o-halide appears crucial  for  high 
potency. In addition,  it  was discovered that as the  size of the  halogen  increases, 67 
 
potency increases (e.g. activity I>Br>Cl>F).
113 
 
Methyl substitution on nitrogen in the isoxazolidine ring also appears important. For 
example with the N-methyl substituted isoxazolidines, the optimal concentration for 
target  inhibition  is 150-250  µM.  However  when  it  is changed  to  N-hydroxyethyl 
moiety the optimal concentration  was  then  increased to 400-500  µM  in order to 
obtain the same level of inhibition. Thus it would appear that the N-methyl moiety is 
neccessary. From  the SAR study  it was concluded that 2-methyl-3-(2-halo)phenyl 
isoxazolidine-4-(4-methylbenzyl)sulfonamides  display  the  highest  potency  (Figure 
37).
113 
 
Figure  37  Structure  of  the  most  potent  compound  where  it  contains  a  4-
methylbenzylsulfonamide, an o-halophenyl and an N-methyl group 
2.4.2  Synthesis  of  isoxazolidinyl  sulfoanimdes  and  optimization  of 
stereoselectivity 
In order to synthesize a collection of isoxazolidinyl sulfonamides for further testing 
against  HIV,  nitrones  140  were  selected  to  undergo  cycloaddition  with  N-(4-
methylbenzyl)ethenesulfonamide 141 (Scheme 47). It was observed that the reaction 
generated  the  3,4-anti,  3,5-anti  and  3,5-syn  isoxazolidinyl  sulfonamides  under 
microwave irradiation. The 3,4-anti isoxazolidinyl sulfonamide  142 appeared to be 
the major product, and the 3,5-anti/syn mixture were detected as the minor products. 
Several purifications were required to isolate the major product resulting in reduced 
yield, in addition the 3,5-anti/syn mixture is unable to be isolated therefore the yield 
reported is for the 3,4-anti isoxazolidinyl sulfonamide (Scheme 47). 68 
 
 
Scheme 47 Collection of the isoxazolidinyl sulfonamides 
2.4.2.1  Stereochemical  implications  of  aminolysis  reactions  of  isoxazolidinyl 
sulfonates 
To date the synthesis of isoxazolidinyl sulfonamides has been carried out via two 
different approaches: (1) the classical aminolysis  via  isoxazolidinyl PFP sulfonate 
esters, and (2) 1,3-dipolar cycloaddition of ethenesulfonamide with nitrones (Scheme 
48). Both approaches present potential problems such as regio-, stereoselectivity and 
difficulties  in  compound  isolation.  Such  problems  decrease  the  efficiency  of  the 
route; therefore this section describes an investigation of the stereochemical outcome 
of the aminolysis reactions. 
 
Scheme 48 Synthesis of isoxazolidinyl sulfonamides via (1) aminolysis and (2) 1,3-
dipolar cycloaddition 
As mentioned in 1.3.4, aminolysis proceeds through a sulfene intermediate with the 69 
 
presence of an α-H. During amine addition, a carbanion is formed, which can then be 
re-protonated from either faces of the molecule to form two diastereomers (Scheme 
49.). 
 
Scheme 49 Formation of diastereomeric sulfonamides from aminolysis 
Prior  to  the  optimization,  it  is  of  our  interest  to  investigate  which  diastereomer 
possesses more thermodynamic stability. With the original aminolysis condition as a 
reference point (3 eq. amine, DBU, THF reflux for 3 hours) a representative 3,4-syn 
isoxazolidinyl  sulfonamide  143a  was  selected  for  epimerization  studies  in  the 
presence of DBU, DMF at higher temperatures (Table 9 entry a&b). However, only 
the  starting  material  was  recovered,  therefore  a  stronger/bulkier  base  and  proton 
source  was  introduced  in  order  to  enhance  the  rate  of  epimerization  (entry  c-e). 
However, from the NMR analysis it appeared that no epimerization has occurred. 
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Entry  Substrate 
 
Base/ 
H
+ source 
Solvent  Temperature 
/Time 
Ratio 
anti:syn 
a  143a  ---  DBU 
(1.2 eq) 
DMF  153 °C/ 3 h  0:1 
b  143a  ---  DBU 
(1.2 eq) 
DMF  153 °C/ 24 h  0:1 
c  143a  --- 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
THF  66 °C/ 3 h  0:1 
d  143a  --- 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
THF  66 °C/ 24 h  0:1 
e  143a  --- 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
THF  66 °C/ 48 h  0:1 
f  143a  --- 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
Dioxane  101 °C/ 48 h  1:6 
76%
a 
g  143a  --- 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
DMF  153 °C/ 48 h  1:1* 
35%
a 
 
h  143b  3 eq 
tBuOK 
(1.2 eq) 
/
 tBuOH 
(1.2 eq) 
DMF  153 °C/ 3 h  1:1 
69%
b 71 
 
Table  9  Epimerization  and  optimization  of  diastereoselectivity.  Reaction  using 
forcing  conditions  (
tBuOH, 
tBuOK,  DMF)  generates  1:1  anti/syn  mixture.  
* Contain  trace amount of decomposition. 
a Starting  material recovery. 
b  Overall 
yields. 
It was noted that when solvents are changed to allow for higher reaction temperature, 
epimerization  was  observed  (entry  f&g).  Therefore  it  was  observed  that  at  high 
temperature using strong base and a bulky proton source, the 3,4-anti isoxazolidinyl 
sulfonamide is generated slowly over time. 
 
Applying  these  conditions  to  the  aminolysis  (entry  h)  it  was  observed  that  the 
diastereomeric ratio again stays at 1:1, and further reaction modification (prolonging 
the reaction period and varying the amount of 
tBuOH) did not improve the diastereo- 
mixture beyond 1:1.  
 
In conclusion, at  higher temperature,  thermodynamic  mixture of 1:1 anti/syn  was 
achieved  inspite of  using bulkier proton  source. On the other  hand, our original 
aminolysis condition (3 eq. amine, DBU and THF reflux for 3 hours) promotes 3:1 to 
4:1 ratio in favour of the anti protuct, therefore it was disappointed to observe that a 
reduction  in  diastereomeric  ratio  when  the  reaction  conditions  were  modified  to 
enhance the diastereoselectivity.  
2.4.3  Affinity chromatography 
Affinity chromatography is a technique used for capturing protein from biological 
mixture. Affinity chromatography works by tighly binding the target protein to the 
ligand-tagged  immobilized  matrix  via  either  electrostatic,  hydrophobic,  van  der 
Waal’s or H-bonding. The target protein is then released from the column by means 
of changing the pH, polarity, ionic strength or counter ion exchange. The released 
protein  is  then  identified  by  mass  spectrometry.
164  To  perform  an  affinity 
chromatography, the active compound has to first bind covalently to the immobilized 
bead (ie. biotin complex or sepharose) to form the solid support. A mixture of the 
biological proteins is then introduced into the column; where only the target protein 
will  interact  with  the  molecule  of  interest.  The  remaining  unattached  protein 
complexes can be eluted, followed by releasing of the target protein by changing pH, 72 
 
ionic strength or ion exchange (Figure 38). 
 
Figure 38 Affinity chromatography
164 
2.4.3.1  Preparation of  candidate substrates for affinity matrix attachment 
Through the testing of several PFP sulfonates and sulfonamides for activity against 
HIV, sulfonamide 139 is identified as the most promising candidate for the pull-down 
study. Together with 139, the o-fluorinated analogue 142g (Figure 39). 
 
Figure 39 Candidate sulfonamides selected for affinity chromatography 
Previous work by Mok attempted to link biotin onto the active compound via the 
sulfonamide  moiety,  however  attempts  were  unsuccessful  in  identification  of  the 
target  protein,  and  it  was  suspected  that  the  sulfonamide  moiety  is  crucial  for 
interacting with the target protein, therefore it is not a suitable attachment position.
113 
It was decided that the nitrogen atom on the isoxazolidine ring could potentially be 
another point of attachment. Therefore a  novel strategy was proposed based on a 
hydroxyl group; which provides suitable attachment for the candidate substrates to an 
affinity matrix (Scheme 50). 73 
 
 
Scheme 50 Alternative route for attachment via nitrogen on isoxazolidine 
Due to the previous attempt in affinity chromatography, where the loss of potency 
was associated with the attachment of biotin onto the sulfonamide moiety, it was also 
of  interest  to  change  the  affinity  matrix  to  epoxy-activated  sepharose  6B.  The 
advantage of using epoxy-activated sepharose  is that  it contains a 13-atom spacer 
which is able to link directly to the active compound for the affinity chromatography 
(Scheme 51); whereas biotin requires an additional protein-ligand interaction to the 
affinity matrix (avidin).  
 
Scheme 51 Attachment of epoxy-activated sepharose 6B with an alcohol 
The  multi-step synthesis started  from  mono protection of ethylene  glycol  to  give 
72% of 144 (Scheme 52); Swern oxidation furnished aldehyde 145 in 53% yields. It 
then  underwent  condensation  with  hydroxylamine  hydrochloride  to  produce  a 
mixture of  geometric  isomers of oxime  146  in 91%  yields. Subsequent reductive 
amination using NaBH3CN furnished hydroxylamine 147 in 87% yields, which was 
followed by secondary condensation to furnish nitrone 148 in near quantitative yield. 
Cycloaddition  between  nitrone  and  PFP  ethenesulfonate  110  gave  the  3,4-anti 
isoxazolidine 149 as the sole product.  
 
Subsequent  aminolysis  with  4-methylbenzylamine  generated  the  syn  and  anti 74 
 
diastereoisomers  150 and 151  in a 4:1 ratio.  Repeated  flash chromatography  was 
required in order to separate the two diastereomers with some loss in yield, and the 
major  product  150  (3,4-anti  isoxazolidinyl  sulfonamides)  then  underwent  silyl 
deprotection using TBAF at 0 °C to produce alcohol 152 in 79% yield. This was then 
ready to couple to epoxy-activated sepharose 6B. 
 
 
Scheme 52 Stepwise synthesis towards candidate substrate for affinity matrix 
2.4.3.2  Preparation of the immobilized ligands for affinity chromatography 
In order to successfully attach the alcohol 152 onto the epoxy-activated sepharose, an 
optimization of the reaction condition was required. However, because of the multi-
step process required to synthesize the valuable candidate compounds, as well as the 
higher cost of the affinity matrix, a model substrate was selected for the optimization. 
 
Due to the sensitivity of the epoxy-activated sepharose, the reaction conditions are 
limited due to the following factors: 
• The affinity matrix may denature at elevated temperature, and 75 
 
• The magnetic stirrer may disrupt the affinity matrix 
Therefore  in order to  investigate the optimal reaction conditions  it was envisaged 
that, the model substrates must react at room temperature (or below 40 °C) using a 
shaking water bath (Table 10). 
 
Entry  Alcohol  Epoxide  Reagent/ 
catalyst 
Solvent/ 
Temperature 
Time/ 
h 
Yield 
a     
1 eq 
TFA 
0.01 eq 
THF 
25 °C 
3  N/A 
b     
1 eq 
TFA 
0.01 eq 
DCM 
25 °C 
3  N/A 
c     
10 eq 
TFA 
0.01 eq 
THF 
25 °C 
3  N/A 
d     
10 eq 
SnCl4 
0.01 eq 
DCM 
25 °C 
3  N/A 
e     
10 eq 
Na2CO3  DMF 
25 °C 
16  N/A 
f     
10eq 
Na2CO3  DMF/H2O 
25 °C 
16  N/A 
g 
 
 
10 eq 
Na2CO3  DMSO/H2O 
25 °C 
16  N/A 
h 
 
Epoxy-
activated 
sepharose 
Na2CO3  DMF 
25 °C 
16  N/A 
i 
 
Epoxy-
activated 
sepharose 
Na2CO3  DMF/H2O 
25 °C 
16  N/A 
Table 10 Optimization for attaching candidate substrate onto the affinity matrix 
Under the initial reaction conditions, TFA (and later SnCl4) was chosen as the lewis 
acid; and the solvent and the amount of styrene oxide were varied (Table 10 entry a, 76 
 
b, c and d). However, the NMR spectra indicated a mixture with no evidence of the 
desired product or starting material. 
 
Fortunately, an appropriate coupling method had been developed by the sepharose 
distributor. This coupling  method suggested a requirement  for pre-washing of the 
affinity matrix prior to the coupling, and the dissolution of candidate ligand in buffer 
solution (up to 50% DMF/H2O) at pH 9-10 (Table 10 entry e-i). The reaction must be 
shaken at room temperature for 16 hours before blocking the excess epoxy-activated 
sepharose  with  ethanolamine.
164  However,  it  became  clear  that  monitoring  the 
reaction was going to be problematic because of the inability to use NMR or MS for 
analysis of the resin bound products.  We therefore abandoned this approach and re-
assessed the possibility of  using biotin and considered that past  failures  might be 
associated with the position of attachment and hence embarked upon a new approach 
in which the position of attachment was modified. 
 
In order to form a stable (amide) bond between the candidate substrate and D-biotin, 
it was necessary to change the functional group on the candidate substrate from a 
hydroxyethyl to ethylamine group. This functional group transformation incorporated 
three simple steps: mesylation, azide addition and hygrogenation as it was carried out 
in succession.
165 The amine was now available to couple to D-biotin (Scheme 53).
113 
 
Scheme 53 Functional group modification and coupling of D-biotin 
Upon coupling to the enantiomerically pure  D-biotin we saw that the biotinylated 
3,4-anti isoxazolidine 154 was a mixture of two diastereoisomers which could not be 
separated. They were sent off to our collaborator for pull-down study as a mixture. 
2.4.4  Further biological evaluation of heterocyclic sulfonates and sulfonamides 
2.4.4.1  Testing results of the compound efficacy 
All biological testings were carried out by Fassati and coworkers, and from screening 
a collection of synthesized isoxazolidines, four of the active compounds 135, 136, 77 
 
138 and 139 were selected for effect on healthy cells growth, cycle, viability and the 
effect on HIV life cycle (Figure 40). 
 
Figure 40 Structure of the lead compounds 
Active compounds 135, 136, 138 and 139 were also tested on HeLa cell (cervical 
cancer) and embryonic  fibroblastic cell 293T. It was  found that HIV activity  was 
inhibited to  varying degrees  in different cell  lines. In addition,  healthy cells were 
incubated with the active compounds, and  infected with Murine Leukaemia Virus 
(MLV, another retrovirus). It was found that the Murine Leukaemia Virus activity 
was also inhibited. Therefore suggesting that the active compounds 135, 136, 138 
and 139  may not act on the virus  itself, but thay are probably acting on the  host 
factors required for viral infection.
166 
2.4.4.2  Effect of active compounds on SupT1 cell growth 
This experiment investigated the effect of the active compounds 135, 136, 138 and 
139 on SupT1 (healthy T cell) cell growth. Compounds were incubated with SupT1 
cell  for  48  hours  at  various  concentrations  and  the  amount  of  viable  cells  were 
counted every 24 hours (Figure 41 & Figure 42). It was observed that 138 and 139 do 
not significantly alter cell growth at 100-150 µM compare to the untreated healthy T-
cells (in DMSO). However it was observed that both compounds 138 and 139 slow 
down cell growth at 200-300 µM concentration, and eventually leads to termination 
of cell growth at 48 hours. In addition, at 100-125 µM concentration of 135 and 136, 
cell  growth  is  intact compare to the  untreated  healthy T-cells. However,  at higher 
concentration  of  135  and  136  (400-500  µM),  the  viable  cell  count  shows  initial 
increase of cell growth up to 24 hours, but the cell growth slow down after 24 hours, 
and eventually  leads to termination of cell growth at 48 hours. This suggested that 
the active compounds 135, 136, 138 and 139 appear to show minimal alteration in 
cell  growth at 100-150  µM  concentration  within 24  hour period compare  to the 
healthy T-cells; however, termination of cell growth occurs at higher concentration or 
prolong exposure.
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Figure 41 SupT1 growth rate upon exposure to sulfonamides 
 
Figure 42 SupT1 growth rate upon exposure to PFP sulfonate esters 
2.4.4.3  Toxicity of active compounds on SupT1 cells 
SupT1 cells were incubated with the active compounds 135, 136, 138 and 139 at IC90 
and IC90/2 concentration for 30 hours, and the ratio of live/dead cell was determined 
(Figure  43).  Digitonin  (a  detergent  that  ensure  cell  death)  was  used  as  negative 
control to ensure cell arrest at 30 hours. It showed that 135, 138 and 139 did not 
display cell toxicity unless at IC90 concentration, and surprisingly 136 did not show 
cell toxicity even at IC90 concentration.  
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Figure 43 SupT1 cell toxicity upon exposure to PFP sulfonates and sulfonamides 
2.4.4.4  Effect of active compounds on HeLa cell cycle 
HeLa  cell  (an  immortal  cell  line  derived  from  cervical  cancer.  The  purpose  of 
choosing  HeLa  is  due  to  its  distinctive  phase-transition  in  the  cell  cycle;  which 
makes HeLa an ideal candidate for evaluation of cell cycle alteration) was exposed to 
the active compounds 135, 136, 138 and 139 at IC90 concentration. Aphidicholine 
(DNA polymerase inhibitor) was used as positive control ensuring cell arrest at the 
G1  phase,  and  HeLa  DNA  was  stained  with  propidium  iodide  at  30  hours  to 
determine  the  percentage  of  each  phases.  From  the  graph  it  did  not  show  any 
significant effect of the active compounds to the HeLa cell cycle. This indicated that 
the active compounds retain cell progression and are non-toxic (Figure 44).
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Figure 44 Effect of PFP sulfonate esters and sulfonamides on HeLa cell cycle 
2.4.4.5  Compound effect on HIV life cycle 
Compound inhibition of the HIV life cycle was also investigated. Distinctive stages 
such  as  cell  entry,  reverse  transcription,  nuclear  import/export,  integration, 
transcription,  translation and budding  were systematically  considered. SupT1 cell 
line was incubated with the active compounds 135, 136, 138 and 139, and infected 
with pCSGW pseudoviral vector for 24 hours. Prior to the infection, the viral vector 
was encoded with green fluorescent protein (GFP), therefore as the viral life cycle 
progressed,  GFP  would  be  expressed.  If  the  viral  life  cycle  is  blocked,  GFP 
expression would be impaired. Therefore the amount of viral inhibition is determined 
by the amount of GFP expressed.
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In the  initial experiment, one portion was  infected  with single  cycle pseudoviral 
vector (viral  vector  unable  to bud), and the other portion  infected with wild type 
HIV-1. Both experiments show similar GFP expression (data not shown), and this 
suggests that the active compounds do not inhibit viral budding.  
 
Effect of the active compounds on cell entry was also considered. CD4
+ T-cells were 
incubated with the active compounds 135, 136, 138 and 139, and infected with pan-
tropic HIV vector and wild type HIV-1 in parallel experiments. It was found that both 
experiments presented similar viral infection, where the pan-tropic viral vector (with 
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wider choice of cell entry) displays similar viral infection to the wild type HIV-1 
infection.  Therefore  it  suggested  that  cell  entry  is  not  the  target  for  compound 
activity.
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In order to assess the ability of the active compounds to inhibit reverse transcription, 
viral DNA count was analysed by flow cytometry. However, the viral DNA count 
does not corresponds with the trend in reduced GFP expression at the presence of the 
active compounds.  Therefore  this  indicated  that the  reverse transcription was  not 
impaired by the active compounds 135, 136, 138 and 139 (Figure 45).
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Figure 45 Percentage GFP expression and viral DNA count compare to the system 
where the healthy cells were infected with the viral vector pCSGW at the absence of 
active compounds. 
When  viral  DNA  is  imported  into the  nucleus,  viral  DNA  curls  up  in a circular 
arrangement;  where  the  3’  LTR  (Long  Terminal  Repeats,  described  in  2.3.1)  is 
connected to the 5’ LTR, called the 2LTRs. By counting the number of 2LTRs in 
relation  to  the  total  amount  of  viral  DNA,  the  level  of  nuclear  import  can  be 
determined. From the experiment of counting 2LTRs it was observed that the number 
of 2LTRs is not significantly reduced compare to the viral vector alone, suggesting 
that nuclear import is not greatly inhibited (Figure 46).
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Figure 46 Amount of 2LTRs/total viral DNA count plotted against time. Comparing 
to the pCSGW viral vector, the active compounds do not impaired nuclear import 
In order to determine whether the compounds block viral DNA integration, healthy 
cells were incubated with the active compounds 135, 136, 138 and 139, and infected 
with pCSGW vector for 1 week. The unintegrated DNA was gradually lost through 
dilution and degradation. On a parallel experiment, healthy cells were infected with 
pCSGW  viral  vector,  and  treated  with  an  integrase  inhibitor  Raltegravir  before 
Raltegravir could be washed out after 24 hours. Infected cells that were treated with 
Raltegravir  had significantly reduced DNA count, whereas the system  with active 
compounds  135,  136,  138  and  139  shows  minimal  reduction  in  integrated  DNA 
count, suggesting that compounds 135, 136, 138 and 139 do not block integration.
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In a separate experiment, cells were pre-treated with active compounds 135, 136, 138 
and 139, and transfected with HIV-1 vector that has a deleted env gene and encoded 
GFP. Gene expression was measured by flow cytometry 24 hours later and it was 
found that GFP level was dramatically reduced, suggesting inhibition in transcription 
(Figure 47).
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An untreated SupT1 cells was transfected with pCSGW viral vector, and then the 
active compounds 135, 136, 138 and 139 were introduced for 48 hours. Result shows 
no sign of reduction in viral mRNA count and viral protein level, suggesting that 
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viral mRNA nuclear export and translation were not affected (data not shown).
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Figure 47 Relative GFP expression was plotted against infected SupT1 cells that are 
pre-treated with the active compounds 135, 136, 138 and 139 
Based on the data presented above, it was suggested that nuclear import, integration, 
reverse  transcription,  cell  entry  and  budding  are  mildly  impaired.  Viral  gene 
expression/transcription on the other hand, was significantly impaired, indicating that 
the viral transcription is the most likely target for the candidate compounds. 
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3  Conclusion 
In  conclusion  we  have  synthesized  a  library  of  isoxazolyl  and  isoxazolidinyl 
sulfonates and sulfonamides in a regio- and stereoselective fashion; which a selection 
of  them  were  found  to  display  anti-HIV  activity,  and  demonstrated  the  general 
application of PFP sulfonates and sulfonamides as potential therapeutic agents. 
 
Cycloaddition between PFP-1-bromoethenesulfonate 115 and nitrile oxides furnished 
a collection of isoxazoles in a regiospecific fashion, forming the the 3,5-substituted 
isoxazole PFP sulfonate esters  as verified by NMR and x-ray crystallography. While 
all nitrile oxide cycloadditions proceed under mild conditions (2.5 eq NEt3, Toluene, 
RT, 1 h), cycloadducts containing electron donating groups (p-OMePh, p-ClPh, p-
BrPh,  o-ClPh  and  o-BrPh)  were  obtained  in  higher  yields  than  those  containing 
electron  withdrawing  groups  (p-NO2Ph).  It  was  also  evident  that  the  reaction 
proceeded via nitrile oxides rather than hydroximoyl chlorides, and the rate of the 
cycloaddition  is  directly  influenced  by  the  amount  of  NEt3  used.  Subsequent 
aminolysis were also proceeded smoothly under THF reflux and good yields were 
obtained; however, aminolysis using secondary amine and aromatic amine generated 
relatively  poor  yields,  therefore  tetrabutylammonium  chloride  (TBAC)  was 
introduced to act as a nucleophilic catalyst, and reaction period  was prolonged  in 
order  to  obtain  sulfonamides  in  moderate  yields.  Nontheless,  diversity  oriented 
synthesis of sulfonates and sulfonamides were achieved. 
 
In the HIV study, a selection of isoxazolidinyl PFP sulfonate esters and sulfonamides 
display  excellent  anti  HIV-1  activity  at  100-250  µM  concentration.  In  addition, 
healthy cell growth rate, cell viability and life cycle were also preserved, leading to a 
specific  candidate  for  viral  target.  During  SAR  study,  molecules  containing  4-
methylbenzylsulfonamide  group  and  2-halophenyl  group  appeared  to  exhibit  the 
highest potency;  where  upon  modification on the  sulfonamides  moiety  for  target 
identification,  the  anti-HIV  activity  was  lost,  therefore  suggesting  that  the 
sulfonamide group is crucial in exhibiting anti-HIV activity. Later it was envisaged 
that tagging of an immobilized bead on the isoxazolidine nitrogen would provide a 
suitable  alternative  in  target  identification.  Upon  synthesis  of  the  immobilized 
medium for target identification, epoxy-activated sepharose 6B posed a challenging 85 
 
task;  however  this  problem  was  resolved  by  incorporating  D-biotin  in  place  of 
epoxy-activated  sepharose  6B,  and  target  identification  is  currently  being 
investigated. 
 
If the target identification suggests that isoxazolidine nitrogen linkage remove anti-
HIV activity, future work would entail linking the immobilized bead onto the 5-C 
position on  the  isoxazolidine ring.  However,  if the target enzyme/protein can be 
successfully identified, a suggestion for future work would be to study the binding 
mechanism of the target, and subsequent structure-modification of our molecules to 
enhance binding, in order to achieve higher potency. 
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4  Experimental 
4.1  General experimental 
All the reagents and solvents  were  used  as received without  further purification, 
unless  otherwise  stated.  Reactions  were  carried  out  under  argon  and  anhydrous 
solvents unless otherwise stated. Reactions were monitored by TLC on SIL G/UV254 
silica plates purchased from VWR, and were visualized under UV lamp operating at 
short and  long wavelength ranges with alkaline potassium permanganate solution. 
Flash column chromatography was  carried out  with Kieselgel 60M 0.04/0.063nm 
(230-400 mesh) silica gel. All yields quoted are isolated yields, and when multiple 
products are obtained data are presented in terms of order isolated. 
 
Microwave reactions were carried out in the CEM Discover™ system. Proton (
1H) 
NMR spectra were recorded at 300 MHz and 500 MHz on a Bruker AMX300 or 
Bruker  AMX500  MHz  spectrometer  operating  at  ambient  temperature  using  an 
internal  deuterium  lock  and  chemical  shifts  are  reported  in  parts  per  million. 
Coupling  constants  are  reported  in  Hertz  (Hz).  Carbon  (
13C)  NMR  spectra  were 
recorded at 75 MHz on a Bruker AMX300 and 125 MHz on a Bruker AMX500 MHz 
spectrometer and are reported in ppm using CDCl 3 as an internal standard. Carbon-
fluorine (
13C-
19F) coupling is also observed and recorded at 282 MHz on a Bruker 
AMX300 MHz spectrometer; however it is not quoted for pentafluorophenyl group 
due to its complex plitting pattern. Mass spectra (EI, CI and FAB) were obtained 
from VG70-SE or a MAT 900 XP spectrometer. Infrared Spectra were recorded on a 
Shimadzu FTIR-8700 spectrophotometer  using KBr disc or  using  a Perkin  Elmer 
Spectrum 100 operating in ATR mode. Infrared spectra were run as thin film or neat. 
Melting points were measured, where appropriate, with a Gallenkamp apparatus and 
are uncorrected. Elemental analysis was performed at the Department of Chemistry, 
University College London. 
4.2  Experimental procedure for Chapter 2.2 
Preparation of pentafluoropenyl ethenesulfonate (110)
92, 113 
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2-Chloroethane sulfonyl chloride 111 (10.1 g, 62.5 mmol) in dichloromethane (100 
mL) was cooled to -78 °C. To the cooled solution was added a premixed solution of 
pentafluorophenol (11.5 g, 62.5 mmol) and NEt3 (19.1 mL, 137 mmol, 2.2 eq.) in 
dichloromethane (20 mL) dropwise over 1 h. The reaction was allowed to warm to 
RT and diluted with dichloromethane (100 mL) and washed with water (100 mL), 
2M HCl (100 mL) and saturate NaHCO3 (2 x 100 mL). The organic layer was dried 
over MgSO4 and the solvent removed in vacuo. The crude residue was purified by 
flash chromatography (10% Et2O/ petroleum ether) to give the title compound as a 
white solid (13.9 g, 50.6 mmol, 81%). 
Rf 0.55 (10% Et2O/ petroleum ether); mp 23-25 °C (lit.
113 mp 25 °C); νmax (thin film, 
cm
-1) 2963, 1650, 1625, 1340, 1158.; ʴH (CDCl3, 300 MHz) 6.79 (1 H, dd, J = 16.4, 
9.8 Hz, CH), 6.53 (1 H, dd, J = 16.5,  0.7 Hz, CHHtrans), 6.34 (1 H, dd, J = 9.8, 0.7 
Hz, CHHcis); ʴC (CDCl3, 75 MHz) 133.2 (t), 131.6 (d); LRMS (ES
+) 274 (M
+, 46), 
184 (47), 136 (17), 91 (100). 
 
Preparation of ʱ-bromo pentafluoropenyl ethenesulfonate (115)
113 
 
Bromine (6.15  mL, 120  mmol, 2 eq.)  was dissolved  in  CHCl3 (30  mL) and  was 
added dropwise to the premixed solution of pentafluorophenyl ethenesulfonate 110 
(16.4 g, 60.0 mmol) and AIBN (0.60 g) in chloroform (200 mL) at 70 °C. Additional 
AIBN was added after the addition of the bromine solution and reaction was refluxed 
for 4 h followed by 48 h stirring at RT. The solvent was removed in vacuo and the 
residue was dissolved in toluene (200 mL). A premixed solution of NEt3 (6.06 g, 60.0 
mmol) in toluene (30 mL) was added to the reation solution and stirred at RT for 3 h. 
The  reaction  mixture  was  washed  with  water  and  brine,  dried  over  MgSO4  and 
solvent  was  removed  in  vacuo.  The  crude  residue  was  purified  by  flash 
chromatography (10% Et2O/petroleum ether) to give the title compound as a white 
solid (20 g, 57 mmol, 94%). 
Rf 0.51 (20% Et2O/petroleum ether); mp 37-39 °C (lit.
113 mp 37 °C); νmax (thin film, 
cm
-1) 3120, 3032, 1651, 1606, 1510, 1355, 1140; ʴH (CDCl3, 300 MHz) 7.05 (1 H, d, 
J = 3.5 Hz, CH2), 6.54 (1 H, d, J = 3.5 Hz, CH2); ʴC (CDCl3, 75 MHz) 133.7 (t), 
121.7 (s); LRMS (CI
+) 355 (M
+,
 81Br, 91), 353 (M
+, 
79Br, 91), 352 (33), 184 (100), 88 
 
155 (36); HRMS (CI
+) calcd for C8H2BrF5O3S (M
+) 352.8906, observed 352.8902 
4.2.1  Preparation of oximes 
General Procedure 1 
Aldehyde (50 mmol), Hydroxylamine.HCl (100 mmol) and NEt3 (150 mmol) were 
mixed in dichloromethane (2.4 mL/mmol) and stirred at RT for 2 h. The mixture was 
added  NaHCO3  at  0  °C  and  was  extracted  with  dichloromethane  (50  mL).  The 
organic  layer  was  dried,  filtered  and  solvent  was  removed  in  vacuo.  The  crude 
residue was purified by flash chromatography (10-20% EtOAc/ petroleum ether) and 
all products were  isolated as a single diastereoisomers as  judged by NMR unless 
otherwise stated.
124 
 
4-Methoxybenzoxime (117a)
113, 167 
 
According to general procedure 1 to give the title compound as a white solid and as a 
16:1 diastereo-mixture (6.1 g, 40 mmol, 80%).  
Rf 0.30 (20% EtOAc/petroleum ether); mp 66-67 °C (lit.
167 mp 64 °C);  νmax (thin 
film, cm
-1) 3072, 2922, 1608, 1516; ʴH(CDCl3, 300 MHz) 8.93 (1 H, br s, OH), 8.11 
(1 H, s, CHN) 7.53 (2 H, d, J = 9.5 Hz, ArH), 6.89 (2 H, d, J = 9.5 Hz, ArH), 3.82 (3 
H, s, OCH3); ʴC (CDCl3, 75 MHz) 161.1 (s), 149.9 (d), 128.5 (d), 124.5 (s), 114.2 
(d), 55.3 (q); LRMS (EI) 151 (M
+•, 100), 108 (14); HRMS (EI) calcd for C8H9NO2 
(M
+•) 151.0627, observed 151.0629 
 
Benzoxime (117b)
168 
 
According to general procedure 1 to give the title compound as a white solid (3.9 g, 
32 mmol, 66%). 
Rf 0.67 (20% EtOAc/petroleum ether); mp 34-35 °C(lit.
169 mp 35 °C); νmax (thin 
film, cm
-1) 3242, 3062, 2983, 1630; ʴH (CDCl3, 300 MHz) 9.14 (1 H, br s, OH), 8.11 
(1 H, s, CHN), 7.60 (2 H, t, J = 6.4 Hz, ArH), 7.39-7.41 (3 H, m, ArH); ʴC (CDCl3, 
75 MHz) 150.4 (d), 131.9 (s), 130.1 (d), 128.8 (d), 127.1 (d); LRMS (EI) 121 (M
+•, 89 
 
100%), 103 (33), 94 (51); HRMS (EI) calcd for C7H7NO(M
+•) 121.0522, observed 
121.0518 
 
4-Chlorobenzoxime (117c)
168 
 
According to general procedure 1 to give the title compound as a white solid (6.8 g, 
44 mmol, 87%). 
Rf 0.53 (20% EtOAc/petroleum ether); mp 112-114 °C (lit.
170 mp 111 °C); νmax (thin 
film, cm
-1) 3311, 3311, 2997, 1595; ʴH (CDCl3, 300 MHz) 8.32 (1 H, br s, OH), 8.11 
(1 H, s, CHN), 7.51 (2 H, d, J = 8.4 Hz, ArH), 7.36 (2 H, d, J = 8.3 Hz, ArH); ʴC 
(CDCl3, 75 MHz) 149.3 (d), 135 9 (s), 130.4 (s), 129.1 (d), 128.2 (d); LRMS (EI) 
157 (M
+•, 
37Cl, 30), 155, (M+, 
35Cl, 100), 112 (75); HRMS (EI) calcd for C7H6ClNO 
(M
+•) 155.0132, observed 155.0129 
 
3-Chlorobenzoxime (117d)
171, 172 
 
According to general procedure 1 to give the title compound as a white solid and as a 
21:1 diastereo-mixture (7.2 g, 46 mmol, 93%). 
Rf 0.22 (10% EtOAc/petroleum ether); mp 69-71 °C (lit.
173 mp 72 °C); νmax (thin 
film, cm
-1) 3558, 3319, 3053, 2985, 1598; ʴH (CDCl3, 300 MHz) 8.29 (1 H, br s, 
OH), 8.10 (1 H, s, CHN), 7.59 (1 H, s, ArH), 7.44 (1 H, d, J = 7.1 Hz, ArH), 7.29-
7.39 (2 H, m, ArH); ʴC (CDCl3, 75 MHz) 149.2 (d), 134.9 (s), 133.8 (s), 130.0 (d), 
127.1 (d), 126.8 (d), 125.3 (d); LRMS (EI) 157 (M
+•, 
37Cl, 28), 155 (M
+, 
35Cl, 100), 
128  (39),  112  (32),  111  (29),  75  (38);  HRMS  (EI)  calcd  for  C7H6ClNO  (M
+•) 
155.0132, observed 155.0139 
 
2-Chlorobenzoxime (117e)
172 
 
According to general procedure 1 to give the title compound as a white solid (6.8 g, 90 
 
44 mmol, 87%). 
Rf 0.53 (20% EtOAc/petroleum ether); mp: 74-75 °C (lit.
174 mp 75 °C); νmax (thin 
film, cm
-1) 3562, 3319, 3053, 2985; ʴH(CDCl3, 300 MHz) 8.75 (1 H, br s, OH), 8.51 
(1 H, s, CHN), 7.80~7.83 (1 H, m, ArH), 7.26~7.40 (3 H, m, ArH); ʴC(CDCl3, 75 
MHz) 147.6 (d), 134.0  (s), 131.1 (d), 130.0 (s), 129.7 (d), 127.2 (d), 127.1 (d); 
LRMS (CI
+) 157 (M
+, 
37Cl, 37), 155 (M
+, 
35Cl, 100), 138 (50), 112 (31), 91 (28); 
HRMS (CI
+) calcd for C7H6ClNO(MH
+) 156.0216, observed 156.0210 
 
4-Bromobenzoxime (117f) 
 
According to general procedure 1 to give the title compound as a white solid (9.6 g, 
48 mmol, 96%). 
Rf 0.64 (20% EtOAc/petroleum ether); mp 114-118 °C; νmax (thin film, cm
-1) 3562, 
3315, 3053, 2987, 1595; ʴH (CDCl3, 300 MHz) 8.64 (1 H, br s, OH), 8.11 (1 H, s, 
CHN), 7.53 (2 H, d, J = 8.5 Hz, ArH), 7.44 (2 H, d, J = 8.5 Hz, ArH) ; ʴC (CDCl3, 75 
MHz) 149.4 (d), 132.1 (d), 130.8 (s), 128.5 (d), 124.3 (s); LRMS (EI) 201 (M
+•, 
81Br, 
98),  199  (M
+, 
79Br,  100),  156  (45),  102  (37),  75  (43);  HRMS  (EI)  calcd  for 
C7H6BrNO (M
+•) 198.9627, observed 198.9622 
 
3-Bromobenzoxime (117g) 
 
According to general procedure 1 to give the title compound as a white solid (8.6 g, 
43 mmol, 86%). 
Rf 0.24 (10% EtOAc/petroleum ether); mp 70-72 °C; νmax (thin film, cm
-1) 3562, 
3319, 3053, 2985; ʴH (CDCl3, 300 MHz) 8.09 (1 H, s, CHN), 7.40 (1 H, s, ArH), 
7.50 (2 H, d, J = 7.9 Hz, ArH), 7.26 (1 H, t, J = 7.9 Hz, ArH); ʴC (CDCl3, 75 MHz) 
133.9 (s), 132.6 (d), 132.5 (d), 129.9 (d), 128.9 (d), 125.1 (d), 123.1 (s); LRMS (EI) 
201 (M
+•, 
81Br, 7), 199 (M
+•, 
79Br, 7), 183 (46), 181 (44), 102 (50); HRMS (EI) calcd 
for C7H6BrNO (M
+•) 198.9627, observed 198.9621 
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2-Bromobenzoxime (117h) 
 
According to general procedure 1 to give the title compound as a white solid and as a 
19:1 diastereo-mixture (9.4 g, 47 mmol, 95%). 
Rf 0.14 (10% EtOAc/petroleum ether); mp 100-103 °C; νmax (thin film, cm
-1) 3562, 
3298, 3053, 2985; ʴH (CDCl3, 300 MHz) 8.68 (1 H, br s, OH), 8.55 (1 H, s, CHN), 
7.80 (1 H, dd, J = 7.7, 1.7 Hz, ArH), 7.58 (1 H, dd, J = 7.7, 1.6 Hz, ArH), 7.32 (1 H, 
t, J = 7.5 Hz, ArH), 7.24 (1 H, td, J = 7.6, 1.6 Hz, ArH); ʴC (CDCl3, 75 MHz) 149.8 
(d), 133.2 (d), 131.3 (d), 127.6 (d), 127.5 (s), 127.5 (d), 123.9 (s); LRMS (EI) 201 
(M
+•, 
81Br, 56), 199 (M
+•, 
79Br, 58), 120 (100), 102 (60), 92 (26), 76 (36), 75 (42), 65 
(42); HRMS (EI) calcd for C7H6BrNO (M
+•) 198.9627, observed 198.9622 
 
2-Fluorobenzoxime (117i)
175 
 
According to general procedure 1 to give the title compound as a white solid (5.9 g, 
42 mmol, 86%). 
Rf 0.15 (10% EtOAc/petroleum ether); mp 65-66 °C (lit.
176 mp 65 °C);  νmax (thin 
film, cm
-1) 3570, 3300, 3055, 1614; ʴH (CDCl3, 300 MHz) 9.12 (1 H, br s, OH), 8.39 
(1 H, s, CHN), 7.72-7.84 (1 H, m, ArH), 7.37 (1 H, t, J = 7.4 Hz, ArH), 7.16-7.25 (1 
H, m, ArH), 7.08 (1 H, d, J = 7.5 Hz, ArH); ʴC (CDCl3, 75 MHz) 160.8 (s, JCF = 
252.6 Hz), 144.4 (d, JCF = 3.2 Hz), 131.6 (d, JCF = 8.8 Hz), 127.3 (d), 124.5 (d, JCF = 
3.5 Hz), 119.8 (s, JCF = 10.6 Hz), 116.1 (d, JCF = 21.1 Hz); LRMS (EI) 139 (M
+•, 25), 
121  (100),  111  (30),  94  (72);  HRMS  (EI)  calcd  for  C7H6FNO  (M
+•)  139.0428, 
observed 139.0430 
 
4-Nitrobenzoxime (117j)  
 
According to general procedure 1 to give the title compound as a yellow solid (7.6 g, 
46 mmol, 91%). 
Rf 0.26 (20% EtOAc/petroleum ether); mp 129-131 °C; νmax (thin film, cm
-1) 3556, 92 
 
3300, 3053, 2987, 1601, 1558, 1361; ʴH (CDCl3, 300 MHz) 8.24 (2 H, d, J = 6.9 Hz, 
ArH), 8.20 (1 H, s, CHN), 7.90 (1 H, br s, OH), 7.75 (2 H, d, J = 6.9 Hz, ArH); ʴC 
(CDCl3, 75 MHz) 149.4 (s), 148.0 (s), 140.9 (d), 128.4 (d), 124.8 (d); LRMS (EI) 
166 (M
+•, 35), 136 (100), 65 (35); HRMS (EI) calcd for C7H6N2O3 (M
+•) 166.0372, 
observed 166.0376 
 
2-Naphthaloxime (17l)
177 
 
According to general procedure 1 to give the title compound as a white solid (7.9 g, 
46 mmol, 92%). 
Rf 0.30 (20% EtOAc/petroleum ether); mp 152-154 °C (lit.
178 mp 154 °C); νmax (thin 
film, cm
-1) 3265, 3053, 2929, 2854; ʴH (CDCl3, 300 MHz) 8.30 (1 H, s, CHN), 7.89 
(1 H, s, ArH), 7.62-7.80 (4 H, m, ArH), 7.52-7.59 (2 H, m, ArH); ʴC (CDCl3, 75 
MHz) 166.1 (s), 157.2 (d), 151.0 (s), 134.8 (s), 129.8 (d), 129.4 (d), 129.2 (d), 128.9 
(d), 127.9 (d), 127.7 (d), 123.9 (d); LRMS (EI) 171 (M
+•, 100), 153 (47), 144 (54), 
128  (49),  127  (50),  115  (32);  HRMS  (EI)  calcd  for  C11H9NO  (M
+•)  171.0678, 
observed 171.0680 
 
2-Iodobenzoxime (117m)
174 
 
According to general procedure 1 to give the title compound as a cream solid (1.0 g, 
4.2 mmol, 97%). 
Rf 0.23 (20% EtOAc/petroleum ether); mp 105-107 °C (lit.
176 mp 107 °C); νmax (thin 
film, cm
-1) 3170, 2057, 2995; ʴH (CDCl3, 300 MHz) 8.42 (1 H, s, CHN), 7.86 (1 H, 
dd, J = 8.0, 1.6 Hz, ArH), 7.75 (1 H, dd, J = 8.0, 1.3 Hz, ArH), 7.35 (1 H, t, J = 7.8 
Hz, ArH), 7.07 (1H, td, J = 8.3, 1.6 Hz, ArH); ʴC (CDCl3, 75 MHz) 154.0 (s), 139.8 
(d), 134.3 (s), 131.4 (d), 128.4 (d), 127.4 (d), 98.8 (d); LRMS (EI) 247 (M
+•, 95), 
120  (100),  103  (90);  HRMS  (EI)  calcd  for  C7H6INO  (M
+•)  246.9488,  observed 
246.9492 
 
 93 
 
2-Furoxime (117n)
179 
 
According to general procedure 1 to give the title compound as a white solid and as a 
48:1 diastereo-mixture (2.6 g, 23 mmol, 46%). 
Rf 0.17 (10% EtOAc/petroleum ether); mp 92-94 °C (lit.
180 mp 92 °C);  νmax (thin 
film, cm
-1) 3230, 2960, 2929, 2869; ʴH (CDCl3, 300 MHz) 10.34 (1 H, s, OH), 7.44-
7.61 (2 H, m, CHN & FurylH), 7.30 (1 H, t, J = 3.1 Hz, FurylH), 6.65 (1 H, m, 
FurylH); ʴC (CDCl3, 75 MHz) 145.1 (s), 143.5 (d), 137.0 (d), 118.2 (d), 112.3 (d); 
LRMS  (CI)  112  (MH
+,  68),  94  (100);  HRMS  (CI)  calcd  for  C5H5NO2  (MH
+) 
112.0398 observed 112.0397 
 
Cyclohexanal oxime (117o)
181 
 
According to general procedure 1 to give the title compound as a white solid and as a 
8:1 diastereo-mixture (4.4 g, 35 mmol, 70%). 
Rf 0.54 (20% EtOAc/petroleum ether); mp 88-91 °C (lit.
181 mp 90 °C);  νmax (thin 
film, cm
-1) 3258, 3111, 1653; ʴH (CDCl3, 300 MHz) 9.25 (1 H, br s, OH), 7.29 (1 H, 
d, J = 6.2 Hz, CHN), 2.18-2.25 (1 H, m, CH), 1.23-1.77 (10 H, m, CH2); ʴC (CDCl3, 
75 MHz) 155.9 (d), 38.5 (d), 30.2 (t), 29.4 (t), 25.4 (t); LRMS (EI) 128 (MH
+•, 26), 
127(M
+, 100); HRMS (EI) calcd for C7H13NO (M
+•) 127.0991, observed 127.0993 
 
Pentoxime (117p)
182 
 
According to general procedure 1 to give the title compounds as a white solid and as 
a 1:1 diastereo-mixture (2.3 g, 23 mmol, 46%). 
Rf 0.14 and 0.10 (10% EtOAc/petroleum ether); mp 49-52 °C (lit.
182 mp 51 °C); νmax 
(thin film, cm
-1) 3249, 3055, 2960, 2864; ʴH (CDCl3, 300 MHz) 10.12 (1 H, br s, 
OH), 9.81 (1 H, br s, OH), 7.34 (1 H, t, J = 6.2 Hz, CHN), 6.62 (1 H, t, J = 5.4 Hz, 
CHN), 2.30 (2 H, q, J = 5.4 Hz, NCCH2), 2.14 (2 H, q, J = 6.2 Hz, NCCH2), 1.31-
1.40 (8 H, m, NCCCH2CH2), 0.85 (3 H, t, J = 7.2 Hz, CH3), 0.84 (3 H, t, J = 7.2 Hz, 
CH3); ʴC (CDCl3, 75 MHz) 152.6 (d), 152.1 (d), 29.0 (t), 28.6 (t), 28.1 (t), 24.6 (t), 
22.6 (t), 22.4 (t), 13.6 (q) 13.5 (q); LRMS (EI) 102 (MH
+•, 100 ), 97 (33), 84 (66), 69 94 
 
(65); HRMS (EI) calcd for C5H11NO (MH
+•) 102.0918, observed 102.0918 
4.2.2  Preparation of ʱ-chloroaldoximes 
General procedure 2 
Oxime  117  (30  mmol)  was  dissolved  in  dry  DMF  (0.5  mL/mmol).  A  premixed 
solution of NCS (30 mmol) in dry DMF (15 mL) was added to the mixture at such a 
rate that the internal temperature did not rise above 40 °C. After the addition of NCS 
solution the reaction was stirred at RT for 1 h. The reaction mixture was added Et2O 
(100 mL) and washed with water. The organic layer was dried with MgSO4, filtered 
and  solvent  was  removed  in  vacuo.  All  products  were  collected  as  a  single 
diastereoisomer as judged by NMR unless otherwise stated.
167 
 
ʱ-Chloro-4-methoxybenzoxime (116a)
183 
 
According to general procedure 2, 117a gave the title compound as a yellow solid 
(5.2 g, 28 mmol, 94%). 
Rf 0.45 (10% Et2O/petroleum ether); mp 82-84 °C (lit.
184 mp 86 °C); νmax (thin film, 
cm
-1) 3541, 3330, 3053, 2985, 1606, 1510; ʴH (CDCl3, 300 MHz) 8.71 (1 H, br s, 
OH), 7.78 (2 H, d, J = 8.9 Hz, ArH), 6.91 (2 H, d, J = 8.9 Hz, ArH), 3.84 (3 H, s, 
CH3); ʴC (CDCl3, 75 MHz) 161.6 (s), 140.1 (s), 128.7 (d), 124.9 (s) 113.9 (d), 55.5 
(q); LRMS (CI
+) 188 (M
+, 
37Cl, 1), 186 (M
+, 
35Cl, 3), 152 (26), 150 (75), 134 (100); 
HRMS (CI
+) calcd for C8H8ClNO2 (M
+) 186.0321, observed 186.0324 
 
ʱ-Chlorobenzoxime (116b)
182 
 
According to general procedure 2, 117b gave the title compound as a white solid (4.5 
g, 29 mmol, 98%). 
Rf 0.26 (10% Et2O/petroleum ether); mp 46-49 °C (lit.
185 mp 45 °C); νmax (thin film, 
cm
-1) 3533, 3330, 3055, 1610; ʴH (CDCl3, 300 MHz) 8.99 (1 H, br s, OH), 7.82-7.85 
(3 H, m, ArH), 7.38-7.42 (2 H, m, ArH); ʴC (CDCl3, 75 MHz) 132.2 (d), 132.1 (s),  95 
 
130.8 (d), 124.3 (d), 116.8 (d); LRMS (EI)  157 (M
+•, 
37Cl, 6), 155 (M
+•, 
35Cl, 19), 
119 (72), 105 (100);  HRMS (EI) calcd  for C7H6ClNO (M
+•) 155.0083, observed 
155.0085 
ʱ-Chloro-4-chlorobenzoxime (116c)
186 
 
According to general procedure 2, 117c gave the title compound as a white solid and 
as a 8:1 diastereo-mixture (5.5 g, 29 mmol, 96%). 
Rf 0.32 (10% Et2O/petroleum ether); mp 87-89 °C (lit.
173 mp 85 °C); νmax (thin film, 
cm
-1) 3533, 3319, 3053, 1595, 1490; ʴH (CDCl3, 300 MHz) 8.48 (1 H, br s, OH), 
7.77 (2 H, d, J = 8.8 Hz, ArH), 7.38 (2 H, d, J = 8.8 Hz, ArH); ʴC (CDCl3, 75 MHz) 
139.3 (s), 137.0 (s), 130.8 (s), 128.8 (d), 128.4 (d); LRMS (CI
+) 194 (M
+, 
37Cl
37Cl, 
0.5), 192 (M
+, 
37Cl
35Cl, 2.5), 190 (M
+, 
35Cl
35Cl, 4), 154 (50), 156 (100), 138 (39); 
HRMS (CI
+) calcd for C7H5Cl2NO (M
+) 189.9826, observed 189.9828 
 
ʱ-Chloro-3-chlorobenzoxime (116d)
187 
 
According to general procedure 2, 117d gave the title compound as a white solid and 
as a 6:1 diastereo-mixture (5.6 g, 29 mmol, 98%). 
Rf 0.32 (10% Et2O/petroleum ether); mp 69-70 °C (lit.
173 mp 69 °C); νmax (thin film, 
cm
-1) 3533, 3332, 3053, 2985, 1598; ʴH (CDCl3, 300 MHz) 8.65 (1 H, br s, OH), 
7.83 (1 H, s, ArH), 7.73 (1 H, d, J = 7.5 Hz, ArH), 7.42 (1 H, d, J = 7.3 Hz, ArH), 
7.34 (1 H, t, J = 7.2 Hz, ArH); ʴC (CDCl3, 75 MHz) 138.7 (s), 134.6 s), 134.1 (s), 
130.7 (d), 129.7 (d), 127.2 (d), 125.3 (d); LRMS (CI
+) 194 (M
+, 
37Cl
37Cl, 3), 192 
(M
+, 
37Cl
35Cl, 14), 190 (M
+, 
35Cl
35Cl, 23), 155 (92), 154 (37), 139 (40), 137 (42), 125 
(30),  123  (31),  111  (42);  HRMS  (CI
+)  calcd  for  C7H5Cl2NO  (M
+)  189.9826, 
observed 189.9820 
 
 
 96 
 
ʱ-Chloro-2-chlorobenzoxime (116e)
187 
 
According to general procedure 2, 117e gave the title compound as a yellow solid 
(5.5 g, 29 mmol, 96%). 
Rf 0.25 (10% Et2O/petroleum ether); mp  50-52 °C (lit.
188 mp 54 °C); νmax (thin film, 
cm
-1) 3329, 3053, 2985, 1593; ʴH (CDCl3, 300 MHz) 9.36 (1 H, br s, OH), 7.31-7.49 
(4 H, m, ArH); ʴC (CDCl3, 75 MHz) 137.2 (s), 133.7 (s), 133.1 (s), 131.5 (d), 131.1 
(d), 130.3 (d), 126.9 (d); LRMS (CI
+) 194 (M
+, 
37Cl
37Cl, 5), 192 (M
+, 
37Cl
35Cl, 26), 
190 (M
+, 
35Cl
35Cl, 42), 156 (100), 154 (92), 153 (62), 126 (52); HRMS (CI
+) calcd 
for C7H5Cl2NO (M
+) 189.9826, observed 189.9820 
 
ʱ-Chloro-4-bromobenzoxime (116f)
189 
 
According to general procedure 2, 117f gave the title compound as a white solid and 
as a 6:1 diastereo-mixture (6.5 g, 28 mmol, 93%). 
Rf 0.29 (10% Et2O/petroleum ether); mp 89-93 °C (lit.
190 mp 89 °C); νmax (thin film, 
cm
-1) 3533, 3335, 3053, 1596; ʴH (CDCl3, 300 MHz) 8.73 (1 H, br s, OH), 7.69 (2 H, 
d, J = 8.6 Hz, ArH), 7.53 (2 H, d, J = 8.6 Hz, ArH); ʴC (CDCl3, 75 MHz) 139.6 (s), 
131.8 (s), 131.2 (s), 132.1 (d), 128.6 (d); LRMS (CI
+) 236 (M
+, 
81Br
37Cl, 16), 234 
(M
+, 
81/79Br
37/35Cl, 22), 232 (M
+, 
79Br
35Cl, 5), 156 (100), 154 (92), 153 (62), 126 
(52); HRMS (EI) calcd for C7H5BrClNO (M
+•) 232.9237, observed 232.9234 
 
ʱ-Chloro-3-bromobenzoxime (116g) 
 
According to general procedure 2, 117g gave the title compound as a white solid and 
as a 7:1 diastereo-mixture (6.9 g, 29 mmol, 98%). 
Rf 0.38 (10% Et2O/petroleum ether); mp 71-72 °C; νmax (thin film, cm
-1) 3533, 3319, 97 
 
3053, 2985, 1597; ʴH (CDCl3, 300 MHz) 8.53 (1 H, br s, OH), 7.99 (1 H, s, ArH), 
7.77 (1 H, dd, J = 7.9, 0.9 Hz, ArH), 7.57 (1 H, dd, J = 7.9, 1.0 Hz, ArH), 7.28 (1 H, 
t, J = 7.9 Hz, ArH); ʴC (CDCl3, 75 MHz) 138.7 (s), 134.3 (s), 133.7 (d), 130.1 (d), 
130.0  (d),  125.8  (d),  122.6  (s);  LRMS  (EI)  236  (M
+•, 
81Br
37Cl,  36),  234  (M
+•, 
81/79Br
37/35Cl, 51), 232 (M
+•, 
79Br
35Cl, 12), 102 (26), 90 (100); HRMS (EI) calcd for 
C7H5BrClNO (M
+•) 232.9237, observed 232.9241 
ʱ-Chloro-2-bromobenzoxime (116h) 
 
According to general procedure 2, 117h gave the title compound as a yellow solid 
(6.5 g, 28 mmol, 92%). 
Rf 0.34 (10% Et2O/petroleum ether); mp 66-68 °C; νmax (thin film, cm
-1) 3286, 3058, 
2977, 1589; ʴH (CDCl3, 300 MHz) 9.82 (1 H, br s, OH), 7.60 (1 H, dd, J = 7.7, 1.4 
Hz, ArH), 7.43 (1 H, d, J = 7.6 Hz, ArH), 7.33 (1 H, td, J = 7.6, 1.1 Hz, ArH), 7.25 (1 
H, td, J= 7.5, 1.5 Hz, ArH); ʴC (CDCl3, 75 MHz) 138.3 (s), 134.5 (s), 133.5 (d), 
131.7 (d), 131.3 (d), 127.6 (d), 122.2 (s); LRMS (EI) 236 (M
+•, 
81Br
37Cl, 3), 234 
(M
+•, 
81/79Br
37/35Cl, 3), 232 (M
+•, 
79Br
35Cl, 1), 199 (100), 197 (93), 102 (26), 90 (91), 
88 (49); HRMS (EI) calcd for C7H5BrClNO (M
+•) 232.9237, observed 232.9237 
 
ʱ-Chloro-2-fluorobenzoxime (116i) 
 
According to general procedure 2, 117i gave the title compound as a white solid (5.1 
g, 29 mmol, 98%). 
Rf 0.32 (10% Et2O/petroleum ether);  mp 98-100 °C; νmax (thin  film, cm
-1) 3531, 
3330, 3055, 2987, 1616; ʴH (CDCl3, 300 MHz) 9.22 (1 H, br s, OH), 7.69 (1 H, td, J 
= 7.6, 1.8 Hz, ArH), 7.44 (1 H, dddd, J = 7.6, 7.4, 5.0 (F), 1.8 Hz, ArH), 7.23 (1 H, 
td, J = 7.6, 1.2 Hz, ArH), 7.16 (1 H, ddd, J = 11.0 (F), 7.6, 1.2 Hz, ArH); ʴC (CDCl3, 
75 MHz) 159.9 (s, JCF =  255.6 Hz), 135.4 (s, JCF =  5.6 Hz), 132.2 (d, JCF =  8.5 Hz), 
130.8 (s), 124.3 (d, JCF =  3.8 Hz), 120.9 (d, JCF =  10.3 Hz), 116.6 (d, JCF =  22.1 
Hz); LRMS (FAB
+) 174 (M
+, 37), 154 (100); HRMS (FAB
+) calcd for C7H5FClNO 
(M
+) 174.0122, observed 174.0118 98 
 
ʱ-Chloro-4-nitrobenzoxime (116j)  
 
According to general procedure 2, 117j gave the title compound as a yellow solid 
(5.1 g, 25 mmol, 87%). 
Rf 0.02 (10% Et2O/petroleum ether); mp 126-129 °C; νmax (thin film, cm
-1) 3386, 
2987, 1593, 1360; ʴHv(CDCl3, 300 MHz) 8.27 (2 H, d, J = 7.2 Hz, ArH), 8.05 (2 H, 
d, J = 7.2 Hz, ArH); ʴC (CDCl3, 75 MHz) 138.7 (s), 132.2 (s), 131.8 (s) 128.0 (d), 
123.6 (d); LRMS (EI) 202 (M
+•, 
37Cl, 25), 200 (M
+•, 
35Cl, 83), 166 (85), 164 (100); 
HRMS (EI) calcd for C7H5N2O3(M
+•) 199.9983, observed 199.9977 
 
ʱ-Chloronaphthyloxime (116l)
186 
 
According to general procedure 2, 117l gave the title compound as a white solid (4.3 
g, 21 mmol, 99%). 
Rf 0.25 (10% Et2O/petroleum ether); mp 113-115 °C (lit.
191 mp 127 °C); νmax (thin 
film, cm
-1) 3480, 3332, 3053, 2987, 1603; ʴH (CDCl3, 300 MHz) 8.93 (1 H, br s, 
OH), 8.34 (1 H, s, ArH), 7.94 (2 H, d, J = 8.6 Hz, ArH), 7.83 (2 H, d, J = 3.6 Hz, 
ArH), 7.55 (2 H, t, J = 8.6 Hz, ArH); ʴC (CDCl3, 75 MHz) 151.1 (s), 140.7 (s), 134.3 
(s), 132.7 (s), 128.9 (d), 128.3 (d), 128.2 (d), 127.9 (d), 127.7 (d), 126.8 (d), 123.3 
(d); LRMS (EI) 207 (M
+•, 
37Cl, 4), 205 (M
+•, 
35Cl, 12), 169 (73), 153 (66), 140 (100), 
114 (33); HRMS (EI) calcd for C11H8ClNO (M
+•) 205.0288, observed 205.2792 
 
ʱ-Chloro-2-iodobenzoxime (116m) 
 
According  to general procedure 2, 117m  gave the title compound as a yellow oil 
(0.60 g, 2.13 mmol, 99%). 
Rf 0.32 (10% Et2O/petroleum ether);  νmax (thin  film, cm
-1) 3271, 3052, 2861; ʴH 
(CDCl3, 300 MHz) 9.68 (1 H, br s, OH), 7.88 (1 H, d, J = 7.7 Hz, ArH), 7.34-7.43 (2 99 
 
H,  m, ArH), 7.08-7.19 (1 H, m, ArH); ʴC  (CDCl3, 75 MHz) 139.9 (d), 139.5 (s), 
138.5 (s), 131.5 (d), 130.6 (d), 128.3 (d), 96.3 (s); LRMS (EI) 283 (M
+•, 
37Cl, 5), 281 
(M
+•, 
35Cl,  22),  245  (100),  229  (21),  203  (28),  102  (53);  HRMS  (EI)  calcd  for 
C7H5ClNO (M
+•) 280.9098, observed 280.9088 
 
ʱ-Chloro-cyclohexyloxime (116o) 
 
According to general procedure 2, 117o gave the title compound as a yellow oil and 
as a 7:1 diastereo-mixture (1.9 g, 12 mmol, 94%). 
Rf 0.38 (10% Et2O/petroleum ether); νmax (thin  film, cm
-1)  3331, 3053, 2937;  ʴH 
(CDCl3, 300 MHz) 9.48 (1 H, br s, OH), 2.38-2.46 (1 H, m, CH), 1.65-1.90 (5 H, m, 
CH2), 1.06-1.41 (5 H, m, CH2); ʴC (CDCl3, 75 MHz) 146.6 (s), 45.3 (d), 30.2 (t), 
30.6 (t), 25.7 (t), 25.6 (t), 25.3 (t); LRMS (CI
+) 250 (2M-2Cl, 100), 162 (M+H, 7), 
151 (13), 144 (21), 126 (16) 
 
ʱ-Chloropentoxime (116p) 
 
According to general procedure 2, 117p gave the title compound as a yellow oil and 
as a 4:1 diastereo-mixture (0.91 g, 6.7 mmol, 89%). 
Rf 0.35 (10% Et2O/petroleum ether); νmax (thin  film, cm
-1) 3332, 2962, 2935;  ʴH 
(CDCl3, 300 MHz) 9.06 (1 H, br s, OH), 2.50 (2 H, t, J = 7.2 Hz, ClCCH2), 1.62 (2 
H, quin, J = 7.2 Hz, ClCCCH2), 1.32 (2 H, hex, J = 7.3 Hz, ClCCCCH2), 0.90 (3 H, 
t, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 142.9 (s), 36.3 (t), 28.2 (t), 21.6 (t), 13.6 
(q); LRMS (EI) 137 (M
+•, 
37Cl, 6), 135 (M
+•, 
35Cl, 21), 114 (22), 101 (100), 84 (91); 
HRMS (EI) calcd for C5H10ClNO (M
+•) 135.0396, observed 135.0393 
4.2.3  Preparation of nitrones 
N-(
tButyl)-C-phenylnitrone (113) 
 100 
 
N-
tBuNHOH 112 (0.63 g, 5.0 mmol), benzaldehyde (0.53 g, 5.0 mmol) and NaHCO3 
(1.3  g,  15  mmol,  3  eq.)  were  mixed  in  dichloromethane  (20  mL)  and  refluxed 
overnight. NaHCO3 was filtered off by gravity and solvent was removed in vacuo. 
The remaining solid was recrystallized from EtOAc and petroleum ether to give the 
title compound as a cream solid and as a single diastereoisomer as judged by NMR 
(0.39 g, 2.2 mmol, 44%). 
νmax (thin  film, cm
-1) 3049, 2978, 2937, 1577;  mp 127-129 °C; ʴH  (CDCl3, 300 
MHz) 8.28 (2 H, d, J = 9.7 Hz, ArH), 7.56 (1 H, s, CH), 7.38-7.44 (3 H, m, ArH), 
1.61 (9 H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 131.2 (s), 130.1 (d), 129.6 (d), 128.8 
(d), 128.4 (d), 34.2 (s), 28.3 (q); LRMS (CI
+) 178 (M+H, 100), 162 (4), 136 (1), 122 
(75); HRMS (CI
+) calcd for C11H16NO (M+H) 178.1226, observed 178.1230 
4.2.4  Preparation of isoxazolidines-4-PFP sulfonates 
2-(
tButyl)-3-phenylisoxazole-4-pentafluorophenyl sulfonate ester (114) 
 
To a solution of pentafluorophenyl ethanesulfonate 110 (0.27 g, 1.0 mmol) in dry 
toluene (10 mL) was added N-(tert-butyl)-C-phenylnitrone 113 (0.35 g, 2.0 mmol, 2 
eq.)  and  was  refluxed  overnight.  The  crude  product  was  purified  by  flash 
chromatography (10% Et2O/petroleum ether) to give title compound as a white solid 
and as a single diastereoisomer as judged by NMR (0.23 g, 0.50 mmol, 50%). 
Rf 0.55(10% Et2O/petroleum ether);  mp 101-104 °C; νmax (thin  film, cm
-1) 3057, 
2977, 2935, 2871, 1517, 1367, 1140; ʴH (CDCl3, 300 MHz) 7.54 (2 H, dd, J = 7.9, 
1.2 Hz, ArH), 7.29-7.32 (3 H, m, ArH), 4.65 (1 H, d, J = 5.2 Hz, NCH), 4.57 (1 H, 
dd, J = 10.6, 1.8 Hz, SCHCHH), 4.40 (1H, dd, J = 10.6, 6.9 Hz, SCHCHH), 4.10-
4.15 (1H, m, SCH), 1.06 (9 H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 136.5 (s), 128.9 (d), 
128.3 (d), 127.4 (d), 73.1 (d), 65.6 (t), 64.3 (d), 60.7 (s), 26.2 (q); LRMS (EI) 451 
(M
+•, 18), 436 (20), 395 (100); HRMS (EI) calcd for C19H18F5NO4 (M
+•) 451.0871, 
observed 451.0866 
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4.2.5  Preparation of isoxazole-5- pentafluorophenyl sulfonate esters 
General procedure 3 
α-Chloroaldoxime 116 (7.2 mmol), α-bromo-pentafluorophenyl ethenesulfonate 115 
(6 mmol) and NEt3 (30 mmol) were mixed in toluene (6.9 mL/mmol) and stirred at 
RT for 1 h. The solvent was removed in vacuo and crude product was purified by 
flash  chromatography  (2-10%  Et2O/petroleum  ether).  Product  was  recrystallized 
from  EtOAc/hexane  and  all  products  were  collected  as  a  single  regioisomer  as 
judged by NMR. 
 
3-(4-Methoxyphenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118a) 
 
According to general procedure 3, 116a gave the title compound as white crystals 
(0.09 g, 0.21 mmol, 92%). 
Rf 0.32 (10% Et2O/petroleum ether); mp 133-135 °C; νmax (thin film, cm
-1) 3055, 
2987, 1612, 1309, 1130; ʴH (CDCl3, 300 MHz) 7.76 (2 H, d, J = 8.9 Hz, ArH), 7.32 
(1 H, s, IsoxH), 7.01 (2 H, d, J = 8.9 Hz, ArH), 3.87 (3 H, s, OCH3); ʴC (CDCl3, 75 
MHz)  162.6 (s), 162.1 (s), 160.3 (s), 118.8 (s), 128.5 (d), 114.7 (d), 109.4 (d), 55.5 
(q); ʴF (CDCl3, 282 MHz) -150.9 (ArF), -153.6 (ArF), -160.3 (ArF); LRMS (EI) 421 
(M
+•, 81), 174 (51), 146 (100), 92 (39); HRMS (EI) calcd for C16H8F5NO5S (M
+•) 
420.9988, observed 420.9989;  Anal. calcd C, 45.61, H, 1.91, N, 3.32,  found: C, 
45.49, H, 1.83, N, 3.12. 
 
3-Phenyl isoxazole-5-pentafluorophenyl sulfonate ester (118b) 
 
According to general procedure 3, 116b gave the title compound as white crystals 
(1.9 g, 4.9 mmol, 86%). 102 
 
Rf 0.26 (10% Et2O/petroleum ether); mp 105-107 °C; νmax (thin film, cm
-1) 3055, 
1593, 1346, 1130; ʴH (CDCl3, 300 MHz) 7.82 (1 H, s, IsoxH), 7.38-7.53 (5 H, m, 
ArH); ʴC (CDCl3, 75 MHz) 163.1 (s), 160.7 (s), 129.0 (s), 131.0 (d), 128.9 (d), 126.6 
(d),  109.6  (d);  ʴF  (CDCl3,  282  MHz)  -151.0  (ArF),  -153.6  (ArF),  -160.2  (ArF); 
LRMS (EI) 391 (M
+•, 40), 238 (31), 178 (100); HRMS (EI) calcd for C15H6F5NO4S 
(M
+•) 390.9932, observed 390.9934 
 
3-(4-Chlorophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118c) 
 
According to general procedure 3, 116c gave the title compound as white crystals 
(2.2 g, 5.1 mmol, 88%). 
Rf 0.32 (10% Et2O/petroleum ether); mp 106-107 °C; νmax (thin film, cm
-1) 3055, 
1519, 1327, 1149; ʴH (CDCl3, 300 MHz) 7.78 (2 H, d, J = 8.5 Hz, ArH), 7.51 (2 H, d, 
J = 8.5 Hz, ArH), 7.37 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz)  162.1 (s), 161.4 (s), 
137.8 (s), 129.7 (d), 128.3 (d), 124.9 (s), 109.3 (d); ʴF (CDCl3, 282 MHz) -150.9 
(ArF), -153.4 (ArF), -160.0 (ArF); LRMS (EI) 427 (M
+•, 
37Cl, 30), 425 (M
+•, 
35Cl, 
89), 242 (67), 150 (100),  111  (53); HRMS (EI) calcd  for C15H5ClF5NO4S (M
+•) 
424.9493, observed 424.9483 
 
3-(3-Chlorophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118d) 
 
According to general procedure 3, 116d gave the title compound as white crystals 
(1.3 g, 3.9 mmol, 75%). 
Rf 0.3 (10% Et2O/petroleum ether); mp 93-95 °C; νmax (thin film, cm
-1) 3055, 1525, 
1324, 1136; ʴH (CDCl3, 300 MHz) 7.85 (1 H, s, ArH), 7.72 (1 H, dd, J = 7.3, 1.5 Hz, 
ArH), 7.45-7.54 (2 H, m, ArH), 7.36 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 135.5 (s), 103 
 
131.5 (s), 130.7 (d), 130.5 (s), 128.1 (d) 127.1 (d), 125.1 (d), 124.3 (s), 109.4 (d); ʴF 
(CDCl3, 282 MHz) -150.9 (ArF), -153.4 (ArF), -160.0 (ArF); LRMS (EI) 427 (M
+•, 
37Cl, 33), 425 (M
+•, 
35Cl, 100), 242 (16);  HRMS (EI)  calcd  for C15H5ClF5NO4S 
(M
+•) 424.9542, observed 424.9543 
 
3-(2-Chlorophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118e) 
 
According to general procedure 3, 116e gave the title compound as white crystals 
(2.1 g, 5.0 mmol, 87%). 
Rf 0.3 (10% Et2O/petroleum ether); mp 89-90 °C; νmax (thin film, cm
-1) 3055, 2985, 
1596, 1317, 1132; ʴH (CDCl3, 300 MHz) 7.79 (1 H, dd, J = 7.3, 1.8 Hz, ArH), 7.56 (1 
H, s, IsoxH), 7.40-7.54 (3 H, m, ArH); ʴC (CDCl3, 75 MHz) 162.8 (s), 161.7 (s), 
159.7 (s), 132.9 (s), 132.3 (d), 131.0 (d), 130.7 (d), 127.6 (d), 112.7 (d); ʴF (CDCl3, 
282 MHz) -151.0 (ArF), -153.5 (ArF), -160.1 (ArF); LRMS (EI) 427 (M
+•, 
37Cl, 18), 
425 (M
+•, 
35Cl, 45), 242 (35), 178 (100), 155 (40), 150 (79); HRMS (EI) calcd for 
C15H5ClF5NO4S (M
+•) 424.9542, observed 424.9546 
 
3-(4-Bromophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118f) 
 
According to general procedure 3, 116f gave the title compound as white crystals 
(2.5 g, 5.2 mmol, 87%). 
Rf 0.29 (10% Et2O/petroleum ether); mp 110-113 °C; νmax (thin film, cm
-1) 3055, 
1596, 1519, 1340, 1139; ʴH (CDCl3, 300 MHz) 7.72 (2 H, d, J = 8.6 Hz, ArH), 7.67 
(2 H, d, J = 8.6 Hz, ArH), 7.37 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz)  162.2 (s), 161.0 
(s), 132.7 (d), 128.4 (d), 126.1 (s), 125.4 (s), 109.3 (d); ʴF (CDCl3, 282 MHz) -151.0 
(ArF), -153.4 (ArF), -160.1 (ArF); LRMS (EI) 471 (M
+•, 
81Br, 100), 469 (M
+•, 
79Br, 
96), 336 (22), 288 (30), 186 (26), 224 (32), 196 (86), 194 (96), 157 (42); HRMS (EI) 104 
 
calcd for C15H5BrF5NO4S (M
+•) 468.8987, observed 468.8990 
 
3-(3-Bromophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118g) 
 
According to general procedure 3, 116g gave the title compound as cream coloured 
crystals (1.6 g, 3.5 mmol, 69%). 
Rf 0.18 (10% Et2O/petroleum ether); mp 106-107 °C; νmax (thin film, cm
-1) 3055, 
2987, 1525, 1367, 1134; ʴH (CDCl3, 300 MHz) 8.00 (1 H, s, ArH), 7.78 (1 H, d, J = 
7.7 Hz, ArH), 7.68 (1 H, d, J = 7.7 Hz, ArH), 7.41 (1 H, t, J = 7.7 Hz, ArH), 7.38 (1 
H, s, IsoxH); ʴC (CDCl3, 75 MHz) 162.2 (s), 162 0 (s), 153. (s), 130.8 (s), 134.4 (d), 
130.9 (d), 130.0 (d), 125.6 (d), 109.3 (d); ʴF (CDCl3, 282 MHz) -151.0 (ArF), -153.4 
(ArF), -160.1 (ArF); LRMS (EI) 471 (M
+•, 
81Br, 70), 469 (M
+•, 
79Br, 67), 288 (62), 
286 (61), 224 (63), 222 (64), 196 (42), 194 (44), 157 (62), 155 (100), 102 (35), 76 
(55),  75  (53);  HRMS  (EI)  calcd  for  C15H5BrF5NO4S  (M
+•)  468.9037,  observed 
468.9025 
 
3-(2-Bromophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118h) 
 
According to general procedure 3, 116h gave the title compound as white crystals 
(2.1 g, 4.5 mmol, 86%). 
Rf 0.25 (10% Et2O/petroleum ether); mp 100-102 °C; νmax (thin film, cm
-1) 3055, 
2985, 1519, 1199;  ʴH  (CDCl3, 300 MHz) 7.68-7.75 (2 H,  m, ArH), 7.53 (1 H, s, 
IsoxH), 7.40-7.48 (2 H, m, ArH); ʴC (CDCl3, 75 MHz) 163.1 (s), 159.6 (s), 133.9 (d), 
132.3 (d), 131.4 (d), 128.1 (d), 127.8 (s), 122.2 (s), 112.9 (d); ʴF (CDCl3, 282 MHz) -
150.9 (ArF), -153.4 (ArF), -160.1 (ArF) ; LRMS (EI) 471 (M
+•, 
81Br, 9), 469 (M
+•, 
79Br, 8), 288 (7), 286 (7), 222 (15), 220 (17), 196 (24), 194 (27), 155 (25), 115 (100), 105 
 
88 (75); HRMS (EI) calcd for C15H5BrF5NO4S (M
+•) 468.8987, observed 468.8982 
 
3-(2-Fluorophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118i) 
 
According to general procedure 3, 116i gave the title compound as white crystals (1.6 
g, 4.0 mmol, 68%). 
Rf 0.30 (10% Et2O/petroleum ether); mp 76-77 °C; νmax (thin film, cm
-1) 3055, 2987, 
1519, 1360, 1197; ʴH (CDCl3, 300 MHz) 8.05 (1 H, td, J = 7.6, 1.7 Hz, ArH), 7.54 (1 
H, s, IsoxH), 7.51-7.58 (1 H, m, ArH), 7.23-7.34 (2 H, m, ArH); ʴC (CDCl3, 75 MHz) 
161.4 (s), 159.6 (s, JCF = 259.1 Hz), 159.4 (s), 133.4 (s, JCF = 8.6 Hz), 129.0 (d), 
125.1 (d, JCF = 3.8 Hz), 116.7 (d, JCF = 22.1 Hz), 114.8 (s, JCF = 11.5 Hz), 112.0 (d, 
JCF = 11.5 Hz); ʴF (CDCl3, 282 MHz) -114.4 (ArF), -150.9 (ArF), -153.6 (ArF), -
160.3 (ArF); LRMS (EI) 409 (M
+•, 100), 226 (45), 162 (35), 134 (45), 107 (19); 
HRMS (EI) calcd for C15H5F6NO4S (M
+•) 408.9788, observed 408.9781 
 
3-(4-Nitrophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118j) 
 
According to general procedure 3, 116j gave the title compound as a cream solid (1.1 
g, 3.6 mmol, 50%). 
Rf 0.2 (20% Et2O/petroleum  ether);  mp 126-128 °C; νmax (thin  film, cm
-1) 3131, 
1567, 1516, 1341, 1198; ʴH (CDCl3, 300 MHz) 8.40 (2 H, d, J = 8.7 Hz, ArH), 8.06 
(2 H, d, J = 8.7 Hz, ArH), 7.48 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz)  162.1 (s), 161.3 
(s), 132.1 (s), 129.8 (s), 128.1 (d), 124.6 (d), 109.4 (d); ʴF (CDCl3, 282 MHz) -151.0 
(ArF), -153.1 (ArF), -159.7 (ArF); LRMS (EI) 436 (M
+•, 57), 253 (79), 189 (36), 
143 (100); HRMS (EI) calcd for C15H5F5N2O3S (M
+•) 435.9783, observed 435.9798 
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3-naphthyl-isoxazole-5-pentafluorophenyl sulfonate ester (118k) 
 
According to general procedure 3, 116k gave the title compound as white crystals 
(2.1 g, 4.8 mmol, 80%). 
Rf 0.25 (10% Et2O/petroleum ether); mp 120-121 °C; νmax (thin film, cm
-1) 3055, 
2987, 1517, 1351, 1136; ʴH (CDCl3, 300 MHz) 8.28 (1 H, s, ArH), 7.89-8.01 (4 H, m, 
ArH), 7.57-7.63 (2 H, m, ArH), 7.53 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 163.1 (s), 
160.2 (s), 140.0 (d), 134.6 (s), 130.0 (s), 129.4 (d), 128.6 (d), 127.9 (d), 127.4 (d), 
127.2 (d), 123.8 (s), 123.3 (d), 109.7 (d); ʴF (CDCl3, 282 MHz) -150.9 (ArF), -153.6 
(ArF), -160.2 (ArF); LRMS (EI) 441 (M
+•, 17), 184 (100), 74 (45), 70 (44); HRMS 
(EI) calcd for C19H8F5NO4S (M
+•) 441.0088, observed 441.0084 
 
3-(2-Iodophenyl) isoxazole-5-pentafluorophenyl sulfonate ester (118l) 
 
According to general procedure 3, 116l gave the title compound as a cream solid (0.7 
g, 1.4 mmol, 50%). 
Rf 0.25 (10% Et2O/petroleum ether); mp 109-110 °C; νmax (thin film, cm
-1) 3177, 
1515, 1321, 1156; ʴH (CDCl3, 300 MHz) 8.01 (1 H, d, J = 7.5 Hz, ArH), 7.56 (1 H, 
dd, J = 7.7, 1.8 Hz, ArH), 7.50 (1 H, t, J = 7.6 Hz, ArH), 7.45 (1H, s, IsoxH), 7.23 
(1H, td, J = 7.7, 1.7 Hz, ArH); ʴC (CDCl3, 75 MHz) 165.3 (s), 160.2 (s), 132.2 (s), 
131.9 (s), 131.1 (d), 128.7 (d), 125.2 (d), 112.8 (d), 96.1 (d); ʴF (CDCl3, 282 MHz) -
150.9 (ArF), -153.6 (ArF), -160.2 (ArF); LRMS (EI) 517 (M
+•, 68), 275 (95), 242 
(100), 203 (37), 155 (27), 155 (64);  HRMS (EI) calcd  for C15H5IF5NO4S (M
+•) 
516.8850, observed 516.8856 
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4.2.6  Preparation of isoxazole-5-sulfonic-acid-4-methylbenzene- sulfonamide 
General procedure 4 
To a stirred solution of the  isoxazole-5-pentafluorophenyl sulfonate esters 118 (0.5 
mmol)  in  dry  THF  (12  mL/mmol)  was  added  4-methylbenzylamine  (1.5  mmol) 
followed by NEt3 (0.75 mmol). The reaction was refluxed for 0.5-1 h and the mixture 
was diluted with dichloromethane (20 mL), washed with 2M HCl (20 mL), saturated 
NaHCO3 (20 mL) and water (20  mL). The organic  layer was dried over MgSO4, 
filtered, and solvent was removed in vacuo. The crude residue was purified by flash 
chromatography (20%  Et2O/petroleum ether) and all products were collected as a 
single regioisomer as judged by NMR. 
 
3-(4-Methoxyphenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119a) 
 
According to general procedure 4, 118a gave the title compound as a white solid (78 
mg, 0.22 mmol, 71%). 
Rf 0.09 (20% Et2O/petroleum ether); mp 135-137 °C; νmax (thin film, cm
-1) 3369, 
3055, 2985, 1612, 1346, 1170; ʴH (CDCl3, 300 MHz) 7.70 (2 H, d, J = 8.7 Hz, ArH), 
7.16 (2 H, d, J = 8.1 Hz, ArH), 7.10 (2 H, d, J = 8.1 Hz, ArH), 7.00 (2H, d, J = 8.6 
Hz, ArH), 6.93 (1 H, s, IsoxH), 5.19 (1 H, t, J = 5.9 Hz, NH), 4.33 (2 H, d, J = 5.9 
Hz, NCH2), 3.87 (3 H, s, OCH3), 2.25 (3 H, s, CH3); ʴC (CDCl3, 75 MHz) 165.5 (s), 
162.4 (s), 162.3 (s), 138.2 (s), 132.2 (s), 119.9 (s), 129.5 (d), 128.4 (d), 128.0 (d), 
114.6 (d), 105.7 (d), 55.4 (q), 47.4 (t), 21.0 (q); LRMS (FAB
+) 359 (M+H, 15), 307 
(27), 154 (100); HRMS (FAB
+) calcd for C18H19N2O4S (M+H) 359.1065, observed 
359.1057; Anal. calcd: C, 60.32, H, 5.06, N, 7.82, found: C, 59.99, H, 5.20, N, 8.38. 
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3-Phenyl isoxazole-5-sulfonic acid-4-methylbenzylamide (119b) 
 
According to general procedure 4, 118b gave the title compound as a white solid 
(0.18 g, 0.55 mmol, 95%). 
Rf 0.06 (20% Et2O/petroleum ether); mp 119-120 °C; νmax (thin film, cm
-1) 3363, 
3055, 2985, 1595, 1342, 1168; ʴH (CDCl3, 300 MHz) 7.74-7.77 (2 H, m, ArH), 7.47-
7.50 (3 H, m, ArH), 7.15 (2 H, d, J = 8.1 Hz, ArH), 7.08 (2 H, d, J = 8.1 Hz, ArH), 
6.96 (1 H, s, IsoxH), 5.33 (1 H, t, J = 5.8 Hz, NH), 4.34 (2 H, d, J = 5.8Hz, NCH2), 
2.23 (3 H, s, CH3); ʴC (CDCl3, 75 MHz) 162.4 (s), 161.9 (s), 147.5 (s), 138.3 (s), 
132.2 (s), 130.9 (d), 129.5 (d), 129.2 (d), 128.0 (d), 126.9 (d), 105.9 (d), 47.4 (t), 21.2 
(q); LRMS (FAB
+) 329 (M+H, 100), 237 (8); HRMS (FAB
+) calcd for C17H16N2O3S 
(M+H) 329.0959, observed 329.0951 
 
3-(4-Chlorophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119c) 
 
According  to general procedure 4, 118c gave the title compound as a white solid 
(0.16 g, 0.44 mmol, 83%). 
Rf 0.10 (20% Et2O/petroleum ether); mp 153-155 °C; νmax (thin film, cm
-1) 3375, 
3053, 2985, 1170; ʴH (CDCl3, 300 MHz) 7.70 (2 H, d, J = 8.6 Hz, ArH), 7.47 (2 H, d, 
J = 8.6 Hz, ArH), 7.15 (2 H, d, J = 8.1 Hz, ArH), 7.09 (2 H, d, J = 8.1 Hz, ArH), 6.93 
(1 H, s, IsoxH), 5.27 (1 H, t, J = 5.9 Hz, NH), 4.34 (2 H, d, J = 5.9 Hz, NCH2, 2.24 
(3 H, s, CH3); ʴC (CDCl3, 75 MHz) 166.8 (s), 161.5 (s), 138.2 (s), 137.1 (s), 132.1 
(s), 129.5 (d), 129.5 (d), 128.2 (d), 128.0 (d), 125.8 (s),  105.3 (d), 47.5 (t), 21.0 (q); 
LRMS (FAB
+) 365 (M
+, 
37Cl, 6), 363 (M
+, 
35Cl, 18), 289 (10), 220 (6), 154 (100); 
HRMS (FAB
+) calcd for C17H15ClN2O3S (M
+) 363.0570, observed 363.0579 
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3-(3-Chlorophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119d) 
 
According to general procedure 4, 118d gave the title compound as a white solid 
(0.11 g, 0.31 mmol, 72%). 
Rf 0.08 (20% Et2O/petroleum ether); mp 101-104 °C; νmax (thin film, cm
-1) 3363, 
3055, 2985, 1575, 1172; ʴH (CDCl3, 300 MHz) 7.74 (1 H, s, ArH), 7.62 (1 H, d, J = 
6.7 Hz, ArH), 7.46 (1 H, t, J = 6.7 Hz, ArH), 7.41 (1 H, d, J = 6.9 Hz, ArH), 7.14 (2 
H, d, J = 7.0 Hz, ArH), 7.08 (2 H, d, J = 7.0 Hz, ArH), 6.91 (1 H, s, IsoxH), 5.43 (1 
H, br s, NH), 4.34 (2 H, s, NCH2), 2.22 (3 H, s, CH3); ʴC (CDCl3, 75 MHz) 166.9 (s), 
161.4 (s), 138.5 (s), 135.2 (s), 132.1 (s), 130.9 (d), 130.5 (d), 129.5 (d),  129.0 (s), 
128.1 (d), 127.0 (d), 125.0 (d), 105.8 (d), 47.4 (t), 21.0 (q); LRMS (FAB
+) 365 (M
+, 
37Cl,  13),  363  (M
+, 
35Cl,  40),  289  (12),  154  (100);  HRMS  (FAB
+)  calcd  for 
C17H15ClN2O3S (M
+) 363.0570, observed 363.0576 
 
3-(2-Chlorophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119e) 
 
According to general procedure 4, 118e gave the title compound as a pale yellow 
solid (0.15 g, 4.2 mmol, 82%). 
Rf 0.06 (20% Et2O/petroleum ether); mp 84-86 °C; νmax (thin film, cm
-1) 3300, 3055, 
1353, 1170; ʴH (CDCl3, 300 MHz) 7.68 (1 H, dd, J = 7.3, 1.9 Hz, ArH), 7.52 (1 H, 
dd, J = 7.3, 1.9 Hz, ArH), 7.44 (1 H, td, J = 7.3, 2.1 Hz, ArH), 7.37 (1 H, td, J = 7.4, 
2.0 Hz, ArH), 7.15 (2 H, d, J = 8.1 Hz, ArH), 7.15 (1 H, s, IsoxH), 7.08 (2 H, d, J = 
8.1 Hz, ArH), 5.65 (1 H, t, J = 5.9 Hz, NH), 4.35 (2 H, d, J = 6.0 Hz, NCH2), 2.25 (3 
H, s, CH3); ʴC (CDCl3, 75 MHz) 165.9 (s), 161.1 (s), 138.0 (s), 132.9 (s), 132.3 (s), 
131.7 (d), 131.0 (d), 130.6 (d), 129.5 (d), 128.0 (d), 127.3 (d), 126.6 (s), 108.8 (d), 
47.4 (t), 21.0 (q); LRMS (FAB
+) 365 (M
+, 
37Cl, 30), 363 (M
+, 
35Cl, 86), 307 (34), 110 
 
289  (18),  165  (100);  HRMS  (FAB
+)  calcd  for  C17H15ClN2O3S  (M
+)  363.0570, 
observed 363.0573 
 
3-(4-Bromophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119f) 
 
According to general procedure 4, 118f gave the title compound as a white solid (0.2 
g, 0.3 mmol, 73%). 
Rf 0.06 (20% Et2O/petroleum ether); mp 156-158 °C; νmax (thin film, cm
-1) 3373, 
3053, 2985, 1170; ʴH (CDCl3, 300 MHz) 7.63 (4 H, s, ArH), 7.15 (2 H, d, J = 8.1 Hz, 
ArH), 7.09 (2 H, d, J = 8.1 Hz, ArH), 6.93 (1 H, s, IsoxH), 5.25 (1 H, t, J = 5.9 Hz, 
NH), 4.34 (2 H, d, J = 5.9 Hz, NCH2), 2.24 (3 H, s, CH3) ; ʴC (CDCl3, 75 MHz) 
166.1 (s), 161.3 (s), 138.2 (s), 132.5 (d), 132.2 (s), 129.5 (d), 128.3 (d), 128.0 (d), 
125.0 (s), 114.7 (s), 105.7 (d), 47.5 (t), 21.0 (q); LRMS (FAB
+) 409 (M
+, 
81Br, 26), 
407  (M
+, 
79Br,  26),  307  (17),  286  (33),  154  (100);  HRMS  (FAB
+)  calcd  for 
C17H15BrN2O3S (M
+) 407.0065, observed 407.0048 
 
3-(3-Bromophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119g) 
 
According  to general procedure 4, 118g gave the title compound as a white solid 
(0.18 g, 0.46 mmol, 84%). 
Rf 0.06 (20% Et2O/petroleum ether); mp 101-103 °C; νmax (thin film, cm
-1) 3367, 
3055, 2985, 1326, 1172; ʴH (CDCl3, 300 MHz) 7.89 (1 H, s, ArH), 7.61-7.68 (2 H, m, 
ArH), 7.36 (1 H, t, J = 7.8 Hz, ArH), 7.14 (2 H, d, J = 7.8 Hz, ArH), 7.08 (2 H, d, J = 
7.8 Hz, ArH), 6.90 (1 H, s, IsoxH), 5.47 (1 H, br s, NH), 4.34 (2 H, s, NCH2), 2.22 (3 
H, s, CH3); ʴC (CDCl3, 75 MHz) 166.9 (s), 161.3 (s), 138.2 (s), 133.8 (d), 132.1 (s), 
130.7 (d), 129.9 (d), 129.5 (d), 129.3 (s), 128.1 (d), 125.5 (d), 123.2 (s), 105.7 (d), 111 
 
47.4 (t), 21.0 (q); LRMS (FAB
+) 409 (M
+, 
81Br, 44), 407 (M
+, 
79Br, 46), 307 (15), 
154  (100);  HRMS  (FAB
+)  calcd  for  C17H15BrN2O3S  (M
+)  407.0065,  observed 
407.0060 
 
3-(2-Bromophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119h) 
 
According to general procedure 4, 118h gave the title compound as a waxy white 
solid (0.18 g, 0.46 mmol, 90%). 
Rf 0.10 (20% Et2O/petroleum ether); mp 102-104 °C; νmax (thin film, cm
-1) 3365, 
2052, 2985, 1170; ʴH (CDCl3, 300 MHz) 7.70 (1 H, dd, J = 7.6, 1.8 Hz, ArH), 7.61 (1 
H, dd, J = 7.6, 1.8 Hz, ArH), 7.44 (1H, td, J= 7.5, 1.8 Hz, ArH), 7.36 (1H, td, J= 7.6, 
2.1 Hz, ArH), 7.15 (1 H, s, IsoxH), 7.15 (2 H, d, J = 8.2 Hz, ArH), 7.10 (2 H, d, J = 
8.2 Hz, ArH), 5.47 (1 H, t, J = 5.8 Hz, NH), 4.36 (2 H, d, J = 5.8 Hz, NCH2), 2.29 (3 
H, s, CH3); ʴC (CDCl3, 75 MHz) 165.7 (s), 162.5 (s), 138.1 (s), 133.8 (d), 132.3 (s), 
131.8 (d), 131.4 (d), 129.5 (d), 128.7 (s), 122.2 (s), 127.9 (d), 127.8 (d), 108.9 (d), 
47.4 (t), 21.1 (q); LRMS (FAB
+) 409 (M
+, 
81Br, 91), 407 (M
+, 
79Br, 100), 219 (30), 
154  (36);  HRMS  (FAB
+)  calcd  for  C17H15BrN2O3S  (M
+)  407.0065,  observed 
407.0061 
 
3-(2-Fluorophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119i) 
 
According  to  general procedure 4, 118i gave the title compound as a white solid 
(0.13 g, 0.38 mmol, 84%). 
Rf 0.08 (20% Et2O/petroleum ether); mp 111-113 °C; νmax (thin film, cm
-1) 3365, 
3055, 2985, 1170; ʴH (CDCl3, 300 MHz) 7.96 (1 H, td, J = 5.8, 1.7 Hz, ArH), 7.50-
7.61 (1 H, m, ArH), 7.18-7.30 (2 H, m, ArH), 7.15 (2 H, d, J = 8.9 Hz, ArH), 7.12 (1 
H, s, IsoxH), 7.09 (2 H, d, J = 8.9 Hz, ArH), 5.30 (1 H, t, J = 5.9 Hz, NH), 4.34 (2 H, 112 
 
d, J = 5.9 Hz, NCH2), 2.24 (3 H, s, CH3); ʴC (CDCl3, 75 MHz) 166.4 (s), 160.1 (s, 
JCF = 252.6 Hz), 157.9 (s), 138.2 (s), 132.7 (s, JCF = 8.5 Hz), 132.2 (s), 129.5 (d), 
129.0 (d), 128.0 (d), 125.3 (d), 124.8 (d,  JCF = 3.8 Hz), 116.6 (d, JCF = 21.4 Hz), 
108.2 (d, JCF = 9.7 Hz), 47.4 (t), 21.0 (q); LRMS (FAB
+) 347 (M
+, 100), 251 (20), 
154  (58)  ;  HRMS  (FAB
+)  calcd  for  C17H15FN2O3S  (M
+)  347.0865,  observed 
347.0869 
 
3-(4-Nitrophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119j) 
 
According  to general procedure 4, 118j  gave the  title compound as a white solid 
(0.13 g, 0.36 mmol, 72%). 
Rf 0.10 (40% Et2O/petroleum ether); mp 183-184 °C; νmax (thin film, cm
-1) 3274, 
3055, 1328,  1164; ʴH (CDCl3, 300 MHz) 8.37 (2 H, d, J = 8.9 Hz, ArH), 7.96 (2 H, 
d, J = 8.9 Hz, ArH), 7.16 (2 H, d, J = 8.1 Hz, ArH), 7.10 (2 H, d, J = 8.1 Hz, ArH), 
7.01 (1 H, s, IsoxH), 5.24 (1 H, br s, NH), 4.37 (2 H, s, NCH2), 2.24 (3 H, s, CH3); 
ʴC (CDCl3, 75 MHz) 167.8 (s), 160.8 (s), 149.3 (s), 138.4 (s), 133.4 (s), 132.0 (s), 
129.6 (d), 128.1 (d), 127.9 (d), 124.5 (d), 105.8 (d), 47.6 (t), 21.1 (q); LRMS (FAB
+) 
374 (M+H, 6), 307 (24), 289 (14), 154 (100); HRMS (FAB
+) calcd for C17H16N3O5S 
(M+H) 374.0810, observed 374.0806 
 
3-Naphthyl isoxazole-5-sulfonic acid-4-methylbenzylamide (119k) 
 
According to general procedure 4, 118k gave the title compound as a white solid 
(0.14 g, 0.36 mmol, 83%). 
Rf 0.06 (20% Et2O/petroleum ether); mp 131-133 °C; νmax (thin film, cm
-1) 3365, 
3307, 3055, 2985, 1341, 1170; ʴH (CDCl3, 300 MHz) 8.20 (1 H, s, ArH), 7.88-7.97 (4 
H, m, ArH), 7.54-7.61 (2 H, m, ArH), 7.17 (2 H, d, J = 8.2 Hz, ArH), 7.12 (1 H, s, 113 
 
IsoxH), 7.10 (2 H, d, J = 8.2 Hz, ArH), 5.28 (1 H, t, J = 5.8 Hz, NH), 4.37 (2 H, d, J 
= 5.8 Hz, NCH2), 2.22 (3 H, s, CH3); ʴC (CDCl3, 75 MHz) 166.6 (s), 162.5 (s), 138.3 
(s), 134.3 (s), 133.0 (s), 132.2 (s), 129.5 (d), 129.1 (d), 128.6 (d), 128.0 (d), 127.9 
(d), 127.6 (d), 127.1 (d), 127.0 (d), 124.7 (s), 123.5 (d), 106.0 (d), 47.5 (t), 21.0 (q); 
LRMS (FAB
+) 379 (M+H, 100), 307 (11), 194 (18), 154 (83); HRMS (FAB
+) calcd 
for C21H19N2O3S (M+H) 379.1116, observed 379.1107 
 
3-(2-Iodophenyl) isoxazole-5-sulfonic acid-4-methylbenzylamide (119l) 
 
According to general procedure 4, 118l gave the title compound as a yellow solid 
(0.20g, 0.45 mmol, 71%). 
Rf 0.2 (20% Et2O/petroleum ether);  mp 115-117 °C; νmax (thin  film, cm
-1) 3297, 
1354, 1165; ʴH (CDCl3, 300 MHz) 8.02 (1 H, dd, J = 7.5, 1.1 Hz, ArH), 7.52 (1 H, td, 
J = 7.6, 1.1 Hz, ArH), 7.43 (1 H, dd, J = 7.5, 1.3 Hz, ArH), 7.24 (1 H, td, J = 7.8, 1.1 
Hz, ArH), 7.14 (2 H, d, J = 8.3 Hz, ArH), 7.09 (2 H, d, J = 8.3 Hz, ArH), 7.01 (1 H, s, 
IsoxH), 6.82 (1 H, t, J = 5.9 Hz, NH), 4.28 (2 H, d, J = 5.9 Hz, NCH2), 2.24 (3 H, s, 
CH3); ʴC (CDCl3, 75 MHz) 167.2 (s), 165.9 (s), 141.3 (d), 138.6 (s), 134.4 (s), 134.0 
(s), 132.9 (d), 131.9 (d), 130.2 (d), 129.7 (d), 129.0 (d), 109.7 (d), 97.0 (s), 47.7 (t), 
21.3 (q); LRMS (EI) 454 (M
+•, 22), 336 (20), 270 (44), 242 (55), 229 (86), 118 (86), 
104 (100); HRMS (EI) calcd for C17H16N2O3S (M
+•) 453.9846, observed 453.9864. 
4.2.7  Preparation of 5-sulfonic-acid-allylsulfonamide 
General Procedure 5 
To a stirred solution of the  isoxazole-5-pentafluorophenyl  sulfonate ester  118 (0.5 
mmol)  in dry THF (12  mL/mmol) was added allylamine (1.5  mmol)  followed by 
NEt3 (0.75 mmol). The reaction was refluxed for 1.5-2 h and the mixture was diluted 
with dichloromethane (20 mL), washed with 2M HCl (20 mL), saturated NaHCO3 
(20 mL) and water (20 mL). The organic layer was dried over MgSO4 and filtered, 
and  solvent  was  removed  in  vacuo.  The  crude  residue  was  purified  by  flash 
chromatography (10% EtOAc/petroleum ether) and all products were collected as a 114 
 
single regioisomer as judged by NMR. 
3-(4-Methoxyphenyl) isoxazole-5-sulfonic-acid-allylamide (120a) 
 
According to general procedure 5, 118a gave the title compound as a cream solid (92 
mg, 0.31 mmol, 66%). 
Rf 0.1 (20% EtOAc/petroleum ether); mp 106-108 °C; νmax (thin film, cm
-1) 3277, 
1606, 1589, 1344, 1162; ʴH (CDCl3, 300 MHz) 7.73 (2 H, d, J = 8.9 Hz, ArH), 7.06 
(1 H, s, IsoxH), 6.99 (2 H, d, J = 8.9 Hz, ArH), 5.80-5.88 (1 H, m, CH2CH), 5.26 (1 
H, dd, J = 17.1, 0.8 Hz, CHCHHtrans), 5.19 (1 H, dd, J= 10.2, 0.8 Hz, CHCHHcis), 
3.86 (3 H, s, OCH3), 3.80-3.87 (2 H, m, NCH2); ʴC  (CDCl3, 75 MHz)  166.7 (s), 
161.7 (s), 132.1 (d), 128.4 (d), 119.4 (s), 118.2 (t), 114.6 (d), 105.6 (d), 68.2 (s), 55.4 
(q), 46.0 (t); LRMS (EI) 294 (M
+•, 46), 174 (85), 146 (100); HRMS (EI) calcd for 
C13H14N2O4S (M
+•) 294.0668, observed 294.0673; Anal. calcd: C, 53.05, H, 4.79, N, 
9.52, found: C, 53.18, H, 5.04, N, 9.96. 
 
3-Phenylisoxazole-5-sulfonic-acid-allylamide (120b) 
 
According to general procedure 5, 118b gave the title compound as a cream solid (85 
mg, 0.32 mmol, 64%). 
Rf 0.1 (20% EtOAc/petroleum ether);  mp 74-76 °C; νmax (thin  film,  cm
-1) 3256, 
1352, 1169;  ʴH  (CDCl3, 300 MHz) 7.81-7.90 (2 H,  m, ArH), 7.50-7.65 (3 H,  m, 
ArH), 7.12 (1 H, s, IsoxH), 5.80-5.89 (1 H, m, CH2CH), 5.27 (1 H, dd, J = 17.1, 1.0 
Hz, CHCHHtrans), 5.19 (1H, dd, J = 10.2, 1.0 Hz, CHCHHcis), 5.10 (1 H, t, J = 5.9 
Hz, NH), 3.86 (2 H, app.t, J = 5.9 Hz, NCH2); ʴC (CDCl3, 75 MHz) 166.5 (s), 162.6 
(s), 132.1 (d), 131.0 (s), 129.2 (d), 127.3 (d), 126.9 (d), 118.6 (t), 105.6 (d), 46.0 (t); 
LRMS (EI) 264 (M
+•, 12), 144 (100), 116 (74), 103 (25), 89 (37), 77 (96); HRMS 
(EI) calcd for C12H12N2O3S (M
+•) 264.0563, observed 264.0570 115 
 
3-(4-Chlorophenyl) isoxazole-5-sulfonic-acid-allylamide (120c) 
 
According to general procedure 5, 118c gave the title compound as a white solid (90 
mg, 0.30 mmol, 60%). 
Rf 0.13 (20% EtOAc/petroleum ether); mp 123-125 °C; νmax (thin film, cm
-1) 3273, 
1601, 1329, 1159; ʴH (CDCl3, 300 MHz) 7.75 (2 H, d, J = 8.6 Hz, ArH), 7.47 (2 H, d, 
J = 8.6 Hz, ArH), 7.10 (1 H, s, IsoxH), 5.74-5.87 (1 H, m, CH2CH), 5.27 (1 H, dd, J 
= 17.1, 0.9 Hz, CHCHHtrans), 5.19 (1 H, dd, J = 10.2, 0.9 Hz, CHCHHcis), 5.12 (1 
H, t, J = 6.0 Hz, NH), 3.85 (2 H, app.tt, J = 5.9, 1.4 Hz, NHCH2); ʴC (CDCl3, 75 
MHz) 166.9 (s), 161.7 (s), 137.2 (s), 132.0 (d), 129.5 (d), 128.2 (d), 125.8 (s), 118.7 
(t), 105.6 (d), 46.0 (t); LRMS (EI) 300 (M
+•, 
37Cl, 9), 298 (M
+ •, 
35Cl, 24),  178 (100), 
152 (40), 150 (98), 123 (34), 111 (60), 75 (56); HRMS (EI) calcd for C12H11ClN2O3S 
(M
+•) 298.0173, observed 298.0169 
 
3-(3-Chlorophenyl) isoxazole-5-sulfonic-acid-allylamide (120d) 
 
 
According to general procedure 5, 118d gave the title compound as a white solid (78 
mg, 0.27 mmol, 53%). 
Rf 0.16 (20% EtOAc/petroleum ether); mp 76-79 °C; νmax (thin film, cm
-1) 3271, 
1347, 1169; ʴH (CDCl3, 300 MHz) 7.82 (1 H, s, ArH), 7.68 (1 H, dt, J = 7.2, 1.6 Hz, 
ArH), 7.42-7.51 (2 H, m, ArH), 7.10 (1 H, s, IsoxH), 5.73-5.87 (1 H, m, CH2CH), 
5.27 (1 H, dd, J = 17.1, 1.1 Hz, CHCHHtrans), 5.20 (1 H, dd, J = 10.2, 1.1 Hz, 
CHCHHcis), 5.09 (1 H, t, J = 5.9 Hz, NH), 3.85 (2 H, app.tt, J = 5.9, 1.3 Hz, NCH2); 
ʴC (CDCl3, 75 MHz) 167.0 (s), 161.5 (s), 135.3 (s), 132.0 (d), 131.0 (d), 130.5 (d), 
129.0 (s), 127.0 (d), 125.0 (d), 118.7 (t), 105.7 (d), 46.0 (t); LRMS (EI) 300 (M
+ •, 116 
 
37Cl, 5), 298 (M
+  •, 
35Cl, 13), 207 (15), 178 (100), 150 (52), 111 (60); HRMS (EI) 
calcd for C12H11ClN2O3S (M
+ •) 298.0173, observed 298.0163 
 
3-(2-Chlorophenyl) isoxazole-5-sulfonic-acid-allylamide (120e) 
 
 
According to general procedure 5, 118e gave the title compound as a yellow oil (96 
mg, 0.32 mmol, 64%). 
Rf 0.11 (20% EtOAc/petroleum ether); νmax (thin film, cm
-1) 3292, 1351, 1166; ʴH 
(CDCl3, 300 MHz) 7.71 (1 H, dd, J = 7.5, 0.8 Hz, ArH), 7.48-7.54 (1 H, m, ArH), 
7.41 (1 H, dd, J = 7.5, 0.8 Hz, ArH), 7.36 (1 H, td, J = 7.5, 0.8 Hz, ArH), 7.27 (1 H, 
s, IsoxH), 5.71-5.85 (1 H, m, CH2CH), 5.57 (1 H, t, J = 5.9 Hz, NH), 5.24 (1 H, dd, J 
= 17.1, 1.1 Hz, CHCHHtrans), 5.15 (1H, dd, J = 10.2, 1.1 Hz, CHCHHcis), 3.85 (2 
H, t, J = 5.9 Hz, NCH2); ʴC (CDCl3, 75 MHz) 165.9 (s), 161.2 (s), 132.9 (s), 132.1 
(d), 131.8 (d), 131.0 (d), 130.6 (d), 127.4 (d), 126.6 (s), 118.5 (t), 108.8 (d), 46.0 (t); 
LRMS (EI) 300 (M
+ •, 
37Cl, 2), 298 (M
+ •, 
35Cl, 5), 207 (21), 178 (100), 150 (94), 123 
(53),  111  (43),  97  (40),  75  (68);  HRMS  (EI)  calcd  for  C12H11ClN2O3S  (M
+  •) 
298.0173, observed 298.0160 
 
3-(4-Bromophenyl) isoxazole-5-sulfonic-acid-allylamide (120f) 
 
 
According  to general procedure 5,  118f  gave the  title compound as a white solid 
(0.11 g, 0.33 mmol, 67%). 
Rf 0.13 (20% EtOAc/petroleum ether); mp 134-135 °C; νmax (thin film, cm
-1) 3272, 
1595, 1329, 1159; ʴH (CDCl3, 300 MHz) 7.68 (2 H, d, J = 8.8 Hz, ArH), 7.63 (2 H, d, 
J = 8.8 Hz, ArH), 7.09 (1 H, s, IsoxH), 5.73-5.87 (1 H, m, CH2CH), 5.26 (1 H, dd, J 117 
 
= 17.1, 0.8 Hz, CHCHHtrans), 5.19 (1 H, dd, J = 10.2, 0.8 Hz, CHCHHcis), 5.00 (1 
H, t, J = 5.9 Hz, NH), 3.85 (2 H, app.tt,  J = 5.9, 1.3 Hz, NCH2); ʴC (CDCl3, 75 
MHz) 168.1 (s), 162.5 (s), 137.4 (s), 132.5 (d), 132.0 (d), 128.4 (d), 125.0 (s), 118.7 
(t), 105.6 (d), 46.1 (t); LRMS (EI) 344 (M
+  •, 
81Br, 39), 342 (M
+  •, 
79Br, 36), 224 
(100), 222 (100), 196 (74), 194 (75), 157 (35), 155 (57), 102 (35); HRMS (EI) calcd 
for C12H11BrN2O3S (M
+ •) 341.9668, observed 341.9664 
 
3-(3-Bromophenyl) isoxazole-5-sulfonic-acid-allylamide (120g) 
 
 
According  to general procedure 5,  118g gave the title compound as a white solid 
(0.11 g, 0.33 mmol, 67%). 
Rf 0.14 (20% EtOAc/petroleum ether); mp 90-92 °C; νmax (thin film, cm
-1) 3287, 
1350, 1169; ʴH (CDCl3, 300 MHz) 7.97 (1 H, t, J = 1.3 Hz, ArH), 7.73 (1 H, app. dt, 
J = 7.7, 1.6 Hz, ArH), 7.63 (1 H, app. dt, J = 7.6, 1.6 Hz, ArH), 7.37 (1 H, t, J = 7.7 
Hz, ArH), 7.10 (1 H, s, IsoxH), 5.79-5.86 (1 H, m, CH2CH), 5.26 (1 H, dd, J = 16.8, 
0.8 Hz, CHCHHtrans), 5.19 (1 H, dd, J = 10.2, 0.8 Hz, CHCHHcis), 5.12 (1 H, t, J = 
6.2 Hz, NH), 3.85 (2 H, t, J = 6.2 Hz, NCH2); ʴC (CDCl3, 75 MHz) 167.0 (s), 161.4 
(s), 133.9 (d), 132.0 (d), 130.7 (d), 129.9 (d), 129.3 (s), 125.5 (d), 123.3 (s), 118.7 (t), 
105.6 (d), 46.0 (t); LRMS (EI) 344 (M
+ •, 
81Br, 30), 342 (M
+ •, 
79Br, 28), 253 (22), 
251 (29), 224 (100), 222 (100), 196 (56), 194 (56), 157 (77), 155 (80);  HRMS (EI) 
calcd for C12H11BrN2O3S (M
+ •) 341.9668, observed 341.9669  
 
3-(2-Bromophenyl) isoxazole-5-sulfonic-acid-allylamide (120h) 
 
 118 
 
According to general procedure 5, 118h gave the title compound as a yellow oil (0.13 
g, 0.37 mmol, 68%). 
Rf 0.19 (20% EtOAc/petroleum ether); νmax (thin film, cm
-1) 3287, 1351, 1165; ʴH 
(CDCl3, 300 MHz) 7.68 (1 H, dd, J = 7.7, 1.6 Hz, ArH), 7.62 (1 H, dd, J = 7.7, 1.8 
Hz, ArH), 7.41 (1 H, td, J = 7.7, 1.7 Hz, ArH), 7.34 (1 H, td, J = 7.7, 1.8 Hz, ArH), 
7.24 (1 H, s, IsoxH), 5.71-5.85 (1 H, m, CH2CH), 5.58 (1 H, t, J = 5.9 Hz, NH), 5.24 
(1  H,  dd,  J  =  16.8,  0.8  Hz,  CHCHHtrans),  5.15  (1  H,  dd,  J  = 10.2,  0.8  Hz, 
CHCHHcis), 3.85 (2 H, t, J = 5.9 Hz, NCH2); ʴC (CDCl3, 75 MHz) 165.7 (s), 162.6 
(s), 133.8 (d), 132.1 (d), 131.9 (d), 131.4 (d), 128.6 (s), 127.9 (d), 122.6 (s), 118.5 (t), 
108.9 (d), 46.0 (t); LRMS (EI) 344 (M
+ •, 
81Br, 4), 342 (M
+ •, 
79Br, 4), 224 (100), 222 
(100), 197 (85), 194 (83), 115 (52); HRMS (EI) calcd for C12H11BrN2O3S (M
+  •) 
341.9668, observed 341.9664 
 
3-(2-Fluorophenyl) isoxazole-5-sulfonic-acid-allylamide (120i) 
 
 
According  to  general procedure 5,  118i gave the title compound as a white solid 
(0.11 g, 0.38 mmol, 77%). 
Rf 0.14 (20% EtOAc/petroleum ether); mp 80-83 °C; νmax (thin film, cm
-1) 3263, 
1353, 1168; ʴH (CDCl3, 300 MHz) 7.98 (1 H, td, J = 7.5, 1.6 Hz, ArH), 7.49-7.61 (1 
H, m, ArH), 7.21-7.31 (2 H, m, ArH), 7.18 (1 H, d, J = 7.5 Hz, IsoxH), 5.73-5.87 (1 
H, m, CH2CH), 5.27 (1 H, dd, J = 16.8, 0.8 Hz, CHCHHtrans), 5.19 (1 H, dd, J = 
10.4, 0.8 Hz, CHCHHcis), 5.04 (1 H, t, J = 5.8 Hz, NH), 3.86 (2 H, app.tt, J = 5.8, 
1.3 Hz, NCH2); ʴC (CDCl3, 75 MHz) 166.5 (s), 160.6 (s, JCF = 253.9 Hz), 158.1 (s), 
132.8 (d, JCF = 7.7 Hz), 132.1 (d), 129.1 (d, JCF = 2.7 Hz), 124.9 (d, JCF = 3.8 Hz), 
118.7 (t), 116.7 (d, JCF = 21.6 Hz), 115.6 (s, JCF = 12.1 Hz), 108.2 (d, JCF = 9.6 Hz), 
45.9 (t);  LRMS (CI
+) 283 (M+H, 100), 219 (31), 164 (67), 162 (73), 122 (70); 
HRMS (CI
+) calcd for C12H12FN2O3S (M+H) 283.0552, observed 283.0557 
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3-(4-Nitrophenyl) isoxazole-5-sulfonic-acid-allylamide (120j) 
 
 
According to general procedure 5, 118j gave the title compound as a cream solid 
(0.11 g, 0.34 mmol, 69%). 
Rf 0.10 (20% EtOAc/petroleum ether); mp 131-133 °C; νmax (thin film, cm
-1) 3247, 
1613, 1536, 1343, 1160; ʴH (CDCl3, 300 MHz) 8.36 (2 H, d, J = 7.5 Hz, ArH), 8.00 
(2 H, d, J = 7.5 Hz, ArH), 7.19 (1 H, s, IsoxH), 5.72-5.88 (1 H, m, CH2CH), 5.27 (1 
H, d, J = 14.0 Hz, CHCHHtrans), 5.20 (1 H, d, J = 9.9 Hz, CHCHHcis), 3.88 (2 H, d, 
J = 5.3 Hz, NCH2); ʴC (CDCl3, 75 MHz) 167.8 (s), 160.8 (s), 149.1 (s), 133.3 (s), 
131.9 (d), 127.9 (d), 124.5 (d), 118.7 (t), 105.7 (d), 46.0 (t); LRMS (CI
+) 310 (M+H, 
100), 248 (27), 216 (26), 189  (48); HRMS (CI
+) calcd  for C12H12N3O5S (M+H) 
310.0497, observed 310.0501 
 
3-Naphthyl-isoxazole-5-sulfonic-acid-allylamide (120k) 
 
According to general procedure 5, 118k gave the title compound as a white solid 
(0.11g, 0.33 mmol, 69%). 
Rf 0.20 (20% EtOAc/petroleum ether); mp 112-114 °C; νmax (thin film, cm
-1) 3280, 
1347, 1166; ʴH (CDCl3, 300 MHz) 8.25 (1 H, s, ArH), 7.91-8.02 (4 H, m, ArH), 7.56-
7.62 (2 H, m, ArH), 7.25 (1 H, s, IsoxH), 7.75-7.89 (1 H, m, CH2CH), 5.29 (1 H, d, J 
= 16.8 Hz, CHCHHtrans), 5.20 (1 H, d, J = 10.4 Hz, CHCHHcis), 5.10 (1 H, t, J = 
5.7 Hz, NH), 3.88 (2 H, t, J = 5.7 Hz, NCH2); ʴC (CDCl3, 75 MHz) 167.3 (s), 162.6 
(s), 134.3 (s), 133.0 (s), 132.1 (d), 129.2 (d), 128.6 (d), 127.9 (d), 127.6 (d), 127.2 
(d), 127.0 (d), 124.7 (s), 123.5 (d), 118.6 (t), 105.9 (d), 46.1 (t); LRMS (EI) 314 (M
+ 
•, 73), 194 (94), 166 (45), 127 (100); HRMS (EI) calcd  for C16H14N2O3S (M
+  •) 
314.0719, observed 314.0720 120 
 
4.2.8  Preparation of isoxazole-5-sulfonic-acid-tert-butylsulfonamide 
General Procedure 6 
To a stirred solution of the  isoxazole  pentafluorophenyl  sulfonate esters  118 (0.5 
mmol)  in dry THF (12  mL/mmol) was added TBAC (1 mmol)  followed by NEt3 
(0.75 mmol) and tert-butylamine (1.5 mmol). The reaction was refluxed for 1-3 h and 
the  mxture  was diluted with dichloromethane (20  mL), washed  with 2M HCl (20 
mL), saturated NaHCO3 (20 mL) and water (20 mL). The organic layer was dried 
over MgSO4, filtered under gravity, and solvent was removed in vacuo. The crude 
residue was purified by flash chromatography (20% EtOAc/petroleum ether) and all 
products were collected as a single regioisomer as judged by NMR. 
 
3-(4-Methoxyphenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121a) 
 
According to general procedure 6, 118a gave the title compound as a cream solid (89 
mg, 0.29 mmol, 63%). 
Rf 0.18 (20% EtOAc/petroleum ether); mp 143-146 °C; νmax (thin film, cm
-1) 3281, 
1346, 1154; ʴH (CDCl3, 300 MHz) 7.73 (2 H, d, J = 8.8 Hz, ArH), 7.04 (1 H, s, 
IsoxH), 6.97 (2 H, d, J = 8.8 Hz, ArH), 5.28 (1 H, br s, NH), 3.85 (3 H, s, OCH3), 
1.34 (9 H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 168.4 (s), 162.2 (s), 161.6 (s), 128.4 (d), 
119.9 (s), 114.5 (d), 104.8 (d), 56.1 (s), 55.4 (q), 29.8 (q); LRMS (EI) 310 (M
+•, 47), 
174 (100), 146 (60), 92 (14);  HRMS (EI) calcd for C14H18N2O4S (M
+•) 310.0981, 
observed 310.0985;  Anal. calcd: C, 54.18, H, 5.85, N, 9.03, found: C, 54.16, H, 
5.84, N, 9.02. 
 
3-Phenyl-isoxazole-5-sulfonic-acid-tert-butylamide (121b) 
 121 
 
According to general procedure 6, 118b gave the title compound as a white solid (69 
mg, 0.25 mmol, 49%). 
Rf 0.19 (20% EtOAc/petroleum ether); mp 121-124 °C; νmax (thin film, cm
-1) 3282, 
3158, 1345, 1156; ʴH (CDCl3, 300 MHz) 7.82-7.93 (2 H, m, ArH), 7.48-7.58 (3 H, m, 
ArH), 7.11 (1 H, s, IsoxH), 5.21 (1 H, br s, NH), 1.35 (9 H, s, C(CH3)3); ʴC (CDCl3, 
75 MHz) 168.7 (s), 162.6 (s), 130.8 (d), 129.1 (d), 127.5 (s), 126.9 (d), 105.0 (d), 
56.2 (s), 29.9 (q); LRMS (EI) 280 (M
+•, 6), 265 (58), 144 (100), 116 (15); HRMS 
(EI) calcd for C13H16N2O3S (M
+•) 280.0876, observed 280.0868 
 
3-(4-Chlorophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121c) 
 
According to general procedure 6, 118c gave the title compound as a white solid (74 
mg, 0.24 mmol, 47%). 
Rf 0.26 (20% EtOAc/petroleum ether); mp 153-156 °C; νmax (thin film, cm
-1) 3295, 
3153, 1602, 1346, 1160; ʴH (CDCl3, 300 MHz) 7.75 (2 H, d, J = 8.8 Hz, ArH), 7.46 
(2 H, d, J = 8.8 Hz, ArH), 7.08 (1 H, s, IsoxH), 5.17 (1 H, br s, NH), 1.35 (9 H, s, 
C(CH3)3); ʴC (CDCl3, 75 MHz) 169.0 (s), 161.7 (s), 137.0 (s), 129.4 (d), 128.2 (d), 
126.0 (s), 104.8 (d), 56.3 (s), 30.0 (q); LRMS (EI) 316 (M
+•, 
37Cl, 2), 314 (M
+•, 
35Cl, 
5), 301 (6), 299 (18), 180 (12), 178 (35); HRMS (EI) calcd for C13H15ClN2O3S (M
+•) 
314.0486, observed 310.0480 
 
3-(3-Chlorophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121d) 
 
According to general procedure 6, 118d gave the title compound as a white solid (69 
mg, 0.22 mmol, 44%). 
Rf 0.29 (20% EtOAc/petroleum ether); mp 122-125 °C; νmax (thin film, cm
-1) 3303, 122 
 
3158, 1345, 1159; ʴH (CDCl3, 300 MHz) 7.81 (1 H, t, J = 1.6 Hz, ArH), 7.69-7.77 (1 
H, m, ArH), 7.38-7.49 (2 H, m, ArH), 7.10 (1 H, s, IsoxH), 5.34 (1 H, br s, NH), 1.35 
(9 H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 169.1 (s), 161.6 (s), 135.2 (s), 130.9 (d), 
130.5 (d), 129.2 (s), 127.0 (d), 125.1 (d), 104.8 (d), 56.3 (s), 29.9 (q); LRMS (EI) 
316 (M
+•, 
37Cl, 2), 314 (M
+•, 
35Cl, 5), 301 (9), 299 (18), 281 (100), 265 (47), 180 
(17),  178  (34);  HRMS  (EI)  calcd  for  C13H15ClN2O3S  (M
+•)  314.0486,  observed 
310.0484 
 
3-(2-Chlorophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121e) 
 
According to general procedure 6, 118e gave the title compound as a cream solid (82 
mg, 0.26 mmol, 52%). 
Rf 0.27 (20% EtOAc/petroleum ether); mp 91-95 °C; νmax (thin film, cm
-1) 3279, 
1345, 1155; ʴH (CDCl3, 300 MHz) 7.74 (1 H, dd, J = 7.5, 1.6 Hz, ArH), 7.51 (1  H, 
dd, J = 7.5, 1.6 Hz, ArH), 7.35-7.48 (2 H, m, ArH), 7.25 (1 H, s, IsoxH), 5.16 (1 H, 
br s, NH), 1.36 (9 H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 167.9 (s), 161.2 (s), 132.9 (s), 
132.1 (d), 131.5 (s), 130.9 (d), 130.3 (d), 127.1 (d), 108.2 (d), 56.2 (s), 29.9 (q); 
LRMS (EI) 316 (M
+•, 
37Cl, 1), 314 (M
+•, 
35Cl, 3), 301 (19), 299 (51), 180 (30), 178 
(100); HRMS (EI) calcd for C13H15ClN2O3S (M
+•) 314.0486, observed 310.0480 
 
3-(4-Bromophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121f) 
 
According to general procedure 6, 118f gave the title compound as a cream solid (70 
mg, 0.19 mmol, 41%). 
Rf 0.28 (20% EtOAc/petroleum ether); mp 160-163 °C; νmax (thin film, cm
-1) 3324, 
3161, 1596, 1343, 1157; ʴH (CDCl3, 300 MHz) 7.68 (2 H, d, J =  8.8 Hz, ArH), 7.61 
(2 H, d, J = 8.8 Hz, ArH), 7.07 (1 H, s, IsoxH), 5.13 (1 H, br s, NH), 1.35 (9 H, s, 123 
 
C(CH3)3); ʴC (CDCl3, 75 MHz) 169.0 (s), 161.7 (s), 132.4 (d), 128.0 (d), 126.4 (s), 
125.3 (s), 104.7 (d), 56.2 (s), 30.0 (q); LRMS (EI) 360 (M
+•, 
81Br, 22), 358 (M
+•, 
79Br, 21), 345 (100), 343 (93), 224 (85), 222 (90), 196 (29), 194 (24); HRMS (EI) 
calcd for C13H15BrN2O3S (M
+•) 357.9861, observed 357.9857 
 
3-(3-Brorophenyl)-isoxazole-4-sulfonic-acid-tert-butylamide (121g) 
 
According to general procedure 6, 118g gave the title compound as a cream solid (71 
mg, 0.20 mmol, 41%). 
Rf 0.27 (20% EtOAc/petroleum ether); mp 130-133 °C; νmax (thin film, cm
-1) 3293, 
3148, 1598, 1500, 1339, 1157; ʴH (CDCl3, 300 MHz) 7.97 (1 H, t, J = 1.9 Hz, ArH), 
7.73 (1 H, app.dt, J = 7.7, 1.9 Hz, ArH), 7.61-7.68 (1 H, m, ArH), 7.36 (1 H, t, J = 
7.7 Hz, ArH), 7.09 (1 H, s, IsoxH), 5.20 (1 H, br s, NH), 1.35 (9 H, s, C(CH3)3); ʴC 
(CDCl3, 75 MHz) 169.1 (s), 161.4 (s), 133.8 (d), 130.7 (d), 129.9 (d), 129.4 (s), 
125.5 (d), 123.2 (d), 104.8 (d), 56.2 (s), 30.0 (q); LRMS (EI) 360 (M
+•, 
81Br, 10), 
358 (M
+•, 
79Br, 10), 345 (94), 343 (100), 224 (69), 222 (67), 196 (13), 194 (12), 157 
(17),  155  (19);  HRMS  (EI)  calcd  for  C13H15BrN2O3S  (M
+•)  357.9861,  observed 
357.9863 
 
3-(2-Bromophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121h) 
 
According to general procedure 6, 118h gave the title compound as a white solid (89 
mg, 0.25 mmol, 52%). 
Rf 0.28 (20% EtOAc/petroleum ether); mp 111-113 °C; νmax (thin film, cm
-1) 3284, 
1595, 1347, 1158; ʴH (CDCl3, 300 MHz) 7.69 (1 H, dd, J = 7.7, 1.3 Hz, ArH), 7.64 (1 
H, dd, J = 7.7, 1.3 Hz, ArH), 7.43 (1 H, td, J = 7.7, 1.4 Hz, ArH), 7.38 (1 H, td, J = 124 
 
7.7, 1.3 Hz, ArH), 7.22 (1 H, s, IsoxH), 5.26 (1 H, br s, NH), 1.35 (9 H, s, C(CH3)3); 
ʴC (CDCl3, 75 MHz) 167.7 (s), 162.6 (s), 133.7 (d), 132.7 (s), 131.8 (d), 131.3 (d), 
128.9 (s), 127.8 (d), 108.3 (d), 56.2 (s), 29.9 (q); LRMS (EI) 360 (M
+•, 
81Br, 6), 358 
(M
+•, 
79Br, 6), 345 (82), 343 (82), 224 (98), 222 (100), 196 (48), 194 (51); HRMS 
(EI) calcd for C13H15BrN2O3S (M
+•) 357.9861, observed 357.9855 
 
3-(2-Fluorophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121i) 
 
According to general procedure 6, 118i gave give the title compound as a cream solid 
(85 mg, 0.28 mmol, 60%). 
Rf 0.21 (20% EtOAc/petroleum ether); mp 115-117 °C; νmax (thin film, cm
-1) 3275, 
1591, 1505, 1345, 1153; ʴH (CDCl3, 300 MHz) 7.99 (1 H, td, J = 7.5, 1.6 Hz, ArH), 
7.44-7.53 (1 H, m, ArH), 7.28 (1 H, dd, J = 7.5, 1.4 Hz, ArH), 7.23 (1 H, s, IsoxH), 
7.17-7.23 (1 H, m, ArH), 5.10 (1 H, br s, NH), 1.35 (9 H, s, C(CH3)3); ʴC (CDCl3, 75 
MHz) 168.6 (s), 159.9 (s,  JCF = 252.6 Hz), 158.0 (s), 132.6 (d,  JCF = 8.5 Hz), 129.0 
(d,  JCF = 2.6 Hz), 124.8 (d,  JCF = 3.2 Hz), 116.6 (d,  JCF = 21.7 Hz), 115.7 (s, JCF = 
11.7 Hz), 107.4 (d, JCF = 9.7 Hz), 56.2 (s), 30.0 (q); LRMS (EI) 298 (M
+•, 3), 283 
(96), 162  (100), 134  (22);  HRMS (EI) calcd  for C13H15FN2O3S (M
+•) 298.0782, 
observed 298.0776 
 
3-(4-Nitrophenyl)-isoxazole-5-sulfonic-acid-tert-butylamide (121j) 
 
According to general procedure 6, 118j gave the title compound as a cream solid (60 
mg, 0.18 mmol, 37%). 
Rf 0.2 (20% EtOAc/petroleum ether); mp 167-168 °C; νmax (thin film, cm
-1) 3203, 
3148, 1343, 1157; ʴH (CDCl3, 300 MHz) 8.26 (2 H, d, J = 8.8 Hz, ArH), 8.01 (2 H, d, 
J = 8.8 Hz, ArH), 7.17 (1 H, s, IsoxH), 5.09 (1 H, br s, NH), 1.37 (9 H, s, C(CH3)3); 125 
 
ʴC (CDCl3, 75 MHz) 169.8 (s), 160.9 (s), 149.2 (s), 133.5 (s), 127.9 (d), 124.4 (d), 
104.9 (d), 56.4 (s), 30.0 (q); LRMS (EI) 326 (M
+•, 7), 310 (80), 189 (100), 143 (96), 
115 (40); HRMS (EI) calcd for C13H15N3O5S (M
+•) 326.0810, observed 326.0813 
 
3-Naphthyl-isoxazole-5-sulfonic-acid-tert-butylamide (121k) 
 
According to general procedure 6, 118k gave the title compound as a cream solid (70 
mg, 0.21 mmol, 42%). 
Rf 0.3 (20% EtOAc/petroleum ether); mp 143-148 °C; νmax (thin film, cm
-1) 3285, 
1604, 1514, 1334, 1154; ʴH (CDCl3, 300 MHz) 8.25 (1 H, s, ArH),, 7.86-7.96 (4 H, 
m, ArH), 7.25-7.34 (2 H, m, ArH), 7.25 (1 H, s, IsoxH), 5.20 (1 H, br s, NH), 1.38 (9 
H, s, C(CH3)3); ʴC (CDCl3, 75 MHz) 168.8 (s), 162.7 (s), 134.3 (s), 133.1 (s), 129.1 
(d), 128.6 (d), 127.9 (d), 127.5 (d), 127.1 (d), 126.9 (d), 124.9 (s), 123.5 (d), 105.1 
(d), 56.2 (s), 30.0 (q); LRMS (EI) 330 (M
+•, 45), 194 (100), 166 (27), 127 (65); 
HRMS (EI) calcd for C17H18N2O3S (M
+•) 330.1032, observed 330.1026 
4.2.9  Preparation of isoxazole-5-sulfonic-acid-isopropylsulfonamide 
General Procedure 7 
To a stirred solution of the  isoxazole  pentafluorophenyl  sulfonate esters 118 (0.5 
mmol)  in dry THF (12  mL/mmol) was added TBAC (1 mmol)  followed by NEt3 
(0.75 mmol) and isopropylamine (1.5 mmol). The reaction was refluxed for 1-3 h 
and the mixture was diluted with dichloromethane (20 mL), washed with 2M HCl 
(20 mL), saturated NaHCO3 (20 mL) and water (20 mL). The organic layer was dried 
over MgSO4, filtered under gravity, and solvent was removed in vacuo. The crude 
residue was purified by flash chromatography (20% EtOAc/petroleum ether) and all 
products were collected as a single regioisomer as judged by NMR. 
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3-(4-Methoxyphenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122a) 
 
According to general procedure 7, 118a gave the title compound as a cream solid 
(0.13 g, 0.44 mmol, 89%). 
Rf 0.15 (20% EtOAc/petroleum ether); mp 98-101 °C; νmax (thin film, cm
-1) 3155, 
1610, 1520, 1346, 1176; ʴH (CDCl3, 300 MHz) 7.73 (2 H, d, J = 8.8 Hz, ArH), 7.07 
(1 H, s, IsoxH), 6.97 (2 H, d, J = 8.8 Hz, ArH), 5.13 (1 H, d, J = 7.5 Hz, NH), 3.85 (3 
H, s, OCH3), 3.73-3.80 (1 H, m, CH), 1.21 (6 H, d, J = 6.7 Hz, CH3); ʴC (CDCl3, 75 
MHz) 166.9 (s), 162.2 (s), 161.7 (s), 128.5 (s), 119.8 (d), 114.6 (d), 105.3 (d), 55.4 
(q), 47.3 (d), 23.7 (q); LRMS (EI)  296 (M
+•, 50), 174 (100), 146 (79), 84 (22); 
HRMS  (EI)  calcd  for  C13H16N2O4S  (M
+•)  296.0825,  observed  296.0823;   Anal. 
calcd: C, 52.69, H, 5.44, N, 9.45, found: C, 52.46, H, 5.35, N, 9.82. 
 
3-Phenyl-isoxazole-5-sulfonic-acid-isopropylamide (122b) 
 
According to general procedure 7, 118b gave the title compound as white crystals 
(0.11 g, 0.39 mmol, 79%). 
Rf 0.24 (20% EtOAc/petroleum ether); mp 117-120 °C; νmax (thin film, cm
-1) 3272, 
1605, 1351, 1171; ʴH (CDCl3, 300 MHz) 7.79-7.84 (2 H, m, ArH), 7.46-7.51 (3 H, m, 
ArH), 7.14 (1 H, s, IsoxH), 5.19 (1 H, d, J = 7.3 Hz, NH), 3.75 (1 H, oct, J = 7.3 Hz, 
CH), 1.21 (6 H, d, J = 7.3 Hz, CH3); ʴC (CDCl3, 75 MHz) 167.3 (s), 162.6 (s), 130.9 
(d), 129.2 (d), 127.4 (s), 126.9 (d), 105.5 (d), 47.3 (d), 23.7 (q); LRMS (EI) 266 
(M
+•, 28), 251 (100), 144 (75); HRMS (EI) calcd for C12H14N2O3S (M
+•) 266.0719, 
observed 266.0712 
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3-(4-Chlorophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122c) 
 
According  to general procedure 7,  118c gave the title compound as a white solid 
(0.11 g, 0.37 mmol, 74%). 
Rf 0.28 (20% EtOAc/petroleum ether); mp 121-124 °C; νmax (thin film, cm
-1) 3150, 
1601, 1507, 1353, 1179; ʴH (CDCl3, 300 MHz) 7.74 (2 H, d, J = 8.8 Hz, ArH), 7.45 
(2 H, d, J = 8.8 Hz, ArH), 7.10 (1 H, s, IsoxH), 5.07 (1 H, d, J = 7.2 Hz, NH), 3.75 
(1H, oct, J = 7.2 Hz, CH), 1.22 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 167.6 
(s), 161.7 (s), 137.1 (s), 129.5 (d), 128.2 (d), 125.9 (s), 105.3 (d), 47.3 (d), 23.7 (q); 
LRMS (EI) 302 (M
+•, 
37Cl, 34), 300 (M
+•, 
35Cl, 100), 287 (18), 285 (53); HRMS 
(EI) calcd for C12H13ClN2O3S (M
+•) 300.0330, observed 300.0332 
 
3-(3-Chlorophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122d) 
 
According to general procedure 7, 118d gave the title compound as a cream solid 
(0.11 g, 0.36 mmol, 72%). 
Rf 0.22 (20% EtOAc/petroleum ether); mp 108-110 °C; νmax (thin film, cm
-1) 3226, 
1356, 1175; ʴH (CDCl3, 300 MHz) 7.82 (1 H, s, ArH), 7.69 (1 H, d, J = 8.2 Hz, ArH), 
7.48 (1 H, dt, J = 8.3 Hz, ArH), 7.43 (1 H, t, J = 8.3 Hz, ArH), 7.09 (1 H, s, IsoxH), 
4.83 (1 H, d, J = 7.2 Hz, NH), 3.75 (1H, oct, J = 7.2 Hz, CH), 1.23 (6 H, d, J = 7.2 
Hz, CH3); ʴC (CDCl3, 75 MHz) 168.1 (s), 161.0 (s), 136.6 (s), 130.9 (d), 130.5 (d), 
129.8 (s), 127.0 (d), 125.0 (d), 105.3 (d), 47.3 (d), 23.8 (q); LRMS (EI) 302 (M
+•, 
37Cl, 5), 300 (M
+•, 
35Cl, 15), 287 (30), 285 (92), 180 (28), 178 (100); HRMS (EI) 
calcd for C12H13ClN2O3S (M
+•) 300.0330, observed 300.0320 
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3-(2-Chlorophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122e) 
 
According to general procedure 7, 118e gave the title compound as a cream solid 
(0.12 g, 0.38 mmol, 75%). 
Rf 0.20 (20% EtOAc/petroleum ether); mp 88-89 °C; νmax (thin film, cm
-1) 3266, 
1339, 1122; ʴH (CDCl3, 300 MHz) 7.73 (1 H, dd, J = 7.5, 1.5 Hz, ArH), 7.51 (1 H, 
dd, J = 7.5, 1.3 Hz, ArH), 7.43 (1 H, td, J = 7.5, 1.5 Hz, ArH), 7.37 (1 H, td, J = 7.5, 
1.5 Hz, ArH), 7.27 (1 H, s, IsoxH), 5.13 (1 H, d, J = 7.2 Hz, NH), 3.77 (1 H, oct, J = 
7.2 Hz, CH), 1.22 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 166.6 (s), 161.2 
(s), 132.9 (s), 131.7 (d), 131.1 (d), 130.6 (d), 127.3 (d), 126.7 (s), 108.5 (d), 47.3 (d), 
23.7 (q); LRMS (EI) 302 (M
+•, 
37Cl, 5), 300 (M
+•, 
35Cl, 14), 287 (30), 285 (92); 
HRMS (EI) calcd for C12H13ClN2O3S (M
+•) 300.0330, observed 300.0320 
 
3-(4-Bromophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122f) 
 
According to general procedure 7, 118f gave the title compound as a cream solid 
(0.13 g, 0.38 mmol, 75%). 
Rf 0.26 (20% EtOAc/petroleum ether); mp 132-135 °C; νmax (thin film, cm
-1) 3283, 
1598, 1502, 1354, 1116; ʴH (CDCl3, 300 MHz) 7.67 (2 H, d, J = 8.6 Hz, ArH), 7.60 
(2 H, d, J = 8.6 Hz, ArH), 7.09 (1 H, s, IsoxH), 5.29 (1 H, d, J = 7.2 Hz, NH), 3.73 (1 
H, oct, J = 7.2 Hz, CH), 1.23 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 167.7 
(s), 161.7 (s), 132.4 (d), 128.4 (d), 126.3 (s), 125.4 (s), 105.2 (d), 47.3 (d), 23.7 (q); 
LRMS (EI) 346 (M
+•, 
81Br, 7), 344 (M
+•, 
79Br, 7), 331 (40), 329 (39), 224 (100), 222 
(98), 196 (49), 194 (50), 157 (49), 155 (52); HRMS (EI) calcd for C12H13BrN2O3S 
(M
+•) 343.9825, observed 343.9816 
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3-(3-Bromophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122g) 
 
According to general procedure 7, 118g gave the title compound as a cream solid 
(0.12 g, 0.36 mmol, 72%). 
Rf 0.22 (20% EtOAc/petroleum ether); mp 110-114 °C; νmax (thin film, cm
-1) 3224, 
1357, 1125; ʴH (CDCl3, 300 MHz) 7.96 (1 H, t, J = 1.8 Hz, ArH), 7.73-7.82 (1 H, m, 
ArH), 7.61-7.69 (1 H, m ArH), 7.35 (1 H, t, J = 7.7 Hz, ArH), 7.12 (1 H, s, IsoxH), 
5.30 (1 H, d, J = 7.2 Hz, NH), 3.74 (1 H, oct, J = 7.2 Hz, CH), 1.21 (6 H, d, J = 7.2 
Hz, CH3); ʴC (CDCl3, 75 MHz) 167.7 (s), 161.4 (s), 133.9 (d), 130.7 (d), 129.9 (d), 
129.3 (s), 125.5 (d), 123.2 (s), 105.3 (d), 47.3 (d), 23.7 (q); LRMS (EI) 346 (M
+•, 
81Br, 21), 344 (M
+•, 
79Br, 21), 331 (100), 329 (95), 224 (86), 222 (86); HRMS (EI) 
calcd for C12H13BrN2O3S (M
+•) 343.9825, observed 343.9832 
 
3-(2-Bromophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122h) 
 
According to general procedure 7, 118h gave the title compound as a cream solid 
(0.13 g, 0.38 mmol, 75%). 
Rf 0.2 (20% EtOAc/petroleum ether);  mp 70-71 °C; νmax (thin  film,  cm
-1) 3301, 
1353, 1123; ʴH (CDCl3, 300 MHz) 7.68 (1 H, dd, J = 7.5, 1.6 Hz, ArH), 7.63 (1 H, 
dd, J = 7.5, 1.5 Hz, ArH), 7.41 (1 H, td, J = 7.5, 1.5 Hz, ArH), 7.34 (1 H, td, J = 7.5, 
1.5 Hz, ArH), 7.24 (1 H, s, IsoxH), 5.30 (1 H, d, J = 7.2 Hz, NH), 3.76 (1 H, oct, J = 
7.2 Hz, CH), 1.21 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 166.4 (s), 162.6 
(s), 133.7 (d), 131.8 (d), 131.4 (d), 128.8 (s), 127.9 (d), 122.2 (s), 108.6 (d), 47.3 (d), 
23.6 (q); LRMS (EI) 346 (M
+•, 
81Br, 9), 344 (M
+•, 
79Br, 10), 331 (47), 329 (46), 224 
(98), 222 (100), 196 (67), 194 (68);  HRMS (EI) calcd  for C12H13BrN2O3S (M
+•) 
343.9825, observed 343.9814 130 
 
3-(2-Fluorophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122i) 
 
According  to general procedure 7,  118i gave the title compound as a cream solid 
(0.13 g, 0.45 mmol, 90%). 
Rf 0.24 (20% EtOAc/petroleum ether); mp 86-89 °C; νmax (thin film, cm
-1) 3293, 
1343, 1119; ʴH (CDCl3, 300 MHz) 7.99 (1 H, td, J = 7.5, 1.8 Hz, ArH), 7.45-7.54 (1 
H, m, ArH), 7.24 (1 H, s, IsoxH), 7.17-7.31 (2 H, m, ArH), 4.79 (1 H, d, J = 7.2 Hz, 
NH), 3.76 (1 H, oct, J = 7.2 Hz, , CH), 1.23 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 
MHz) 167.22 (s), 160.4 (s, JCF = 253.5 Hz), 158.1 (s), 132.7 (d, JCF = 8.3 Hz), 129.0 
(d, JCF = 1.9 Hz), 124.9 (d, JCF = 3.9 Hz), 116.6 (d, JCF = 22.6 Hz), 115.6 (s, JCF = 
11.3 Hz), 107.9 (d, JCF = 9.9 Hz), 47.4 (d), 23.8 (q); LRMS (EI) 284 (M
+•, 7), 269 
(87), 162  (100), 134  (44); HRMS (EI) calcd  for C12H13FN2O3S (M
+•) 284.0625, 
observe 284.0629 
 
3-(4-Nitrophenyl)-isoxazole-5-sulfonic-acid-isopropylamide (122j) 
 
According to general procedure 7, 118j gave the title compound as a cream solid 
(0.13 g, 0.41 mmol, 81%). 
Rf 0.16 (20% EtOAc/petroleum ether); mp 150-152 °C; νmax (thin film, cm
-1) 3337, 
1606, 1560, 1353, 1114; ʴH (CDCl3, 300 MHz) 8.36 (2 H, d, J = 8.8 Hz, ArH), 8.01 
(2 H, d, J = 8.8 Hz, ArH), 7.18 (1 H, s, IsoxH), 4.85 (1 H, d, J = 7.2 Hz, NH), 3.78 (1 
H, oct, J = 7.2 Hz, CH), 1.24 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 169.7 
(s), 160.9 (s), 149.4 (s), 144.6 (s), 127.9 (d), 124.4 (d), 105.3 (d), 47.4 (d), 23.8 (q); 
LRMS  (CI
+)  312  (M+H,  100),  147  (19);  312.0654;  HRMS  (CI
+)  calcd  for 
C12H14N3O5S (M+H) 312.0654, observed 312.0654 
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3-Naphthyl-isoxazole-5-sulfonic-acid-isopropylamide (122k) 
 
According to general procedure 7, 118k gave the title compound as a white solid 
(0.13 g, 0.41 mmol, 82%). 
Rf 0.2 (20% EtOAc/petroleum ether); mp 163-165 °C; νmax (thin film, cm
-1) 3288, 
1349, 1126; ʴH (CDCl3, 300 MHz) 8.25 (1 H, s, ArH), 7.85-7.95 (4 H, m, ArH), 7.52-
7.60 (2 H, m, ArH), 7.27 (1 H, s, IsoxH), 5.04 (1 H, d, J = 7.2 Hz, NH), 3.79 (1 H, 
oct, J = 7.2 Hz, CH), 1.24 (6 H, d, J = 7.2 Hz, CH3); ʴC (CDCl3, 75 MHz) 167.3 (s), 
162.9 (s), 134.3 (s), 133.0 (s), 129.1 (d), 128.6 (d), 127.9 (d), 127.6 (d), 127.1 (d), 
127.0 (d), 124.7 (s), 123.5 (d), 105.6 (d), 47.3 (d), 23.8 (q); LRMS (EI) 316 (M
+•, 
70),  194  (100),  127  (49),  84  (54);  HRMS  (EI)  calcd  for  C16H16N2O3S  (M
+•) 
316.0876, observed 316.0880 
4.2.10  Preparation of isoxazole-5-sulfonic-acid-N-methylbenzene sulfonamide  
General Procedure 8 
To a stirred solution of the  isoxazole pentafluorophenyl  sulfonate esters 118 (0.5 
mmol)  in dry THF (12  mL/mmol) was added TBAC (1 mmol)  followed by NEt3 
(0.75 mmol) and N-methylbenzylamine (1.5 mmol). The reaction was refluxed for 
16-24 h and the mixture was diluted with dichloromethane (20 mL), washed with 2M 
HCl (20 mL), saturated NaHCO3 (20 mL) and water (20 mL). The organic layer was 
dried over MgSO4, filtered under gravity, and solvent was removed in vacuo. The 
crude residue was purified by flash chromatography (10% EtOAc/petroleum ether) 
and all products were collected as a single regioisomer as judged by NMR. 
 
3-(4-Methoxyphenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123a) 
 
According to general procedure 8, 118a gave the title compound as a cream solid 132 
 
(0.15 g, 0.42 mmol, 84%). 
Rf 0.19 (20% EtOAc/petroleum ether); mp 98-100 °C; νmax (thin film, cm
-1) 3132, 
1610, 1589, 1495, 1350, 1163; ʴH (CDCl3, 300 MHz) 7.75 (2 H, d, J = 8.5 Hz, ArH), 
7.29-7.41 (5 H, m, ArH), 7.04 (1 H, s, IsoxH), 7.00 (2 H, d, J = 8.5 Hz, ArH), 4.41 (2 
H, s, NCH2), 3.87 (3 H, s, OCH3), 2.85 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 165.6 
(s), 162.1 (s), 161.7 (s), 134.7 (s), 128.8 (d), 128.4 (d), 128.4 (d), 128.3 (d), 119.8 (s), 
114.6 (d), 105.9 (d), 55.4 (q), 54.2 (t), 34.5 (q); LRMS (EI) 358 (M
+•, 45), 239 (100), 
174 (65), 146 (70), 118 (37);  HRMS (EI) calcd for C18H18N2O4S (M
+•) 358.0982, 
observed 358.0976; Anal. calcd: C, 60.32, H, 5.06, N, 7.82, found: C, 60.36, H, 5.01, 
N, 8.00. 
 
3-Phenyl-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123b) 
 
According to general procedure 8, 118b gave the title compound as a cream solid 
(0.11 g, 0.34 mmol, 69%). 
Rf 0.31 (20% EtOAc/petroleum ether); mp 86-89 °C; νmax (thin film, cm
-1) 3153, 
1350, 1153; ʴH (CDCl3, 300 MHz) 7.83 (1 H, d, J = 2.4 Hz, ArH), 7.81 (1 H, d, J = 
2.4 Hz, ArH), 7.51-7.54 (3 H, m, ArH), 7.49-7.51 (1 H, m, ArH), 7.31-7.39 (4 H, m, 
ArH), 7.11 (1 H, s, IsoxH), 4.43 (2 H, s, NCH2), 2.86 (3 H, s, NCH3); ʴC (CDCl3, 75 
MHz) 165.9 (s), 162.5 (s), 134.7 (s), 130.9 (d), 130.6 (s), 129.2 (d), 129.0 (d), 128.9 
(d), 128.8 (d), 128.4 (d), 106.1 (d), 54.3 (t), 34.5 (q); LRMS (EI) 328 (M
+•, 15), 263 
(26),  178  (100),  119  (78);  HRMS  (EI)  calcd  for  C17H16N2O3S  (M
+•)  328.0876, 
observed 328.0870 
 
3-(4-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123c) 
 
According to general procedure 8, 118c gave the title compound as a cream solid 133 
 
(0.11 g, 0.29 mmol, 62%). 
Rf 0.34 (20% EtOAc/petroleum ether); mp 124-1127 °C; νmax (thin film, cm
-1) 3150, 
1600, 1504, 1361, 1161; ʴH (CDCl3, 300 MHz) 7.76 (2 H, dd, J = 8.5, 1.8 Hz, ArH), 
7.48 (2 H, dd, J = 8.5, 1.8 Hz, ArH), 7.31-7.40 (5 H, m, ArCH), 7.07 (1 H, s, IsoxH), 
4.42 (2 H, s, NCH2), 2.86 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 166.3 (s), 161.6 (s), 
137.2 (s), 134.6 (s), 129.9 (d), 128.8 (d), 128.4 (d), 128.3 (d), 128.2 (d), 125.9 (s), 
105.8 (d), 54.8 (t), 34.5 (q); LRMS (EI) 364 (M
+•, 
37Cl, 3), 362 (M
+•, 
35Cl, 8), 196 
(5),  194  (19),  120  (38),  118  (100);  HRMS  (EI)  calcd  for  C17H15ClN2O3S  (M
+•) 
362.0486, observed 362.0491 
 
3-(3-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123d) 
 
According to general procedure 8, 118d gave the title compound as a cream solid 
(0.11 g, 0.31 mmol, 66%). 
Rf 0.42 (20% EtOAc/petroleum ether); mp 93-95 °C; νmax (thin film, cm
-1) 3160, 
1601, 1495, 1353, 1162; ʴH (CDCl3, 300 MHz) 7.81 (1 H, t, J = 1.8 Hz, ArH), 7.69 (1 
H, dt, J = 7.2, 1.8 Hz, ArH), 7.49 (1 H, dt, J = 7.2, 1.8 Hz, ArH), 7.44 (1 H, d, J = 7.2 
Hz, ArH), 7.20-7.39 (5 H, m, ArH), 7.08 (1 H, s, IsoxH), 4.42 (2 H, s, NCH2), 2.86 (3 
H, s, NCH3) ; ʴC (CDCl3, 75 MHz) 166.3 (s), 161.4 (s), 135.3 (s), 134.6 (s), 131.0 
(d), 130.5 (d), 129.3 (d), 128.9 (s), 128.4 (d), 128.3 (d), 127.0 (d), 125.1 (d), 105.9 
(d), 54.2 (t), 34.6 (q); LRMS (EI) 364 (M
+•, 
37Cl, 3), 362 (M
+•, 
35Cl, 8), 180 (6), 178 
(15), 120  (42), 118  (100);  HRMS (EI) calcd  for C17H15ClN2O3S(M
+•) 362.0486, 
observed 362.0482 
 
3-(2-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123e) 
 134 
 
According to general procedure 8, 118e gave the title compound as a yellow solid 
(0.14 g, 0.37 mmol, 79%). 
Rf 0.34 (20% EtOAc/petroleum ether); mp 70-73 °C; νmax (thin film, cm
-1) 3146, 
1598, 1494, 1355, 1162; ʴH (CDCl3, 300 MHz) 7.76 (1 H, dd, J = 7.5, 1.8 Hz, ArH), 
7.52 (1 H, dd, J = 7.5, 1.7 Hz, ArH), 7.46 (1 H, dd, J = 7.5, 1.8 Hz, ArH), 7.42 (1 H, 
t, J = 7.5 Hz, ArH), 7.32-7.38 (5 H, m, ArH), 7.28 (1 H, s, IsoxH), 4.44 (2 H, s, 
NCH2), 2.87 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 165.2 (s), 161.2 (s), 134.5 (s), 
132.9 (s), 131.8 (d), 131.5 (d), 130.6 (d), 130.4 (d), 130.3 (d), 128.8 (d), 128.3 (d), 
122.0 (s), 109.1 (d), 54.2 (t), 34.5 (q); LRMS (EI) 364 (M
+•, 
37Cl, 2), 362 (M
+•, 
35Cl, 
5),  120  (20),  118  (69);  HRMS  (EI)  calcd  for  C17H15ClN2O3S  (M
+•)  362.0486, 
observed 362.0478 
 
3-(4-Bromophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123f) 
 
According to general procedure 8, 118f gave the title compound as a cream solid 
(0.12 g, 0.30 mmol, 62%). 
Rf 0.36 (20% EtOAc/petroleum ether); mp 126-128 °C; νmax (thin film, cm
-1) 2157, 
1595, 1495, 1361, 1161; ʴH (CDCl3, 300 MHz) 7.69 (2 H, d, J = 8.6 Hz, ArH), 7.63 
(2 H, d, J = 8.6 Hz, ArH), 7.29-7.38 (5 H, m, ArH), 7.07 (1 H, s, IsoxH), 4.42 (2 H, s, 
NCH2), 2.88 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 166.3 (s), 161.6 (s), 134.6 (s), 
132.5 (d), 128.8 (d), 128.4 (d), 128.4 (d), 128.3 (d), 126.3 (s), 125.4 (s), 105.8 (d), 
54.2 (t), 34.5 (q); LRMS (EI) 408 (M
+•, 
81Br, 6), 406 (M
+•, 
79Br, 6), 336 (14), 246 
(71), 118 (100);  HRMS (EI) calcd  for C17H15BrN2O3S (M
+•) 405.9981, observed 
405.9991 
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3-(3-Bromophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123g) 
 
According to general procedure 8, 118g gave the title compound as a cream solid 
(0.12 g, 0.29 mmol, 60%). 
Rf 0.3 (20% EtOAc/petroleum ether); mp 111-112 °C; νmax (thin film, cm
-1) 3164, 
1599, 1494, 1364, 1166; ʴH (CDCl3, 300 MHz) 7.97 (1 H, t, J = 1.8 Hz, ArH), 7.74 (1 
H, dt, J = 7.7, 1.8 Hz, ArH), 7.63 (1 H, d, J = 7.7 Hz, ArH), 7.31-7.41 (6 H, m, ArH), 
7.07 (1 H, s, IsoxH), 4.42 (2 H, s, NCH2), 2.86 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 
166.3 (s), 161.3 (s), 134.6 (s), 133.9 (d), 130.8 (d), 129.9 (d), 129.3 (s), 128.8 (d), 
128.4 (d), 128.3 (d), 125.5 (d), 123.3 (s), 105.9 (d), 54.3 (t), 34.6 (q); LRMS (EI) 
408 (M
+•, 
81Br, 9), 406 (M
+•, 
79Br, 8), 336 (10), 246 (40), 120 (100);  HRMS (EI) 
calcd for C17H15BrN2O3S (M
+•) 405.9981, observed 406.0021 
 
3-(2-Bromophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123h) 
 
According to general procedure 8, 118h gave the title compound as a cream solid 
(0.17 g, 0.41mmol, 86%). 
Rf 0.24 (20% EtOAc/petroleum ether); mp 70-71 °C; νmax (thin film, cm
-1) 3147, 
1595, 1495, 1367, 1165; ʴH (CDCl3, 300 MHz) 7.71 (1 H, dd, J = 7.5, 1.0 Hz, ArH), 
7.66 (1 H, dd, J = 7.5, 1.0 Hz, ArH), 7.44 (1 H, td, J = 7.5, 1.0 Hz, ArH), 7.30-7.40 
(6 H, m, ArH), 7.26 (1 H, s, IsoxH), 4.44 (2 H, s, NCH2), 2.87 (3 H, s, NCH3); ʴC 
(CDCl3, 75 MHz) 165.0 (s), 162.5 (s), 134.6 (s), 133.6 (d), 132.2 (d), 131.4 (d), 
128.9 (d), 128.7 (s), 128.4 (d), 128.3 (d), 127.7 (d), 122.2 (s), 109.2 (d), 54.2 (t), 34.5 
(q); LRMS (EI) 408 (M
+•, 
81Br, 8), 406 (M
+•, 
79Br, 8), 336 (10), 246 (16), 120 (100); 
HRMS (EI) calcd for C17H15BrN2O3S (M
+•) 405.9981, observed 405.9989 
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3-(2-Fluorophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123i) 
 
According  to general procedure 8,  118i gave the title compound as a cream solid 
(0.13 g, 0.36 mmol, 73%). 
Rf 0.44 (20% EtOAc/petroleum ether); mp 99-102 °C; νmax (thin film, cm
-1) 3134, 
1599, 1493, 1364, 1166; ʴH (CDCl3, 300 MHz) 7.99 (1 H, td, J = 7.7, 1.1 Hz, ArH), 
7.45-7.55 (1 H, m, ArH), 7.33-7.37 (5 H, m, ArH), 7.29 (1 H, dd, J = 7.7, 1.0 Hz, 
ArH), 7.24 (1 H, s, IsoxH), 7.20 (1 H, t, J = 7.7 Hz, ArH), 4.43 (2 H, s, NCH2), 2.86 
(3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 165.7 (s, JCF = 1.7 Hz), 160.3 (s, JCF = 252.3 
Hz), 158.0 (s, JCF = 1.5 Hz), 134.6 (s), 132.8 (d, JCF = 8.8 Hz), 129.0 (d, JCF = 2.3 
Hz), 128.8 (d), 128.4 (d), 128.3 (d), 124.9 (d, JCF = 3.5 Hz), 116.6 (d, JCF = 21.7 Hz), 
115.6 (s, JCF = 11.7 Hz), 108.4 (d, JCF = 9.9 Hz), 54.2 (t), 34.3 (q); LRMS (EI) 346 
(M
+•,  14),  281  (23),  162  (29),  134  (43),  120  (100);  HRMS  (EI)  calcd  for 
C17H15FN2O3S (M
+•) 346.0782, observed 346.0780 
 
3-(4-Nitrophenyl)-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123j) 
 
According to general procedure 8, 118j gave the title compound as a cream solid (42 
mg, 0.11 mmol, 23%). 
Rf 0.19 (20% EtOAc/petroleum ether); mp 163-167 °C; νmax (thin film, cm
-1) 3184, 
1609, 1560, 1495, 1361, 1164; ʴH (CDCl3, 300 MHz) 8.37 (2 H, d, J = 9.1 Hz, ArH), 
8.01 (2 H, d, J = 9.1 Hz, ArH), 7.31-7.38 (5 H, m, ArH), 7.15 (1 H, s, IsoxH), 4.44 (2 
H, s, NCH2), 2.88 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 167.2 (s), 160.7 (s), 149.2 
(s), 134.4 (s), 133.3 (d), 128.9 (d), 128.4 (d), 128.4 (d), 127.9 (d), 124.5 (s), 105.9 
(d), 54.3 (t), 34.6 (q); LRMS (EI) 373 (M
+•, 100), 343 (24), 189 (91), 143 (39); 
HRMS (EI) calcd for C17H15N3O5S (M
+•) 373.0727, observed 373.0733 
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3-Naphthyl-isoxazole-5-sulfonic-acid-N-methylbenzylamide (123k) 
 
According to general procedure 8, 118k gave the title compound as a cream solid 
(0.14 g, 0.36 mmol, 73%). 
Rf 0.36 (20% EtOAc/petroleum ether); mp 105-108 °C; νmax (thin film, cm
-1) 3156, 
1605, 1515, 1362, 1165; ʴH (CDCl3, 300 MHz) 8.25 (1 H, s, ArH), 7.87-7.97 (4 H, m, 
ArH), 7.55-7.60 (2 H, m, ArH), 7.32-7.39 (5 H, m, ArH), 7.25 (1 H, s, IsoxH), 4.46 
(2 H, s, NCH2), 2.89 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 165.9 (s), 162.6 (s), 134.7 
(s), 134.4 (s), 133.1 (s), 129.2 (d), 128.9 (d), 128.6 (d), 128.4 (d), 128.3 (d), 127.9 
(d), 127.7 (d), 127.2 (d), 127.1 (d), 124.7 (s), 123.5 (d), 106.2 (d), 54.3 (t), 34.6 (q); 
LRMS (EI) 378 (M
+•, 100), 259 (57), 194 (36), 119 (100);  HRMS (EI) calcd for 
C21H18N2O3S (M
+•) 378.1032, observed 378.1043 
4.2.11  Preparation of isoxazole-5-sulfonic-acid-N-phenyl sulfonamide  
General Procedure 9 
To  a  stirred  solution  of  the  isoxazole  pentafluorophenyl  sulfonate  ester  118  (0.5 
mmol)  in dry THF (12  mL/mmol) was added TBAC (1 mmol)  followed by NEt3 
(0.75 mmol) and N-methylbenzylamine (1.5 mmol). The reaction was refluxed for 20 
h and the mixture was diluted with dichloromethane (20 mL), washed with 2M HCl 
(20 mL), saturated NaHCO3 (20 mL) and water (20 mL). The organic layer was dried 
over MgSO4, filtered under gravity, and solvent was removed in vacuo. The crude 
residue was purified by flash chromatography (10% EtOAc/petroleum ether) and all 
products were collected as a single regioisomer as judged by NMR. 
 
3-(4-Methoxyphenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124a) 
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According to general procedure 9, 118a gave the title compound as a cream solid 
(0.15 g, 0.46 mmol, 93%). 
Rf 0.13 (10% EtOAc/petroleum ether); mp 116-117 °C; νmax (thin film, cm
-1) 3167, 
2968, 1608, 1512, 1351, 1162; ʴH (CDCl3, 300 MHz) 7.65 (2 H, d, J = 8.8 Hz, ArH), 
7.32 (2 H, t, J = 7.8 Hz, ArH), 7.20-7.24 (3 H, m, ArH), 7.12 (1 H, s, NH), 6.97 (1 H, 
s, IsoxH), 6.95 (2 H, d, J = 8.8 Hz, ArH) 3.84 (3H, s, OCH3); ʴC (CDCl3, 75 MHz) 
164.9 (s), 162.2 (s), 161.8 (s), 134.5 (s), 129.7 (d), 128.5 (d), 127.0 (s), 123.2 (d), 
119.6 (d), 114.6 (d), 106.5 (d), 55.5 (q);  LRMS (EI) 330 (M
+•, 14), 174 (63), 146 
(100); HRMS (EI) calcd for C16H14N2O4S (M
+•) 330.0668, observed 330.0653; 
 
3-Phenyl-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124b)
192 
 
According to general procedure 9, 118b gave the title compound as a cream solid 
(0.10 g, 0.34 mmol, 68%). 
Rf 0.13 (10% EtOAc/petroleum ether); mp 114-116 °C (lit.
192 mp 120 °C); νmax (thin 
film, cm
-1) 3290, 3067, 1599, 1498, 1353, 1159; ʴH (CDCl3, 300 MHz) 7.74 (2 H, dd, 
J = 8.2, 1.4 Hz, ArH), 7.46-7.53 (3 H, m, ArH), 7.32 (2 H, dd, J = 7.2, 1.6 Hz, ArH), 
7.20-7.25 (3 H, m, ArH), 7.04 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 165.3 (s), 162.7 
(s), 134.4 (s), 131.1 (d), 129.7 (d), 129.2 (d), 127.2 (s), 127.0 (d), 127.0 (d), 123.2 
(d), 107.1 (d); LRMS (EI) 300 (M
+•, 13), 236 (54), 144 (87), 116 (100), 105 (63); 
HRMS (EI) calcd for C15H12N2O3S (M
+•) 300.0563, observed 300.0574 
 
3-(4-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124c) 
 
According to general procedure 9, 118c gave the title compound as a cream solid 139 
 
(0.11 g, 0.34 mmol, 68%). 
Rf 0.10 (20% EtOAc/petroleum ether); mp 153-155 °C; νmax (thin film, cm
-1) 3238, 
3152, 1601, 1492, 1351, 1169; ʴH (CDCl3, 300 MHz) 7.66 (2 H, d, J = 8.5 Hz, ArH), 
7.43 (2 H, d, J = 8.5 Hz, ArH), 7.32 (2 H, t, J = 7.2 Hz, ArH), 7.20-7.25 (3 H, m, 
ArH), 7.10 (1 H, s, NH), 7.01 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 165.7 (s), 161.6 
(s), 137.2 (s), 134.0 (s), 129.7 (d), 129.5 (d), 128.2 (d), 127.1 (d), 125.6 (s), 123.1 
(d), 106.8 (d); LRMS (EI) 336 (M
+•, 
37Cl, 9), 334 (M
+•, 
35Cl, 26), 272 (24), 270 (63), 
152 (35), 150 (100); HRMS (EI) calcd for C15H11ClN2O3S (M
+•) 334.0173, observed 
334.0176 
 
3-(3-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124d) 
 
According to general procedure 9, 118d gave the title compound as a cream solid 
(0.10 g, 0.31 mmol, 62%). 
Rf 0.11 (10% EtOAc/petroleum ether); mp 138-139 °C; νmax (thin film, cm
-1) 3255, 
3076, 1597, 1493, 1348, 1171; ʴH (CDCl3, 300 MHz) 7.74 (1 H, t, J = 1.9 Hz, ArH), 
7.62 (1 H, dt, J = 7.7, 1.6 Hz, ArH), 7.45 (1 H, t, J = 7.6 Hz, ArH), 7.39 (1 H, t, J = 
7.7 Hz, ArH), 7.33 (2 H, t, J = 8.2 Hz, ArH), 7.21-7.25 (3 H, m, ArH), 7.08 (1 H, s, 
NH), 7.02 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 165.7 (s), 161.6 (s), 135.3 (s), 134.3 
(s), 131.1 (d), 130.5 (d), 129.8 (d), 128.9 (s), 127.2 (d), 127.1 (d), 125.1 (d), 123.1 
(d), 107.0 (d); LRMS (EI) 336 (M
+•, 
37Cl, 19), 334 (M
+•, 
35Cl, 59), 272 (17), 270 
(23), 180 (24), 178 (71);  HRMS (EI) calcd  for C15H11ClN2O3S (M
+•) 334.0173, 
observed 334.0183 
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3-(2-Chlorophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124e) 
 
According to general procedure 9, 118e gave the title compound as a cream solid (73 
mg, 0.22 mmol, 43%). 
Rf 0.10 (10% EtOAc/petroleum ether);  mp 94-96 °C;  νmax (thin film, cm
-1) 3149, 
1596, 1494, 1362, 1168; ʴH (CDCl3, 300 MHz) 7.68 (1 H, d, J = 7.5 Hz, ArH), 7.45 
(1 H, t, J = 7.5 Hz, ArH), 7.35-7.42 (2 H, m, ArH), 7.32 (2 H, t, J = 7.5 Hz , ArH), 
7.20-7.25 (3 H, m, ArH), 7.18 (1 H, s, IsoxH);  ʴC (CDCl3, 75 MHz) 164.4 (s), 161.3 
(s), 134.5 (s), 132.9 (s), 131.8 (d), 130.9 (d), 130.5 (d), 129.6 (d), 127.3 (d), 126.9 
(d), 126.4 (s), 123.1 (d), 110.2 (d); LRMS (EI) 336 (M
+•, 
37Cl, 6), 334 (M
+•, 
35Cl, 
21), 272 (17), 270 (54), 180 (28), 178 (76), 152 (34), 150 (100); HRMS (EI) calcd 
for C15H11ClN2O3S (M
+•) 334.0173, observed 334.0183 
 
3-(4-Bromophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124f) 
 
According to general procedure 9, 118f gave the title compound as a cream solid 
(0.15 g, 0.40 mmol, 80%). 
Rf 0.15 (10% EtOAc/petroleum ether); mp 156-158 °C; νmax (thin film, cm
-1) 3241, 
3151, 1597, 1492, 1350, 1175; ʴH (CDCl3, 300 MHz) 7.60 (4 H, br s, ArH), 7.32 (2 
H, t, J = 7.3 Hz, ArH), 7.21-7.25 (3 H, m, ArH), 7.09 (1 H, s, NH), 7.00 (1 H, s, 
IsoxH); ʴC (CDCl3, 75 MHz) 166.0 (s), 161.6 (s), 135.7 (s), 132.2 (d), 129.3 (d), 
128.9 (d), 126.0 (s), 125.4 (d), 124.6 (s), 121.2 (d), 106.9 (d); LRMS (EI) 380 (M
+•, 
81Br, 17), 378 (M
+•, 
79Br, 17), 316 (46), 314 (53), 224 (100), 222 (93), 196 (93), 194 
(96); HRMS (EI) calcd for C15H11BrN2O3S (M
+•) 377.9668, observed 377.9672 
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3-(3-Bromophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124g) 
 
According to general procedure 9, 118g gave the title compound as a cream solid (79 
mg, 0.21 mmol, 42%). 
Rf 0.13 (10% EtOAc/petroleum ether); mp 137-140 °C; νmax (thin film, cm
-1) 3256, 
3074, 1596, 1493, 1349, 1169; ʴH (CDCl3, 300 MHz) 7.89 (1 H, s, ArH), 7.66 (1 H, 
d, J = 7.2 Hz, ArH), 7.60 (1 H, d, J = 7.2 Hz, ArH), 7.33-7.41 (3 H, m, ArH), 7.20-
7.25 (3 H, m, ArH), 7.02 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 165.7 (s), 161.4 (s), 
134.3 (s), 134.0 (d), 130.7 (d), 129.9 (d), 129.8 (d), 129.1 (s), 127.2 (d), 125.5 (d), 
123.3 (s), 123.2 (d), 107.0 (d); LRMS (EI) 380 (M
+•, 
81Br, 15), 378, (M
+•, 
79Br, 15), 
316 (49), 314 (51), 224 (65), 222 (67), 196 (43), 194 (41), 157 (45), 155 (47), 105 
(100); HRMS (EI) calcd for C15H11BrN2O3S (M
+•) 377.9668, observed 377.9668 
 
3-(2-Bromophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124h) 
 
According to general procedure 9, 118h gave the title compound as a cream solid (88 
mg, 0.23 mmol, 47%). 
Rf 0.12 (10% EtOAc/petroleum ether);  mp 81-83 °C;  νmax (thin film, cm
-1) 3149, 
1593, 1493, 1362, 1169; ʴH (CDCl3, 300 MHz) 7.66 (1 H, dd, J = 8.0, 1.3 Hz, ArH), 
7.59 (1 H, dd, J = 8.0, 1.3 Hz, ArH), 7.39 (1 H, td, J = 8.0, 1.4 Hz, ArH), 7.30-7.35 
(3 H, m, ArH), 7.21-7.25 (3 H, m, ArH), 7.13 (1 H, s, IsoxH);  ʴC (CDCl3, 75 MHz) 
164.1 (s), 162.6 (s), 134.1 (s), 133.7 (d), 131.9 (d), 131.3 (d), 129.6 (d), 128.5 (s), 
127.8 (d), 127.9 (d), 123.2 (d), 122.2 (s), 110.4 (d); LRMS (EI) 380 (M
+•, 
81Br, 13), 
378 (M
+•, 
79Br, 13), 316 (64), 314 (63), 224 (55), 222 (58), 196 (99), 194 (100); 142 
 
HRMS (EI) calcd for C15H11BrN2O3S (M
+•) 377.9668, observed 377.9668 
 
3-(2-Fluorophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124i) 
 
According to general procedure 9, 118i gave the title compound as a cream solid (27 
mg, 0.08 mmol, 17%). 
Rf 0.15 (10% EtOAc/petroleum ether); mp  120-122 °C; νmax (thin film, cm
-1) 3218, 
2923, 1598, 1462, 1414, 1360, 1154; ʴH (CDCl3, 300 MHz)  7.93 (1 H, t, J = 7.6 Hz, 
ArH), 7.46 (1 H, t, J = 7.5 Hz, ArH), 7.28-7.35 (3 H, m, ArH), 7.18-7.27 (4 H, m, 
ArH & IsoxH), 7.17 (1 H, t, J= 8.3 Hz, ArH); ʴC (CDCl3, 75 MHz) 165.2 (s), 160.2 
(s, JCF = 252.4 Hz), 158.1 (s), 134.0 (s), 132.8  (d, JCF = 8.6 Hz), 129.7 (d), 129.0 (d, 
JCF = 2.9 Hz),  126.9 (d), 124.9 (d, JCF = 3.8 Hz), 122.9 (d), 116.6 (d, JCF = 21.1 Hz), 
115.4 (s, JCF = 11.5 Hz), 109.4 (d, JCF = 9.6 Hz); LRMS (EI) 318 (M
+•, 100), 254 
(15); HRMS (EI) calcd for C15H11FN2O3S (M
+•) 318.0469, observed 318.0472 
 
3-(4-Nitrophenyl)-isoxazole-5-sulfonic-acid-N-phenylsulfonamide (124j) 
 
According to general procedure 9, 118j gave the title compound as a cream solid (76 
mg, 0.22 mmol, 44%). 
Rf 0.09 (10% EtOAc/petroleum ether); mp 168-171 °C; νmax (thin film, cm
-1) 3283, 
3103, 1611, 1562, 1491, 1355, 1338, 1174; ʴH (CDCl3, 300 MHz) 8.33 (2 H, d, J = 
8.8 Hz, ArH), 7.94 (2 H, d, J = 8.8 Hz, ArH), 7.34 (2 H, t, J = 7.8 Hz, ArH), 7.20-
7.25 (3 H, m, ArH), 7.09 (1 H, m, IsoxH), 6.97 (1 H, s, NH); ʴC (CDCl3, 75 MHz) 
166.5 (s), 160.9 (s), 149.3 (s), 134.1 (s), 133.1 (s), 129.8 (d), 127.9 (d), 127.3 (d), 
124.0 (d), 123.28 (d), 107.0 (d); LRMS (EI) 345 (M
+•, 100), 281 (62), 189 (71), 163 143 
 
(22); HRMS (EI) calcd for C15H11N3O5S (M
+•) 345.0414, observed 345.0414 
 
3-Naphthylisoxazole-5-sulfonic-acid-N-phenylsulfonamide (124k) 
 
According to general procedure 9, 118k gave the title compound as a pink solid (80 
mg, 0.23 mmol, 46%). 
Rf 0.08 (10% EtOAc/petroleum ether); mp 139-141 °C; νmax (thin film, cm
-1) 3220, 
3051, 1595, 1494, 1352, 1170; ʴH (CDCl3, 300 MHz) 8.17 (1 H, s, ArH), 7.89 (1 H, t, 
J = 8.2 Hz, ArH), 7.84-7.87 (3 H, m, ArH), 7.54-7.61 (2 H, m, ArH), 7.33 (2 H, t, J = 
7.2 Hz, ArH), 7.20-7.25 (3 H, m, ArH), 7.19 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 
165.4 (s), 162.7 (s), 134.5 (s), 134.4 (s), 133.0 (s), 129.7 (s), 129.2 (d), 128.6 (d), 
127.9 (d), 127.7 (d), 127.3 (d), 127.1 (d), 127.0 (d), 124.5 (d), 123.5 (d), 123.2 (d), 
107.3  (d);  LRMS  (EI)  350  (M
+•,  30),  286  (23),  194  (100),  166  (61),  127  (65); 
HRMS (EI) calcd for C19H14N2O3S (M
+•) 350.0719, observed 350.0707 
 
4.3  Experimental procedure for Chapter 2.4 
Ethenesulfonic acid-4-methylbenzylamide (141)
113 
 
A premixed suspension of 4-methylbenzylamine (15 mL, 55 mmol, 1.1 eq.) and NEt3 
(14.6 mL, 105 mmol, 2.1 eq.) in dichloromethane (19 mL) was added dropwise to a 
stirring  solution  of  2-chloroethane  sulfonylchloride  111  (8.2  g,  50  mmol)  in 
dichloromethane (75 mL) at -10 °C. The reaction mixture was stirred for further 30 
min after the addition and warmed slowly to RT. The reaction mixture was diluted 
with dichloromethane and washed with 2M HCl and water. The organic layer was 
dried  with  MgSO4,  filtered  and  solvent  removed  in  vacuo.  Crude  residue  was 
purified by flash chromatography (starting 3:1 petroleum ether/Et2O) to give the title 144 
 
compound as a white solid (7.8 g, 37 mmol, 74%). 
Rf 0.21 (1:1 petroleum ether/Et2O); mp 83-86 °C (lit.
113 mp 87 °C); νmax (thin film, 
cm
-1) 3222, 3043, 1611, 1515, 1317, 1146; ʴH (CDCl3, 500 MHz) 7.19 (2 H, d, J = 
8.2 Hz, ArH), 7.14 (2  H, d, J = 8.2 Hz, ArH), 6.46 (1  H, dd,  J = 16.5, 9.9 Hz, 
CH2CH),  6.23  (1  H,  d,  J  =  16.5  Hz,  CHCHHtrans),  5.88  (1  H,  d,  J  =  9.9  Hz, 
CHCHHcis), 4.71 (1 H, t, J = 4.9 Hz, NH), 4.15 (2 H, d, J = 4.9 Hz, NCH2), 2.33 (3 
H, s, CH3); ʴC (CDCl3, 125 MHz) 137.9 (s), 136.1 (d), 133.5 (s), 129.5 (d), 128.0 (d), 
126.7 (t), 46.9 (t), 21.2 (q); LRMS (EI) 211 (M
+•, 6), 120 (100), 105 (23); HRMS 
(EI) calcd for C10H13NO2S (M
+•) 211.0661, observed 211.0666 
4.3.1  Preparation of N-methyl nitrone 
General Procedure 10 
To N-methylhydroxylamine.HCl (24  mmol)  in dry dichloromethane (1  mL/mmol) 
was added aldehyde (20 mmol) and NaHCO3 (60 mmol). The mixture was refluxed 
for 2 h and the  resulting suspension  was  filtered. Solid residue was  washed with 
dichloromethane and the combined organic layer was dried with MgSO4, filtered and 
solvent  was  removed  in  vacuo.  All  products  were  collected  as  a  single 
diastereoisomer as judged by NMR 
 
C-(5-Bromofuryl)-N-methyl nitrone (140a)
113 
 
According to general procedure 10 to give the title compound as a white solid (2.7 g, 
13 mmol, 67%). 
Rf 0.56 (9:1 CH2Cl2/MeOH); mp 143-144 °C (lit.
113 mp 143 °C); νmax (thin film, cm
-
1) 3177, 2942, 1601, 1549, 1483, 1385, 686; ʴH (CDCl3, 500 MHz) 7.68 (1 H, d, J = 
3.7 Hz, furylH), 7.47 (1 H, s, NCH), 6.46 (1 H, d, J = 3.7 Hz, furylH), 3.80 (3 H, s, 
NCH3); ʴC (CDCl3, 125 MHz) 148.7 (s), 125.3 (d), 124.4 (s), 117.5 (d), 114.3 (d), 
52.9 (q); LRMS (EI) 205 (M
+•, 
81Br, 98), 203 (M
+•, 
79Br, 100); HRMS (EI) calcd for 
C6H7BrNO2 (M
+•) 202.9576, observed 202.9567 
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C-(5-Chlorofuryl)-N-methyl nitrone (140b) 
 
According to general procedure 10 to give the title compound as a yellow oil (1.9 g, 
12 mmol, 64%). 
Rf 0.52 (9:1 CH2Cl2/MeOH); νmax (thin film, cm
-1) 3167, 3079, 2941, 1598, 1493, 
1393, 783; ʴH (CDCl3, 500 MHz) 7.67 (1 H, d, J = 3.6 Hz, furylH), 7.43 (1 H, s, 
NCH), 6.28 (1 H, d, J = 3.6 Hz, furylH), 3.77 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 
148.5 (s), 125.2 (d), 124.5(s), 117.2 (d), 109.1 (d), 25.8 (q);  LRMS (EI) 161 (M
+•, 
37Cl, 35), 159 (M
+•, 
35Cl, 100), 129 (41); HRMS (EI) calcd for C6H7ClNO2 (M
+•) 
159.0081, observed 159.0086 
 
N-Methyl-C-phenyl nitrone (140c)
113 
 
According to general procedure 10 to give the title compound as a white solid (1.8 g, 
13 mmol, 66%). 
Rf 0.5 (9:1 CH2Cl 2/MeOH);  mp 87-89 °C (lit.
113 mp 90 °C); νmax (thin film, cm
-1) 
3058, 2932, 1693, 1594, 1399, 1163, 942, 754; ʴH (CDCl3, 300 MHz) 8.14-8.22 (2 H, 
m, ArH), 7.36-7.43 (3 H, m, ArH), 7.33 (1 H, s, NCH), 3.81 (3 H, s, NCH3); ʴC 
(CDCl3, 75 MHz) 135.2 (d), 130.5  (d), 130.4  (s), 128.4  (d), 128.4  (d), 54.4 (q); 
LRMS (EI) 135 (M
+•, 93), 134 (M-H, 92), 118 (21); HRMS (EI) calcd for C8H9NO 
(M
+•) 135.0678, observed 135.0673 
 
C-(4-Chlorophenyl)-N-methyl nitrone (140d)
113 
 
According to general procedure 10 to give the title compound as a white solid (2.7 g, 
16 mmol, 78%). 
Rf 0.5 (9:1 CH2Cl2/MeOH); mp 130-133 °C (lit.
113 mp 135 °C); νmax (thin film, cm
-
1) 3084, 3036, 2944, 1590, 1556, 1482, 704; ʴH (CDCl3, 300 MHz) 8.13 (2 H, d, J = 
8.5 Hz, ArH), 7.34 (2 H, d, J = 8.5 Hz, ArH), 7.32 (1 H, s, NCH), 3.83 (3 H, s, 146 
 
NCH3); ʴC (CDCl3, 75 MHz) 171.8 (s), 135.8 (s), 134.0 (d), 129.5 (d), 128.9 (d), 54.4 
(q); LRMS (EI) 171 (M
+•, 
37Cl, 34), 169 (M
+•, 
35Cl, 97), 141 (22); HRMS (EI) calcd 
for C8H8ClNO (M
+•) 169.0289, observed 169.0287 
 
N-Methyl-C-(2-nitrophenyl) nitrone (140e) 
 
According to general procedure 10 to give the title compound as a yellow solid (2.9 
g, 16 mmol, 81%). 
Rf 0.52 (9:1 CH2Cl2/MeOH);  mp 122-123 °C; νmax (thin  film, cm
-1)  3101, 3051, 
1605, 1508, 1420, 1345; ʴH (CDCl3, 500 MHz) 9.13 (1 H, dd, J = 7.8, 1.4 Hz, ArH), 
8.01 (1 H, dd, J = 7.8, 1.4 Hz, ArH), 8.01 (1 H, s, NCH), 7.68 (1 H, td, J = 7.6, 1.4 
Hz, ArH), 7.51 (1 H, td, J = 7.8, 1.4 Hz, ArH), 3.93 (3 H, s, NCH3); ʴC (CDCl3, 125 
MHz) 147.2 (s), 133.5 (d), 130.2 (d), 129.4 (d), 129.1 (d), 124.9 (d), 124.4 (s), 55.6 
(q);  LRMS (EI) 180 (M
+•, 3), 135 (100); HRMS (EI) calcd  for C8H9N2O3  (M
+•) 
180.0529, observed 180.0525 
 
C-(4-Fluorophenyl)-N-methyl nitrone (140f) 
 
According to general procedure 10 to give the title compound as a white solid (2.9 g, 
19 mmol, 96%). 
Rf 0.48 (9:1 CH2Cl2/MeOH);  mp 113-115 °C; νmax (thin  film, cm
-1)  3079, 3010, 
2946, 1595, 1578, 1499, 1167, 858; ʴH (CDCl3, 500 MHz) 8.23 (2 H, dd, J = 8.8, 2.0 
Hz, ArH), 7.33 (1 H, s, NCH), 7.07 (2 H, d, J = 8.8 Hz, ArH), 3.83 (3 H, s, NCH3); 
ʴC (CDCl3, 125 MHz) 163.3 (s, JCF = 252.4 Hz), 134.1 (d), 130.6 (d, JCF = 8.6 Hz), 
127.0 (s, JCF = 2.9 Hz), 115.7 (d, JCF = 21.1 Hz), 54.3 (q); LRMS (EI) 153 (M
+•, 82), 
152  (M-H,  100),  107  (15);  HRMS  (EI)  calcd  for  C8H8FNO  (M
+•)  153.0584, 
observed 153.0578 
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C-(2-Fluorophenyl)-N-methyl nitrone (140g)
113 
 
According to general procedure 10 to give the title compound as a white solid (2.8 g, 
18 mmol, 92%). 
Rf 0.52 (9:1 CH2Cl 2/MeOH); mp 58-60 °C (lit.
113 mp 59 °C); νmax (thin film, cm
-1) 
3111, 3053, 3001, 2942, 1650, 1609, 1586, 1476, 802; ʴH (CDCl3, 300 MHz) 9.20-
9.27 (1 H, m, ArH), 7.64 (1 H, s, NCH), 7.35-7.42 (1 H, m, ArH), 7.19 (1 H, t, J = 
7.5 Hz, ArH), 7.05-7.09 (1 H, m, ArH), 3.89 (3 H, s, NCH3); ʴC (CDCl3, 75 MHz) 
160.1 (s, JCF = 252.9 Hz), 131.7 (d, JCF = 8.8 Hz), 128.6 (d), 127.4 (d, JCF = 7.9 Hz), 
124.4 (d, JCF = 3.5 Hz), 118.9 (s, JCF = 9.1 Hz), 114.6 (d, JCF = 21.1 Hz), 54.9 (q); 
LRMS (EI) 153 (M
+•, 88), 152 (M-H, 19), 136 (32), 125 (68), 107 (100);  HRMS 
(EI) calcd for C8H8FNO (M
+•) 153.0584, observed 153.0579 
 
C-(4-Iodophenyl)-N-methyl nitrone (140h) 
 
According to general procedure 10 to give the title compound as a white solid (1.9 g, 
7.2 mmol, 92%). 
Rf 0.52 (9:1 CH2Cl2/MeOH);  mp 162-164 °C; νmax (thin  film, cm
-1)  3075, 1927, 
1621, 1589, 1477, 1389, 1165, 827; ʴH (CDCl3, 300 MHz) 7.93 (2 H, dd, J = 8.5, 1.6 
Hz, ArH), 7.73 (2 H, dd, J = 8.5, 1.4 Hz, ArH), 7.31 (1 H, s, NCH), 3.84 (3 H, s, 
NCH3); ʴC (CDCl3, 75 MHz) 137.7 (d), 134.3 (s), 129.8 (d), 129.6 (d), 96.4 (s), 54.6 
(q); LRMS (EI) 261 (M
+•, 100), 260 (M-H, 12); HRMS (EI)  calcd  for C8H8INO 
(M
+•) 260.9645, observed 260.9633 
 
C-(2-Iodophenyl)-N-methyl nitrone (140i)
113 
 
According to general procedure 10 to give the title compound as a white solid (2.0 g, 
7.7 mmol, 98%). 148 
 
Rf 0.58 (9:1 CH2Cl2/MeOH); mp 146-147 °C (lit.
113 mp 124 °C); νmax (thin film, cm
-
1) 3085, 3020, 1572, 1459, 1163, 674; ʴH (CDCl3, 300 MHz) 9.19 (1 H, dd, J = 8.0, 
1.6 Hz, ArH), 7.90 (1 H, dd, J = 8.0, 1.5 Hz, ArH), 7.70 (1 H, s, NCH), 7.42 (1 H, t, J 
= 8.0 Hz, ArH), 7.06 (1 H, td, J = 8.0, 1.6 Hz, ArH), 3.92 (3 H, s, NCH3); ʴC (CDCl3, 
75 MHz) 139.7 (d), 132.3 (s), 131.8 (d), 131.5 (d), 129.1 (d), 128.4 (d), 96.4 (s), 55.2 
(q); LRMS (EI) 261 (M
+•, 3), 107 (7), 91 (100);  HRMS (EI) calcd for C8H8INO 
(M
+•) 260.9645, observed 260.9644  
 
N-Methyl-C-(4-nitrophenyl) nitrone (140j)
113 
 
According to general procedure 10 to give the title compound as a yellow solid (2.3 
g, 13 mmol, 67%). 
Rf 0.58 (9:1 CH2Cl2/MeOH); mp 216-218 °C (lit.
113 mp 219 °C); νmax (thin film, cm
-
1) 3112, 3082, 3022, 2953, 1708, 1597, 1508, 1333, 1164; ʴH (CDCl3, 300 MHz) 8.37 
(2 H, d, J = 8.9 Hz, ArH), 8.25 (2 H, d, J = 8.9 Hz, ArH),7.52 (1 H, s, NCH), 3.95 (3 
H, s, NCH3); ʴC (CDCl3, 75 MHz) 147.9 (s), 136.0 (s), 133.2 (d), 128.7 (d), 123.9 
(d), 55.2 (q); LRMS (EI) 180 (M
+•, 100), 179 (M-H, 56), 133 (54); HRMS (EI) 
calcd for C8H9N2O3 (M
+•) 180.0529, observed 180.0533 
4.3.2  Preparation of isoxazolidine pentafluorophenyl sulfonate ester 
(3S*,  4S*)-3-Furyl-2-methylisoxazolidine-4-pentafluorophenyl  sulfonate  ester 
(135)
122 
 
To a stirred solution of pentafluorophenyl ethenesulfonate 110 (0.41 g, 1.5 mmol) in 
toluene (5 mL) was added C-furyl-N-methyl nitrone (0.27 g, 2.2 mmol, 1.5 eq.) and 
refluxed for 3 h. Solvent was removed in vacuo and the residue was purified by flash 
chromatography (2:1 petroleum ether/Et2O) to give the title compound as a clear oil 
and as a single diastereoisomer as judged by NMR (0.40 g, 1.0 mmol, 67%). 
Rf 0.37 (2:1 petroleum ether/Et2O); νmax (thin film, cm
-1) 2881, 1736, 1515, 1381, 
1187, 990; ʴH (CDCl3, 500 MHz) 7.46 (1 H, br s, furylH), 6.48 (1 H, d, J = 3.2 Hz, 149 
 
furylH), 6.38 (1 H, d, J = 3.2 Hz, furylH), 4.69 (1 H, td, J = 8.8, 3.3 Hz, SCH), 4.59 
(1 H, dd, J = 10.3, 3.3 Hz, SCHCHH), 4.48 (1 H, dd, J = 10.3, 8.8 Hz, SCHCHH), 
4.17 (1 H, br s, NCH), 2.76 (3 H, s, NCH3); ʴC (CDCl3, 125 MHz) 146.7 (s), 144.0 
(d), 111.1 (d), 110.9 (d), 69.8 (d), 67.6 (d), 66.8 (t), 43.0 (q); LRMS (EI) 399 (M
+•, 
14),  125  (20),  107  (43),  94  (100);  HRMS  (EI)  calcd  for  C14H10F5NO5S  (M
+•) 
399.0194, observed 399.0206 
 
(3S*,  4S*)-3-(5-Bromofuryl)-2-methylisoxazolidine-4-pentafluorophenyl 
sulfonate ester (136)
113 
 
To a stirred solution of pentafluorophenyl ethenesulfonate 110 (0.41 g, 1.5 mmol) in 
toluene  (5  mL)  was  added  C-(5-bromofuryl)-N-methyl  nitrone  140a  (0.45  g,  2.2 
mmol, 1.5 eq.) and refluxed for 3 h. Solvent was removed in vacuo and the residue 
was purified by  flash chromatography (2:1 petroleum ether/Et2O) to give the title 
compound as a clear oil and as a single diastereoisomer as judged by NMR (0.52 g, 
1.1 mmol, 73%). 
Rf 0.48 (2:1 petroleum ether/Et2O); νmax (thin film, cm
-1) 3059, 2919, 1728, 1598, 
1577, 1515, 1388, 1186; ʴH (CDCl3, 500 MHz) 6.47 (1 H, d, J = 3.3 Hz, furylH), 
6.31 (1 H, d, J = 3.3 Hz, furylH), 4.65 (1 H, td, J = 8.5, 3.1 Hz, SCH), 4.57 (1 H, dd, 
J = 10.2, 3.1 Hz, SCHCHH), 4.49 (1 H, dd, J = 10.2, 8.4 Hz, SCHCHH), 4.11 (1 H, 
br s, NCH), 2.78 (3 H, s, NCH3); ʴC (CDCl3, 125 MHz) 148.7 (s), 123.9 (s), 113.9 
(d), 112.7 (d), 69.7 (d), 67.5 (d), 66.8 (t), 42.9 (q); LRMS (EI) 479 (M
+•, 
81Br, 96), 
478 (M
+•, 
79Br, 95), 433 (
81Br, 37), 431 (
79Br, 34), 205 (
81Br, 77), 203 (
79Br, 74), 184 
(100), 120 (64); HRMS (EI) calcd  for C14H9BrF5NO5S (M
+•) 476.9299, observed 
476.9303 
4.3.3  Preparation of isoxazolidine-4-methylbenzyl sulfonamide 
General procedure 11 
To a stirred solution of 4-methylbenzyl ethenesulfonamide 141 (1 mmol) in toluene 
(5 mL/mmol) was added nitrone 140 (3 mmol) and the mixture was then heated in 150 
 
microwave  at  140  °C  for  30  min.  The  crude  residue  was  purified  by  flash 
chromatography (starting 10:1 petroleum ether/Et2O) and all products were collected 
as a single diastereoisomer as judged by NMR. 
 
(3S*, 4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic acid 4-methylbenzylamide 
(142a)
113, 122 
 
According to general procedure 11, 140c gave the title compound as a yellow oil 
(0.10 g, 0.30 mmol, 34%). 
Rf 0.29 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3284, 2922, 2874, 1736, 
1516, 1455, 1327, 1147; ʴH (CDCl3, 500 MHz) 7.41-7.45 (2 H, m, ArH), 7.37-7.40 (3 
H, m, ArH), 7.05 (2 H, d, J = 7.9 Hz, ArH), 6.94 (2 H, d, J = 7.9 Hz, ArH), 5.09 (1 H, 
t, J = 5.6 Hz, NH), 4.33 (1 H, dd, J = 9.7, 3.6 Hz, SCHCHH), 4.22 (1 H, app dt, J = 
9.7, 8.3 Hz, SCHCHH), 4.07 (1 H, dd, J = 13.8, 5.6 Hz, NCHHAr), 3.92 (1 H, td, J = 
8.0, 3.6 Hz, SCH), 3.85 (1 H, d, J = 13.8 Hz, NCHHAr), 3.83 (1 H, d, J = 8.0 Hz, 
NCH), 2.57 (3 H, s, NCH3), 2.31 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 137.9 (s), 
136.9 (s), 133.6 (s), 129.6 (d), 129.0 (d), 128.8 (d), 128.5 (d), 128.2 (d) , 74.5 (d), 
73.3 (d), 66.9 (t), 47.0 (t), 42.8 (q), 21.2 (q); LRMS (EI) 346 (M
+•, 12), 160 (100), 
134 (21), 117 (46); HRMS (EI) calcd for C18H22N2O3S (M
+•) 346.1345, observed 
346.1353 
 
(3S*,  4S*)-3-(4-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142b) 
 
According to general procedure 11, 140f gave the title compound as a cream solid 
(94 mg, 0.26 mmol, 26%). 
Rf 0.29 (1:2 petroleum ether/Et2O);  mp 129-132 °C; νmax (thin  film, cm
-1)  3284, 151 
 
2923, 2874, 1606, 1510, 1324, 1146, 841; ʴH (CDCl3, 500 MHz) 7.37 (2 H, d, J = 8.5 
Hz, ArH), 7.07 (2 H, d, J = 8.0 Hz, ArH), 7.03 (2 H, d, J = 8.5 Hz, ArH), 6.97 (2 H, 
d, J = 8.0 Hz, ArH), 4.93 (1 H, t, J = 5.3 Hz, NH), 4.31 (1 H, dd, J = 9.7, 3.3 Hz, 
SCHCHH), 4.19 (1 H, dd, J = 9.7, 7.8 Hz, SCHCHH), 4.11 (1 H, dd, J = 13.7, 5.3 
Hz, NCHHAr), 3.96 (1H, dd, J = 13.7, 5.3 Hz, NCHHAr), 3.79-3.84 (2 H, m, SCH & 
NCH), 2.57 (3 H, s, NCH3), 2.31 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 162.9 (s, JCF = 
248.6 Hz), 138.0 (s), 133.3 (s), 132.8 (s, JCF = 2.9 Hz), 130.0 (d, JCF = 8.6 Hz), 129.6 
(d), 128.0 (d), 116.0 (d, JCF = 22.1 Hz), 73.6 (d), 72.2 (d), 66.9 (t), 46.3 (t), 42.7 (q), 
21.2  (q);  LRMS  (EI)  364  (M
+•,  8),  178  (100),  135  (30);  HRMS  (EI)  calcd  for 
C18H21FN2O3S (M
+•) 364.1251, observed 364.1246 
 
(3S*,  4S*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142c)
113 
 
According to general procedure 11, 140d gave the title compound as a yellow oil 
(0.11 g, 0.30 mmol, 31%). 
Rf 0.29 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3285, 2922, 2874, 1736, 
1599, 1492, 1323, 1145, 736; ʴH (CDCl3, 500 MHz) 7.31-7.34 (4 H, m, ArH), 7.07 (2 
H, d, J = 8.0 Hz, ArH), 6.96 (2 H, d, J = 8.0 Hz, ArH), 5.00 (1 H, t, J = 5.5 Hz, NH), 
4.30 (1 H, dd, J = 9.7, 3.3 Hz, SCHCHH), 4.18 (1 H, dd, J = 9.7, 7.9 Hz, SCHCHH), 
4.11  (1  H,  dd,  J  =  13.8,  5.6  Hz,  NCHHAr),  3.97  (1H,  dd,  J  =  13.8,  5.5  Hz, 
NCHHAr), 3.77-3.82 (2 H, m, SCH & NCH), 2.57 (3 H, s, NCH3), 2.32 (3 H, s, 
CH3); ʴC  (CDCl3, 125 MHz) 137.9 (s), 135.6 (s), 134.6 (s), 133.2 (s), 129.6 (d), 
129.2 (d), 128.9 (d), 128.0 (d), 73.6 (d), 72.2 (d), 67.0 (t), 47.5 (t), 42.8 (q), 21.2 (q); 
LRMS (EI) 382 (M
+•, 
37Cl, 2), 380 (M
+•, 
35Cl, 5), 196 (
37Cl, 38), 194 (
35Cl, 100), 178 
(25), 151  (42), 120  (51); HRMS (EI) calcd  for C18H21ClN2O3S (M
+•) 380.0956, 
observed 380.0963 
 
 
 152 
 
(3S*,  4S*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142d)
113 
 
According to general procedure 11 to give the title compound as a cream solid (0.13 
g, 0.31 mmol, 30%). 
Rf 0.31 (1:2 petroleum ether/Et2O);  mp 112-113 °C (lit.
113 mp 98 °C); νmax (thin 
film, cm
-1) 3284, 2920, 2873, 1736, 1592, 1488, 1324, 1146, 686; ʴH (CDCl3, 500 
MHz) 7.47 (2 H, d, J = 8.2 Hz, ArH), 7.26 (2 H, d, J = 8.2 Hz, ArH), 7.07 (2 H, d, J 
= 7.7 Hz, ArH), 6.96 (2 H, d, J = 7.7 Hz, ArH), 5.04 (1 H, t, J = 5.5 Hz, NH), 4.30 (1 
H, dd, J = 9.7, 3.3 Hz, SCHCHH), 4.15-4.19 (1 H, dd, J = 9.7, 8.5 Hz, SCHCHH), 
4.11  (1  H,  dd,  J  =  13.8,  5.5  Hz,  NCHHAr),  3.97  (1  H,  dd,  J  =  13.8,  5.5  Hz, 
NCHHAr), 3.76-3.80 (2 H, m, SCH & NCH), 2.56 (3 H, NCH3), 2.32 (3 H, s, CH3); 
ʴC (CDCl3, 125 MHz) 138.0 (s), 136.2 (s), 133.2 (s), 132.2 (d), 129.9 (d), 129.4 (d), 
128.2 (d), 122.8 (s), 73.6 (d), 72.1 (d), 67.0 (t), 47.1 (t), 42.8 (q), 21.2 (q); LRMS 
(EI) 426 (M
+•, 
81Br, 7), 424 (M
+•, 
79Br, 6), 240 (
81Br, 100), 238 (
79Br, 95), 214 (
81Br, 
14), 212 (
79Br, 16), 116 (43); HRMS (EI) calcd for C18H21BrN2O3S (M
+•) 424.0450, 
observed 424.0447 
 
(3S*,  4S*)-3-(4-Iodophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142e) 
 
According to general procedure 11, 140h gave the title compound as a cream solid 
(0.17 g, 0.36 mmol, 35%). 
Rf 0.27 (1:2 petroleum ether/Et2O);  mp 132-134 °C; νmax (thin  film, cm
-1)  3283, 
2956, 2899, 1737, 1515, 1327, 1148; ʴH (CDCl3, 500 MHz) 7.68 (2 H, d, J = 8.3 Hz, 
ArH), 7.13 (2 H, d, J = 8.3 Hz, ArH), 7.07 (2 H, d, J = 7.9 Hz, ArH), 6.95 (2 H, d, J = 
7.9 Hz, ArH), 4.97 (1 H, t, J = 5.6 Hz, NH), 4.30 (1 H, d, J = 9.7 Hz, SCHCHH), 153 
 
4.17  (1  H,  dd,  J  =  9.7,  3.3  Hz,  SCHCHH),  4.10  (1  H,  dd,  J  =  13.8,  5.6  Hz, 
NCHHAr), 3.96 (1 H, dd, J = 13.8, 5.6 Hz, NCHHAr), 3.74-3.81 (2 H, m, SCH & 
NCH), 2.56 (3 H, s, NCH3), 2.32 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 138.1 (d), 
136.8 (s), 132.9 (s), 129.9 (d), 129.6 (d), 128.9 (s), 128.2 (d), 94.6 (s), 73.7 (d), 73.5 
(d), 67.0 (t), 47.5 (t), 42.8 (q), 21.3 (q); LRMS (EI) 472 (M
+•, 5), 286 (100), 260 
(12),  120  (30);  HRMS  (EI)  calcd  for  C18H21IN2O3S  (M
+•)  472.0312,  observed 
472.0309 
 
(3S*,  4S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4sulfonic  acid  4-
methylbenzylamide (142f)
113, 122 
 
According to general procedure 11, 140j gave the title compound as a yellow solid 
(0.11 g, 0.28 mmol, 32%). 
Rf 0.16 (1:2 petroleum ether/Et2O);  mp 151-154 °C(lit.
113 mp 149 °C); νmax (thin 
film, cm
-1) 3276, 2956, 1737, 1525, 1348, 1150; ʴH (CDCl3, 500 MHz) 8.15 (2 H, d, 
J = 8.8 Hz, ArH), 7.57 (2 H, d, J = 8.8 Hz, ArH), 7.05 (2 H, d, J = 8.3 Hz, ArH), 7.02 
(2 H, d, J = 8.3 Hz, ArH), 5.23 (1 H, t, J = 5.6 Hz, NH), 4.36 (1 H, dd, J = 9.9, 3.7 
Hz, SCHCHH), 4.14-4.19 (1 H, m, SCHCHH), 4.12 (1 H, d, J = 5.6 Hz, NCHHAr), 
4.09 (1 H, d, J = 5.6 Hz, NCHHAr), 3.97 (1 H, d, J = 6.6 Hz, NCH), 3.73 (1 H, dt, J 
= 6.6, 3.7 Hz, SCH), 2.61 (3 H, s, NCH3), 2.29 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 
148.0 (s), 145.0 (s), 138.2 (s), 135.9 (s), 129.6 (d), 129.1 (d), 128.2 (d), 124.1 (d), 
74.1 (d), 72.9 (d), 67.2 (t), 47.5 (t), 43.0 (q), 21.3 (q); LRMS (EI) 391 (M
+•, 14), 205 
(78),  120  (100);  HRMS  (EI)  calcd  for  C18H21N3O5S  (M
+•)  391.1196,  observed 
391.1199 
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(3S*,  4S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142g)
113, 122 
 
According to general procedure 11, 140g gave the title compound as a yellow oil 
(0.14 g, 0.38 mmol, 35%). 
Rf 0.29 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3286, 2924, 2877, 1737, 
1617, 1588, 1327, 1146, 844; ʴH (CDCl3, 500 MHz) 7.41 (1 H, t, J = 7.1 Hz, ArH), 
7.33-7.38 (1 H, m, ArH), 7.18-7.23 (1 H, m, ArH), 7.07 (1H, t, J = 7.1 Hz, ArH), 
7.04 (2 H, d, J = 7.9 Hz, ArH), 6.95 (2 H, d, J = 7.9 Hz, ArH), 4.85 (1 H, t, J = 5.3 
Hz, NH), 4.38 (1 H, dd, J = 9.7, 3.5 Hz, SCHCHH), 4.27 (1 H, dd, J = 9.7, 8.3 Hz, 
SCHCHH), 4.14 (1 H, dd, J = 13.7, 5.3 Hz, NCHHAr), 4.11 (1 H, app d, J = 3.5 Hz, 
SCH), 4.02 (1 H, d, J = 3.7 Hz, NCH), 3.94 (1 H, dd, J = 13.7, 5.2 Hz, NCHHAr), 
2.60 (3 H, s, NCH3), 2.30 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 161.1 (s, JCF = 248.6 
Hz), 137.9 (s), 113.9 (s), 130.5 (d, JCF = 8.6 Hz), 129.9 (d, JCF = 3.8 Hz), 129.5 (d), 
128.0 (d), 125.0 (d, JCF = 3.8 Hz), 123.7 (s, JCF = 10.6 Hz), 116.2 (d, JCF = 22.1 Hz), 
72.2 (d), 68.1 (d), 67.1 (t), 47.5 (t), 42.9 (q), 21.2 (q); LRMS (CI
+) 365 (M+H, 100), 
178 (24), 120 (4); HRMS (CI
+) calcd for C18H22FN2O3S (M+H) 365.1335, observed 
365.1345 
 
(3S*,  4S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (138)
113 
 
According to general procedure 11 to give the title compound as a yellow oil (87 mg, 
0.23 mmol, 23%).  
Rf 0.25 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3283, 2922, 1737, 1438, 
1328, 1148, 704; ʴH (CDCl3, 500 MHz)7.49 (1 H, d, J = 7.3 Hz, ArH), 7.40 (1 H, app 
dd, J = 7.4, 1.9 Hz, ArH), 7.33-7.36 (2 H, m, ArH), 7.05 (2 H, J = 7.9 Hz, ArH), 7.02 
(2 H, d, J = 7.9 Hz, ArH), 4.54 (1 H, t, J = 5.8 Hz, NH), 4.48 (1 H, d, J = 8.2 Hz, 155 
 
NCH), 4.45 (1 H, dd, J = 9.8, 3.8 Hz, SCHCHH), 4.35 (1 H, dd, J = 9.8, 8.5 Hz, 
SCHCHH), 4.13 (1 H, dd, J = 13.5, 5.7 Hz, NCHHAr), 3.97 (1 H, app.td, J= 8.3, 3.8 
Hz, SCH), 3.80 (1 H, dd, J = 13.5, 5.8 Hz, NCHHAr), 2.63 (3 H, s, NCH3), 2.30 (3 
H, s, CH3); ʴC (CDCl3, 125 MHz) 138.0 (s), 134.5 (s), 134.3 (s), 133.0 (s), 130.1 (d), 
129.9 (d), 129.5 (d), 128.0 (d), 127.9 (d), 127.3 (d), 73.0 (d), 70.2 (d), 67.2 (t), 47.3 
(t), 42.9 (q), 21.2 (q); LRMS (CI
+) 383 (M+H, 
37Cl, 34), 381 (M+H, 
35Cl, 100), 197 
(
37Cl, 17), 195 (
35Cl, 50), 120 (14); HRMS (CI
+) calcd for C18H22ClN2O3S (M+H) 
381.1039, observed 381.1045 
 
(3S*,  4S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (139)
113 
 
According to general procedure 11 to give the title compound as a yellow oil (96 mg, 
0.23 mmol, 23%).  
Rf 0.25 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3251, 2978, 1737, 1328, 
1148, 698; ʴH (CDCl3, 500 MHz) 7.59 (1 H, dd, J = 7.6, 1.1 Hz, ArH), 7.48 (1 H, d, J 
= 7.6 Hz, ArH), 7.38 (1 H, t, J = 7.7 Hz, ArH), 7.24 (1 H, t, J = 7.6 Hz, ArH), 7.01 (2 
H, d, J = 7.7 Hz, ArH), 6.88 (2 H, d, J = 7.7 Hz, ArH), 4.60 (1 H, t, J = 5.7 Hz, NH), 
4.50 (1 H, d, J = 6.9 Hz, NCH), 4.46 (1 H, dd, J = 9.8, 3.6 Hz, SCHCHH), 4.36 (1 H, 
dd, J = 9.8, 8.5 Hz, SCHCHH), 4.13 (1 H, dd, J = 13.6, 5.7 Hz, NCHHAr), 3.95 (1 H 
app.td, J = 8.5, 3.6 Hz, SCH), 3.77 (1 H, dd, J = 13.6, 5.7 Hz, NCHHAr), 2.64 (3 H, 
s, NCH3), 2.30 (3 H, s, CH3); ʴC (CDCl3, 125 MHz) 137.9 (s), 133.4 (d), 132.9 (s), 
130.2 (d), 130.1 (d), 129.5 (d), 128.5 (s), 128.0 (d), 127.4 (d), 124.8 (s), 73.1 (d), 
71.7 (d), 67.2 (t), 47.3 (t), 46.8 (q), 21.2 (q); LRMS (EI) 426 (M
+•, 
81Br, 4), 424 
(M
+•, 
79Br,  4),  240  (39  ),  197  (10),  120  (17),  105  (17);  HRMS  (EI)  calcd  for 
C18H21BrN2O3S (M
+•) 424.0450, observed 424.0446 
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(3S*,  4S*)-3-(2-Iodophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142h)
113 
 
According  to general procedure 11,  140i  gave the title compound as a yellow oil 
(0.17 g, 0.42 mmol, 42%).  
Rf 0.27 (1:2 petroleum ether/Et2O); νmax (thin film, cm
-1) 3310, 2922, 2874, 1736, 
1515, 1432, 1326, 1147; ʴH (CDCl3, 500 MHz) 7.87 (1 H, d, J = 7.9 Hz, ArH), 7.40 
(2 H, d, J = 7.7 Hz, ArH), 7.06-7.10 (1 H, m, ArH), 7.01 (2 H, J = 7.9 Hz, ArH), 6.89 
(2 H, d, J = 7.9 Hz, ArH), 4.70 (1 H, t, J = 5.8 Hz, NH), 4.44 (1 H, d, J = 9.8 Hz, 
SCHCHH),  4.38  (1  H,  d,  J  =  7.1  Hz,  NCH),  4.34  (1  H,  dd,  J  =  9.8,  8.3  Hz, 
SCHCHH), 4.13 (1 H, dd, J = 13.5 , 5.9 Hz, NCHHAr), 3.91-4.04 (1 H, m, SCH), 
3.78 (1 H, dd, J = 13.5, 5.8 Hz, NCHHAr), 2.64 (3 H, s, NCH3), 2.30 (3 H, s, CH3); 
ʴC (CDCl3, 125 MHz) 140.1 (d), 139.1 (s), 137.9 (s), 133.0 (s), 130.5 (d), 129.8 (d), 
129.5 (d), 129.3 (d), 128.0 (d), 101.2 (s), 76.9 (d), 73.4 (d), 67.2 (t), 47.3 (t), 42.6 (q), 
21.2 (q); LRMS (CI
+) 473 (M+H, 100), 287 (52), 120 (20); HRMS (CI
+) calcd for 
C18H22IN2O3S (M+H) 473.0395, observed 473.0403 
 
(3S*,  4S*)-2-Methyl-3-(2-Nitrophenyl)-isoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (142i) 
 
According to general procedure 11, 140e gave the title compound as a yellow oil (61 
mg, 0.15 mmol, 16%). 
Rf 0.21 (1:2 petroleum ether /Et2O); νmax (thin film, cm
-1) 3302, 2923, 2877, 1609, 
1579, 1327, 1147; ʴH (CDCl3, 500 MHz) 7.72 (1 H, d, J = 8.3 Hz, ArH), 7.64 (1 H, d, 
J = 8.2 Hz, ArH), 7.59 (1 H, t, J = 8.2 Hz, ArH), 7.48 (1 H, t, J = 8.2 Hz, ArH), 6.99-
7.02 (4 H, m, ArH), 5.03 (1 H, t, J = 5.8 Hz, NH), 4.47 (1 H, d, J = 6.6 Hz, NCH), 
4.34 (1 H, dd, J = 9.8, 3.8 Hz, SCHCHH), 4.26 (1 H, dd, J = 9.8, 8.4 Hz, SCHCHH), 157 
 
4.16  (1  H,  dd,  J  =  13.9,  5.8  Hz,  NCHHAr),  4.08  (1  H,  dd,  J  =  13.9,  5.8  Hz, 
NCHHAr), 3.97-4.05 (1 H, m, SCH), 2.63 (3 H, s, NCH3), 2.29 (3 H, s, CH3); ʴC 
(CDCl3, 125 MHz) 150.4 (s), 137.9 (s), 133.4 (s), 133.1 (d), 131.4 (s), 130.7 (d), 
129.5 (d), 129.4 (d), 128.0 (d), 124.4 (d), 74.0 (d), 68.5 (d), 67.3 (t), 47.4 (t), 43.3 
(q), 21.2 (q); LRMS (CI
+) 392 (M+H, 100), 374 (50), 206 (38), 120 (30), 105 (52); 
HRMS (CI
+) calcd for C18H22N3O5S (M+H) 392.1280, observed 392.1286 
4.3.4  Preparation of biotinylated compounds 
2-(tert-Butyldimethylsilanyloxy)ethanol (144)
193 
 
To a stirred suspension of ethylene glycol (23.8 mL, 384 mmol, 5 eq.), NEt3 (58.7 
mL, 422 mmol, 5.5 eq.) and DMAP (0.94 g, 7.68 mmol, 0.1 eq.) in dichloromethane 
(390 mL) at 0 °C was added a pre-mixed solution of tert-butyldimethylsilyl chloride 
(11.6 g, 76.8 mmol) in dichloromethane (30 mL) dropwise over 10 min. Stirring was 
continued  overnight  at  RT.  The  reaction  mixture  was  washed  with  10%  HCl, 
saturated NaHCO3 and brine. The organic layer was dried with MgSO4, filtered and 
solvent  was  removed  in  vacuo.  The  crude  residue  was  purified  by  flash 
chromatography (starting 6:1 petroleum ether/EtOAc) to give the title compound as a 
clear oil (8.14 g, 46.2 mmol, 60%). 
Rf 0.36 (2:1 petroleum ether/EtOAc); νmax (thin film, cm
-1) 3271, 3081, 2929, 2858, 
1607, 1519, 1310, 1149, 1041, 824; ʴH (CDCl3, 300 MHz) 3.66 (2 H, t, J = 4.0 Hz, 
OCH2), 3..63 (2 H, t, J = 4.0 Hz, CH2), 2.03 (1 H, br s, OH), 0.84 (9 H, s, C(CH3)3), 
0.07 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 64.1 (t), 63.7 (t), 25.9 (q), 25.6 (q), 18.3 (s); 
LRMS (CI
+) 177 (M+H, 6), 161 (5), 110 (100); HRMS (CI
+) calcd for C8H21O2Si 
(M+H) 177.1310, observed 177.1312 
 
(tert-Butyldimethylsilanyloxy)acetaldehyde (145)
194 
 
To a stirred solution of oxalyl chloride (12.6 g, 106 mmol, 2 eq.) in dichloromethane 
(200 mL) at -78 °C was added slowly DMSO (18.8 mL, 265 mmol, 5 eq.) followed 
by  dropwise  addition  of  2-(tert-butyldimethylsilanyloxy)ethanol  144  (9.5  g,  53 
mmol) in dichloromethane (40 mL) then 20 min stirring at -78 °C. NEt3 (37.6 mL, 
270 mmol, 5.1 eq.) was added dropwise to the reaction and allowed to warm slowly 158 
 
to RT. Solvent was removed in vacuo and the residue remaining was triturated with 
4:1 hexane/EtOAc (400mL) before filtering through a small silica pad. The filtrate 
was concentrated in vacuo and crude residue was purified by flash chromatography 
(starting 12:1 petroleum ether/EtOAc) to give the title compound as a clear oil (5.0 g, 
29 mmol, 53%). 
Rf 0.36 (12:1  petroleum ether /EtOAc); νmax (thin  film, cm
-1)  3272, 3082, 2929, 
2858, 1607, 1519, 1310; ʴH (CDCl3, 300 MHz) 9.73 (1 H, t, J = 1.1 Hz, CHO), 4.21 
(2 H, d, J = 1.0 Hz, CH2), 0.86 (9 H, s, C(CH3)3), 0.10 (6 H, s, CH3); ʴC (CDCl3, 75 
MHz) 202.3 (d), 69.6 (t), 25.8 (q), 25.7 (q), 18.3 (s); LRMS (CI
+) 175 (M+H, 5), 159 
(5), 147 (5), 117 (100); HRMS (CI
+) calcd for C8H19O2Si (M+H) 175.1154, observed 
175.1151 
 
(tert-Butyldimethylsilanyloxy)acetaldehyde oxime (146)
195 
 
(tert-Butyl-dimethylsilanyloxy)acetaldehyde 145 (5.1 g, 29 mmol) was dissolved in 
EtOH (98 mL) and treated with hydroxylamine.HCl (6.1 g, 87 mmol, 3 eq.) followed 
by NEt3 (13.3 mL, 95.7 mmol, 3.3 eq.).The suspension was stirred at RT for 4 h, then 
diluted with water (100 mL) followed by extraction with EtOAc (3 x 100 mL). The 
organic layer was dried with MgSO4, filtered and solvent was removed in vacuo. The 
crude  residue  was  purified  by  flash  chromatography  (starting  12:1  petroleum 
ether/EtOAc) to give 1:1 diastereo-mixture of the title compound as a clear oil (3.9 g, 
21 mmol, 72%). 
Rf 0.21 (12:1 petroleum ether/EtOAc); νmax (thin film, cm
-1) 3271, 3081, 2887, 2858, 
1607, 1519, 1310 1149; ʴH (CDCl3, 500 MHz) 9.43 (1 H, s, OH), 9.11 (1 H, s, OH), 
7.39 (1 H, t, J = 5.5 Hz, CH), 6.77 (1 H, t, J = 5.5 Hz, CH), 4.46 (2 H, d, J = 5.5 Hz, 
CH2), 4.19 (2 H, d, J = 5.5 Hz, CH2), 0.84 (9 H, s, C(CH3)3), 0.83 (9 H, s, C(CH3)3), 
0.02 (6 H, s, CH3), 0.02 (6 H, s, CH3); ʴC (CDCl3, 125 MHz) 153.8 (d), 151.2 (d), 
60.6 (t), 57.9 (t), 26.1 (q), 21.2 (q), 18.5 (q), 14.3 (s), 4.4 (q), 3.7 (q); LRMS (EI) 
189 (M
+•, 2), 174 (8), 144 (12), 132 (100), 123 (20), 105 (74); HRMS (EI) calcd for 
C8H19NO2Si (M
+•) 189.1179, observed 189.1177 
 
N-[2-(tert-Butyldimethylsilanyloxy)ethyl] hydroxylamine (147)
195 
 159 
 
To a stired solution of (tert-butyldimethylsilanyloxy)acetaldehyde oxime 146 (4.0 g, 
21 mmol) in MeOH (150 mL) was treated with NaBH3CN (2.6 g, 42 mmol, 2 eq.) 
and followed by dropwise addition of conc. HCl and maintained the solution at pH 4 
for 45 min. Solvent was removed  in vacuo, the white residue suspended in water 
(150 mL) was basified to pH >9 with 6N KOH. The aqueous layer was saturated 
with NaCl and extracted with chloroform (4 x 70 mL). The organic layer was dried 
with MgSO4, filtered and filtrate concentrated in vacuo to give the title compound as 
a yellow oil (3.48 g, 18.2 mmol, 87%). 
Rf 0.14 (5:1 petroleum ether/EtOAc); νmax (thin film, cm
-1) 3356, 3280, 2953, 2929, 
2857, 1706; ʴH (CDCl3, 300 MHz) 3.77 (2 H, t, J = 5.1 Hz, NCH2), 3.02 (2 H, t, J = 
5.1 Hz, CH2), 0.89 (9 H, s, C(CH3)3), 0.06 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 59.2 
(t), 55.6 (t), 25.6 (q), 21.1 (q), 18.3 (s); LRMS (ES
+) 192 (M+H, 100) ; HRMS (ES
+) 
calcd for C8H22NO2Si (M+H) 192.1420, observed 192.1417 
 
C-(2-Fluorophenyl)-N-[2-(tert-Butyldimethylsilanyloxy)ethyl] nitrone (148a) 
 
To  N-[2-(tert-butyl-dimethyl-silanyloxy)ethyl]  hydroxylamine  147  (1.70  g,  8.91 
mmol, 1.1 eq.)  in dry dichloromethane  (25  mL)  was added 2-fluorobenzaldehyde 
(1.0 g, 8.1 mmol) and NaHCO3 (2.04 g, 24.3 mmol, 3 eq.). The mixture was refluxed 
at 45 °C for 6 h then resulting suspension was filtered and remaining residue washed 
thoroughly with dichloromethane (4 x 40 mL). The solvent was removed in vacuo to 
give the title compound as a yellow oil and as a single diastereoisomer as judged by 
NMR (2.35 g, 7.91 mmol, 97%). 
Rf 0.2 (5:1 petroleum ether /EtOAc); νmax (thin film, cm
-1) 3360, 3136, 2954, 2929, 
2856, 1710; ʴH  (CDCl3, 300 MHz) 9.36 (1 H, t, J = 7.5 Hz, ArH), 7.70 (1 H, s, 
CHN), 7.35-7.41 (1 H, m, ArH), 7.23 (1 H, t, J = 7.3 Hz, ArH), 7.06 (1 H, d, J = 7.3 
Hz, ArH), 4.10-4.23 (2 H, m, NCH2), 4.03-4.08 (2 H, m, OCH2CH2), 0.82 (9 H, s, 
C(CH3)3), 0.05 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 131.6 (d), 131.5 (d), 128.8 (d), 
124.3 (d), 119.0 (s), 114.7 (d), 114.4 (s), 62.2 (t), 59.6 (t), 25.9 (q), 25.7 (q), 18.2 (s); 
LRMS (FAB
+) 298 (M+H, 100), 282 (22), 240 (85), 224 (15); HRMS (FAB
+) calcd 
for C15H25FNO2Si (M+H) 298.1638, observed 298.1630 
 160 
 
C-(2-Bromophenyl)-N-[2-(tert-Butyldimethylsilanyloxy)ethyl] nitrone (148b) 
 
To N-[2-(tert-butyldimethylsilanyloxy)ethyl] hydroxylamine 147 (1.70 g, 8.91 mmol, 
1.1 eq.) in dry dichloromethane (25 mL) was added 2-bromobenzaldehyde (1.5 g, 8.1 
mmol) and NaHCO3 (2.04 g, 24.3 mmol, 3 eq.). The mixture was refluxed at 45 °C 
for  6  h  then  resulting  suspension  was  filtered  and  remaining  residue  washed 
thoroughly with dichloromethane (4 x 40 mL). The solvent was removed in vacuo 
and  crude  residue  was  purified  by  flash  chromatography  (starting  7:1  petroleum 
ether/EtOAc)  to  give  the  title  compound  as  a  yellow  oil  and  as  a  single 
diastereoisomer as judged by NMR (1.9 g, 5.3 mmol, 65%). 
Rf 0.1 (5:1 petroleum ether/EtOAc); νmax (thin film, cm
-1) 3326, 2952, 2928, 2855, 
1462, 1157, 1111, 935, 776; ʴH (CDCl3, 300 MHz) 9.34 (1 H, dd, J = 8.0, 1.6 Hz, 
ArH), 7.88 (1 H, s, CHN), 7.61 (1 H, dd, J = 8.0, 1.4 Hz, ArH), 7.36 (1 H, t, J = 8.3 
Hz, ArH), 7.21 (1 H, dd, J = 8.2, 1.6 Hz, ArH), 4.11-4.20 (2 H, m, NCH2), 4.04-4.10 
(2 H, m, OCH2CH2), 0.84 (9 H, s, C(CH3)3), 0.02 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 
135.3 (s), 134.0 (d), 132.8 (d), 131.2 (d), 129.5 (d), 127.9 (d), 123.2 (s), 70.7 (t), 59.6 
(t), 25.9 (q), 25.8 (q), 18.2 (s); LRMS (EI) 358 (M
+•, 
81Br, 18), 356 (M
+•, 
79Br, 18), 
302 (
81Br, 100), 300 (
79Br, 98), 286 (
81Br, 19), 284 (
79Br, 18), 204 (22); HRMS (EI) 
calcd for C15H25BrNO2Si (M
+•) 357.0754, observed 357.0764 
 
(3S*,  4S*)-2-[2-(tert-Butyldimethylsilanyloxy)ethyl]-3-(2-fluorophenyl)- 
isoxazolidine-4-sulfonic acid pentafluorophenyl ester (149a) 
 
To pentafluorophenyl ethenesulfonate 110 (1.8 g, 6.6 mmol) in dry toluene (40 mL) 
was  added  C-(2-fluorophenyl)-N-[2-(tert-butyldimethylsilanyloxy)ethyl]  nitrone 
148a (2.3 g, 7.9 mmol, 1.2 eq.) and  the mixture was heated to reflux for 6 h. The 
reaction  was  concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash 
chromatography (starting 20:1 petroleum ether/Et2O) to give the title compound as a 
yellow oil and as a single diastereoisomer as  judged by NMR  (1.3  g, 2.2  mmol, 161 
 
33%). 
Rf 0.85 (2:1 petroleum ether/Et2O); νmax (thin film, cm
-1) 2955, 2930, 1517, 1390, 
1185, 993; ʴH (CDCl3, 300 MHz) 7.48-7.60 (1 H, m, ArH), 7.31-7.39 (1 H, m, ArH), 
7.17 (1 H, td, J = 7.5, 1.1 Hz, ArH), 7.11 (1 H, d, J = 7.5 Hz, ArH), 4.62 (1 H, d, J = 
6.9 Hz, NCH), 4.44-4.56 (3 H,  m, SCH  & SCHCH2), 3.79 (2  H, t, J = 5.1 Hz, 
NCH2), 2.91 (2 H, t, J = 5.0 Hz, OCH2CH2), 0.84 (9 H, s, C(CH3)3), 0.01 (6 H, s, 
CH3); ʴC (CDCl3, 75 MHz) 130.9 (s, JCF = 247.6 Hz), 130.8 (s, JCF = 10.6 Hz), 130.0 
(d), 124.7 (d), 116.4 (d, JCF = 3.8 Hz), 116.1 (d, JCF = 22.1 Hz), 72.1 (d), 66.9 (t), 
66.4 (d), 60.7 (t), 57.9 (t), 25.9 (q), 25.8 (q), 18.3 (s); LRMS (EI) 571 (M
+•, 72), 456 
(32), 323 (100), 167 (43), 124 (30);  HRMS (EI) calcd for C23H27F6NO5SSi (M
+•) 
571.1283, observed 571.1280 
 
(3S*,  4S*)-3-(2-Bromophenyl)-2-[2-(tert-butyldimethylsilanyloxy)ethyl]- 
isoxazolidine-4-sulfonic acid pentafluorophenyl ester (149b) 
 
To pentafluorophenyl ethenesulfonate 110 (1.2 g, 4.4 mmol) in dry toluene (28 mL) 
was  added  C-(2-bromophenyl)-N-[2-(tert-butyldimethylsilanyloxy)ethyl]  nitrone 
148b (1.9 g, 5.3 mmol, 1.2 eq.) and the mixture was heated to reflux for 3 h. The 
reaction  was  concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash 
chromatography (starting 14:1 petroleum ether/Et2O) to give the title compound as a 
yellow oil and as a single diastereoisomer as judged by NMR (1.1 g, 1.67  mmol, 
38%). 
Rf 0.6 (2:1 petroleum ether/Et2O); νmax (thin  film, cm
-1) 2954, 2929, 1516, 1394, 
1185, 775; ʴH (CDCl3, 300 MHz) 7.58 (1 H, dd, J = 8.0, 1.8 Hz, ArH), 7.54 (1 H, dd, 
J = 8.0, 1.8 Hz, ArH), 7.35 (1 H, t, J = 8.0 Hz, ArH), 7.20 (1 H, td, J = 8.0, 1.6 Hz, 
ArH), 4.86 (1 H, d, J = 6.9 Hz, NCH), 4.63 (1 H, dd, J = 10.4, 2.9 Hz, SCHCHH), 
4.51-4.61 (1 H, m, SCHCHH), 4.36 (1 H, td, J = 7.1, 2.9 Hz, SCH), 3.76 (2 H, dd, J 
=  6.9,  5.4  Hz,  NCH2),  2.97-3.11  (1  H,  m,  OCHHCH2),  2.84-2.93  (1  H,  m, 
OCHHCH2), 0.84 (9 H, s, C(CH3)3), 0.01 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 134.6 
(s), 133.5 (d), 130.4 (d), 130.2 (d), 128.1 (d), 124.8 (s), 72.9 (d), 70.5 (d), 67.2 (t), 162 
 
60.7 (t), 57.8 (t), 25.9 (q), 25.8 (q), 18.3 (s); LRMS (EI) 633 (M
+•, 
81Br, 11), 631 
(M
+•, 
79Br, 13), 515 (
81Br, 25), 513 (
79Br, 24), 385 (
81Br, 14), 383 (
79Br, 14), 318 
(100), 182 (76); HRMS (EI) calcd for C23H27BrF5NO5SSi (M
+•) 631.0483, observed 
631.0487 
 
(3S*,  4S*)-2-[2-(tert-Butyldimethylsilanyloxy)ethyl]-3-(2-fluorophenyl)- 
isoxazolidine-4-sulfonic  acid  4-methylbenzylamide  and  (3S*,  4R*)-2-[2-(tert-
Butyl  dimethylsilanyloxy)ethyl]-3-(2-fluorophenyl)-isoxazolidine-4-sulfonic acid 
4- methylbenzylamide (150a &151a) 
 
To a stirred solution of (3S*, 4S*)-2-[2-(tert-butyldimethylsilanyloxy) ethyl]-3-(2-
fluorophenyl)-isoxazolidine-4-sulfonic acid pentafluorophenyl ester 149a (1.3 g, 2.3 
mmol), in dry THF (35 mL) was added 4-methylbenzylamine (0.8 mL, 6.9 mmol, 3 
eq.) followed by DBU (0.5 mL, 3.45 mmol, 1.5 eq.). The mixture was refluxed for 2 
h and reaction was concentrated  in vacuo. The crude residue was purified by flash 
chromatography (starting 15:1 petroleum ether/EtOAc) to give 4(anti):1(syn) mixture of 
the title compound as a yellow oil (0.31 g, 0.61 mmol, 27%). A small amount of each 
diastereoisomer  was able to be separated  for analysis;  however the  yields quoted 
were referred as the overall yield. 
Rf  (syn) 0.18 (2:1 petroleum ether/Et2O);  νmax (thin  film, cm
-1)  3286, 2928, 2856, 
1588, 1516, 1491, 1331, 1148, 833; ʴH (CDCl3, 300 MHz) 7.68 (1 H, td, J = 7.5, 1.6 
Hz, ArH), 7.21-7.28 (2 H, m, ArH), 7.11 (4 H, br s, ArH), 6.99 (1 H, J = 7.5 Hz, 
ArH), 4.34-4.20 (2 H, m, SCHCH2), 4.24-4.30 (2 H, m, OCH2CH2), 4.01 (1 H, dd, J 
= 13.9, 5.2 Hz, NCHHAr), 3.82-3.90 (2 H, m, NCH & NCHHAr), 3.54 (1 H, t, J = 
5.2 Hz, NH), 3.43-3.50 (1 H, m, SCH), 2.91-3.01 (1 H, m, OCH2CHH), 2.62-2.72 (1 
H, m, OCH2CHH), 2.32 (3 H, s, ArCH3), 0.86 (9 H, s, C(CH3)3), 0.05 (6 H, s, CH3); 
ʴC (CDCl3, 75 MHz) 161.2 (s, JCF = 253.2 Hz), 137.8 (s), 133.4 (d, JCF = 3.1 Hz), 
130.5 (d, JCF = 3.6 Hz), 129.9 (s), 129.4 (d), 127.9 (d), 124.2 (s, JCF = 9.1 Hz), 114.7 
(d, JCF = 21.3 Hz), 66.8 (d), 64.6 (d), 60.7 (t), 60.4 (t), 58.6 (t), 46.9 (t), 41.3 (q), 22.6 
(q), 21.1 (q), 14.3 (s); LRMS (ES
-) 507 (M-H, 100), 393 (4); HRMS (ES
-) calcd for 163 
 
C25H36FN2O4SSi (M-H) 507.2149, observed 507.2154 
Rf  (anti) 0.11 (2:1 petroleum ether/Et2O);  νmax (thin  film, cm
-1) 3285, 2928, 2857, 
1589, 1517, 1494, 1327, 1147, 833; ʴH (CDCl3, 500 MHz) 7.44 (1 H, t, J = 6.9 Hz, 
ArH), 7.33 (1 H, d, J = 6.9 Hz, ArH), 7.17 (1 H, t, J = 7.1 Hz, ArH), 7.07 (1 H, br s, 
ArH), 7.04 (2 H, d, J = 8.0 Hz, ArH), 6.96 (2 H, d, J = 8.0 Hz, ArH), 4.89 (1 H, t, J = 
5.8 Hz, NH), 4.37 (1 H, dd, J = 9.7, 3.3 Hz, SCHCHH), 4.30 (1 H, d, J = 7.4 Hz, 
NCH), 4.23 (1 H, dd, J = 9.7, 8.5 Hz, SCHCHH), 4.12 (1 H, dd, J = 13.8, 5.8 Hz, 
NCHHAr), 3.92-3.98 (2 H,  m, OCH2CH2)3.70-3.79 (2 H, m, SCH  & NCHHAr), 
2.78-2.89 (2 H, m, OCH2CH2), 2.31 (3 H, s, ArCH3), 0.84 (9 H, s, C(CH3)3), 0.01 (6 
H, s, CH3); ʴC (CDCl3, 125 MHz) 161.2 (s, JCF = 247.6 Hz), 137.8 (d), 133.4 (s), 
130.3 (d, JCF = 8.6 Hz), 130.1 (d, JCF = 2.9 Hz), 129.5 (d), 128.3 (s), 128.0 (d), 124.9 
(d, JCF = 3.8 Hz), 124.1 (s, JCF = 11.5 Hz), 116.0 (d, JCF = 22.1 Hz), 72.1 (d), 67.0 (t), 
66.1 (t), 58.6 (t), 56.1 (q), 46.9 (t), 26.1 (q), 21.1 (q), 15.4 (s); LRMS (ES
-) 507 (M-
H, 100), 477 (10), 393 (3); HRMS (ES
-) calcd for C25H36FN2O4SSi (M-H) 507.2149, 
observed 507.2157 
 
(3S*,  4S*)-3-(2-Bromophenyl)-2-[2-(tert-butyldimethylsilanyloxy)ethyl]- 
isoxazolidine-4-sulfonic  acid  4-methylbenzylamide  and  (3S*,  4R*)-3-(2- 
Bromophenyl)-2-[2-(tert-butyldimethylsilanyloxy)ethyl]-isoxazolidine-4-sulfonic 
acid 4-methylbenzylamide (150b & 151b) 
 
To  a  stirred  solution  of  (3S*,  4S*)-3-(2-bromophenyl)-2-[2-  (tert-
butyldimethylsilanyloxy)ethyl]-isoxazolidine-4-sulfonic acid pentafluorophenyl ester 
149b (1.28  g, 2.02 mmol),  in dry THF (30  mL) was added 4-methylbenzylamine 
(0.77 ml, 6.07 mmol, 3 eq.) followed by DBU (0.45 mL, 3.04  mmol, 1.5 eq.). The 
mixture was refluxed  for 2  h and reaction  was concentrated  in vacuo. The crude 
residue was purified by flash chromatography (starting 15:1 petroleum ether/EtOAc) 
to give 4(anti):1(syn) mixture of the title compound as a yellow oil (0.72 g, 1.2 mmol, 
63 %). A small amount of each diastereoisomer was able to be separated for analysis; 
however the yields quoted were referred as the overall yield. 164 
 
Rf  (syn) 0.19 (2:1 petroleum ether/Et2O);  νmax (thin  film, cm
-1)  3282, 2928, 2856, 
1516, 1372, 1149, 833; ʴH (CDCl3, 300 MHz) 7.74 (1 H, d, J = 7.9 Hz, ArH), 7.51 (1 
H, d, J = 7.7 Hz, ArH), 7.36 (1 H, t, J = 7.7 Hz, ArH), 7.15 (1 H, t, J = 7.4 Hz, ArH), 
7.11 (4 H, br s, ArH), 4.35-4.41 (3 H, m, NCH&SCHCH2), 4.25-4.29 (1 H, m, SCH), 
4.10  (1  H,  dd,  J  =  13.9,  5.8  Hz,  NCHHAr),  4.02  (1  H,  dd,  J  =  13.9,  5.6  Hz, 
NCHHAr), 3.82-3.94 (2 H, m, OCH2CH2), 3.64 (1 H, t, J = 5.9 Hz, NH), 2.90-3.01 
(1 H, m, OCH2CHH), 2.60-2.69 (1 H, m, OCH2CHH), 2.32 (3 H, s, ArCH3), 0.90 (9 
H, s, C(CH3)3), 0.07 (6 H, s, CH3); ʴC (CDCl3, 75 MHz) 137.7 (s), 133.7 (s), 132.9 
(s), 132.2 (d), 131.5 (d), 129.9 (d), 129.4 (d), 127.8 (d), 127.5 (d), 125.3 (s), 71.3 (d), 
66.9 (t), 66.1 (d), 60.8 (t), 58.5 (t), 47.0 (t), 25.9 (q), 23.8 (q), 20.8 (q), 18.3 (s); 
LRMS (ES
-) 569 (M-H, 
81Br, 100), 567 (M-H, 
79Br, 96) 443 (9); HRMS (ES
-) calcd 
for C25H36BrN2O4SSi (M-H) 567.1348, observed 567.1353 
Rf  (anti) 0.12 (2:1 petroleum  ether/Et2O);  νmax (thin  film,  cm
-1)  3298, 2928, 2856, 
1517, 1326, 1147, 832; ʴH (CDCl3, 500 MHz) 7.56 (1 H, dd, J = 8.0, 1.0 Hz, ArH), 
7.48 (1 H, dd, J = 8.0, 1.1 Hz, ArH), 7.35 (1 H, td, J = 7.9, 1.1 Hz, ArH), 7.22 (1 H, 
td, J = 8.0, 1.0 Hz, ArH), 7.01 (2 H, d, J = 7.8 Hz, ArH), 6.90 (2 H, d, J = 7.8 Hz, 
ArH), 4.85 (1 H, t, J = 5.8 Hz, NH), 4.60 (1 H, d, J = 7.4 Hz, NCH), 4.41 (1 H, dd, J 
= 9.7, 3.6 Hz, SCHCHH), 4.29 (1 H, dd, J = 9.7, 8.3 Hz, SCHCHH), 4.11 (1 H, dd, J 
= 13.7, 5.8 Hz, NCHHAr), 3.88-4.01 (1 H, m, SCH), 3.79 (1 H, dd, J = 13.7, 5.8 Hz, 
NCHHAr),  3.73  (2  H,  dd,  J  =  7.1,  4.9  Hz,  OCH2CH2),  2.90-2.96  (1  H,  m, 
OCH2CH2),  2.74-2.80  (1  H,  m,  OCH2CH2),  2.30  (3  H,  s, ArCH3),  0.83  (9  H,  s, 
C(CH3)3), 0.00 (6 H, s, CH3); ʴC (CDCl3, 125 MHz) 137.7 (s), 136.2 (s), 133.2 (d), 
133.1 (d), 130.4 (d), 130.1 (d), 129.4 (d), 128.3 (s), 127.9 (d), 124.8 (s), 72.8 (d), 
70.8 (d), 67.1 (t), 60.9 (t), 57.9 (t), 47.1 (t), 41.0 (q), 25.9 (q), 21.1 (q), 20.9 (s); 
LRMS (ES
-) 569 (M-H, 
81Br, 100), 567 (M-H, 
79Br, 94), 539 (
81Br, 9), 537 (
79Br, 8), 
183  (34);  HRMS  (ES
-)  calcd  for  C25H36BrN2O4SSi  (M-H)  567.1348,  observed 
567.1339 
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(3S*,  4S*)-3-(2-Fluorophenyl)-2-(2-hydroxyethyl)-isoxazolidine-4-sulfonic  acid 
4- methylbenzylamide (152a) 
 
To a stirred solution of (3S*, 4S*)-2-[2-(tert-butyldimethylsilanyloxy)- ethyl]-3-(2-
fluorophenyl)-isoxazolidine-4-sulfonic acid-4-methylbenzylamide 150a (0.24 g, 0.48 
mmol) in dry THF (7.2 mL) at 0 °C was added TBAF (1 M in THF, 0.72 mL, 0.72 
mmol, 1.5 eq.). After 2 h at 0  °C the reaction was concentrated  in vacuo and the 
residue was purified by flash chromatography (starting 1:2 petroleum ether/EtOAc) 
to give the title compound as a clear gel (0.12 g, 0.30 mmol, 63%). 
Rf 0.25 (9:1 CHCl3/MeOH); νmax (thin film, cm
-1) 3503, 3281, 2926, 1515, 1326, 
1146, 1043; ʴH (CDCl3, 300 MHz) 7.32-7.43 (2 H, m, ArH), 7.18 (1 H, td, J = 7.5, 
1.1 Hz, ArH), 7.06-7.12 (1 H, m, ArH), 7.04 (2 H, d, J = 7.7 Hz, ArH), 6.94 (2 H, d, J 
= 7.7 Hz, ArH), 4.95 (1 H, br s, OH), 4.40 (1 H, dd, J = 9.9, 3.7 Hz, SCHCHH), 4.33 
(1 H, d, J = 6.4 Hz, NCH), 4.27 (1 H, d, J = 9.9 Hz, SCHCHH), 4.13 (1 H, d, J = 
13.9 Hz, NCHHAr), 3.90-4.02 (2  H,  m, SCH  & NCHHAr), 3.71-3.79 (1 H,  m, 
OCHHCH2), 3.57-3.65 (1 H, m, OCHHCH2), 2.88-2.96 (1 H, m, OCH2CHH), 2.76-
2.84 (1 H, m, OCH2CHH), 2.30 (3 H, s, ArCH3); ʴC (CDCl3, 75 MHz) 161.1 (s, JCF = 
248.5 Hz), 137.8 (s), 133.1 (s), 130.5 (d, JCF = 8.5 Hz), 129.8 (d, JCF = 3.5 Hz), 129.4 
(d), 127.9 (d), 125.0 (d, JCF = 3.5 Hz), 123.6 (s, JCF = 11.7 Hz), 116.1 (d, JCF = 22.0 
Hz), 71.6 (d), 67.2 (t), 66.2 (d), 60.4 (t), 57.4 (t), 47.1 (t), 21.1 (q); LRMS (ES
-) 393 
(M-H,  100),  363  (40),  184  (51);  HRMS  (ES
-)  calcd  for  C19H22FN2O4S  (M-H) 
393.1284, observed 393.1291 
 
(3S*,  4S*)-3-(2-Bromophenyl)-2-(2-hydroxyethyl)-isoxazolidine-4-sulfonic  acid 
4-methylbenzylamide (152b)
113 
 
To  a  stirred  solution  of  (3S*,  4S*)-3-(2-bromophenyl)-2-[2-(tert-166 
 
butyldimethylsilanyloxy)- ethyl]-isoxazolidine-4-sulfonic acid-4-methylbenzylamide 
150b (0.57 g, 1.0 mmol) in dry THF (16 mL) at 0 °C was added TBAF (1 M in THF, 
1.5 mL, 1.5 mmol, 1.5 eq.). After 2 h at 0 °C the reaction was concentrated in vacuo 
and  the  residue  was  purified  by  flash  chromatography  (starting  6:1  petroleum 
ether/EtOAc) to give the title compound as a clear gel (0.36 g, 0.79 mmol, 79%). 
Rf 0.30 (9:1 CHCl3/MeOH); νmax (thin film, cm
-1) 3497, 3141, 2928, 1874, 1514, 
1320, 1147; ʴH (CDCl3, 300 MHz) 7.59 (1 H, dd, J = 8.0, 0.8 Hz, ArH), 7.46 (1 H, 
dd, J = 8.0, 1.0 Hz, ArH), 7.38 (1 H, t, J = 8.3 Hz, ArH), 7.21-7.28 (1 H, m, ArH), 
7.01 (2 H, d, J = 7.7 Hz, ArH), 6.88 (2 H, d, J = 7.7 Hz, ArH), 7.62-7.72 (2 H, m, 
NCH & NCHHAr), 4.48 (1 H, dd, J = 9.9, 3.5 Hz, SCHCHH), 4.37 (1 H, t, J = 9.9 
Hz, SCHCHH), 4.13 (1 H, dd, J = 13.4, 6.2 Hz, NCHHAr), 3.93 (1 H, td, J = 8.0, 3.5 
Hz, OCHHCH2), 3.74-3.79 (1 H, m, SCH), 3.58-3.65 (1 H, m, OCHHCH2), 2.97-
3.05 (1 H, m, OCH2CHH), 2.76-2.90 (1 H, m, OCH2CHH), 2.30 (3 H, s, ArCH3); ʴC 
(CDCl3, 75 MHz) 171.2 (s), 137.3 (s), 135.8 (s), 133.4 (d), 133.1 (d), 130.2 (d), 
129.4 (d), 128.4 (d), 127.9 (d), 124.6 (s), 72.4 (d), 70.7 (d), 67.4 (t) 60.4 (t), 57.2 (t), 
47.0 (t), 21.1 (q); LRMS (ES
-) 455 (M-H, 
81Br, 100), 453 (M-H, 
79Br, 98), 425 (
81Br, 
41),  423  (
79Br,  40),  184  (62);  HRMS  (ES
-)  calcd  for  C19H22BrN2O4S  (M-H) 
453.0484, observed 453.0490 
 
(3S*,  4S*)-2-(2-Ethylamino)-3-(2-fluorophenyl)-isoxazolidine-4-sulfonic  acid  4- 
methylbenzylamide (153a) 
 
To  a  stirred  solution  of  (3S*,  4S*)-3-(2-fluorophenyl)-2-(2-hydroxyethyl)-
isoxazolidine- 4-sulfonic acid 4-methylbenzylamide 152a (98 mg, 0.25 mmol), NEt3 
(48  µL,  0.35  mmol,  1.4  eq.)  and  dichloromethane  (3.0  mL),  was  added 
methanesulfonyl chloride (21 µL, 0.28 mmol, 1.1 eq.) and reaction was stirred at 0 °C 
for 30  min.  The reaction  was diluted  with dichloromethane and washed with 1% 
HCl. The organic layer was dried over MgSO4, filtered and solvent was removed in 
vacuo. The crude compound (0.15 g, 0.31 mmol) was added DMF (3 mL) and NaN3 
(48 mg, 0.74 mmol 2.4 eq.) and refluxed at 90 °C for 2 h. Solvent was removed in 167 
 
vacuo and the residue was diluted with water and extracted with EtOAc. The organic 
layer dried over MgSO4, filtered and solvent was removed  in vacuo to yield crude 
azide. Azide was hydrogenated at 1 atm over 10% Pd/C (20 mg) in MeOH for 1 h. 
The  solid  residue  was  filtered  under  gravity  and  rinsed  thoroughly  with  MeOH; 
filtrate was concentrated in vacuo to give the title compound as a clear gel (43 mg, 
0.11 mmol, 44%). 
Rf 0.13 (9:1 CHCl3/MeOH); νmax (thin film, cm
-1) 3386, 3273, 2924, 1616, 1493, 
1311, 1143, 760; ʴH (CDCl3, 500 MHz) 7.40-7.49 (1 H, m, ArH), 7.32 (1 H, d, J = 
7.4 Hz, ArH), 7.16 (1 H, t, J = 7.4 Hz, ArH), 7.04-7.12 (1 H, m, ArH), 7.01 (2 H, d, J 
= 7.8 Hz, ArH), 6.96 (2 H, d, J = 7.8 Hz, ArH), 4.35 (1 H, dd, J = 9.7, 3.3 Hz, 
SCHCHH), 4.31 (1 H, d, J = 6.9 Hz, NCH), 4.22 (1 H, app. t, J = 9.6 Hz, SCHCHH), 
4.10 (1 H, d, J = 14.1 Hz, NCHHAr), 3.94 (1 H, d, J = 14.1 Hz, NCHHAr), 3.88-3.92 
(1 H, m, SCH), 2.83-2.94 (2 H, m, NH2CH2CH2), 2.65-2.77 (2 H, m, NH2CH2CH2), 
2.28 (3 H, s, ArCH3); ʴC (CDCl3, 125 MHz) 161.0 (s, JCF = 248.6 Hz), 137.7 (s), 
133.5 (s), 130.5 (d, JCF = 8.6 Hz), 130.0 (d, JCF = 3.2 Hz), 129.4 (d), 128.0 (d), 125.0 
(d, JCF = 2.9 Hz), 124.1 (s, JCF = 11.5 Hz), 116.1 (d, JCF = 22.1 Hz), 71.9 (d), 67.2 (t), 
66.1 (d), 57.9 (t), 47.0 (t), 39.9 (t), 21.2 (q); LRMS (ES
-) 392 (M-H, 100), 362 (61), 
184 (50); HRMS (ES
-) calcd for C19H23FN3O3S (M-H) 392.1444, observed 392.1450 
 
(3S*, 4S*)-3-(2-Bromophenyl)-2-(2-ethylamino)-isoxazolidine-4-sulfonic acid 4- 
methylbenzylamide (153b) 
 
To  a  stirred  solution  of  (3S*,  4S*)-3-(2-bromophenyl)-2-(2-hydroxyethyl)-
isoxazolidine- 4-sulfonic acid 4-methylbenzylamide 152b (0.15 g, 0.33 mmol), NEt3 
(69  µL,  0.50  mmol,  1.5  eq.)  and  dichloromethane  (3.0  mL),  was  added 
methanesulfonyl chloride (28 µL, 0.36 mmol, 1.1 eq.) and reaction was stirred at 0 °C 
for 30  min.  The reaction  was diluted  with dichloromethane and washed with 1% 
HCl. The organic layer was dried over MgSO4, filtered and solvent was removed in 
vacuo. The crude compound (0.19 g, 0.35  mmol) was added  DMF (3.0  mL) and 
NaN3 (51 mg, 0.79 mmol 2.4 eq.) and refluxed at 90 °C for 2 h. Solvent was removed 168 
 
in vacuo and residue was diluted with water and extracted with EtOAc. The organic 
layer dried over MgSO4, filtered and solvent was removed in vacuo to yield crude 
azide. Azide was hydrogenated at 1 atm over 10% Pd/C (20 mg) in MeOH for 1 h. 
The  solid  residue  was  filtered  under  gravity  and  rinsed  thoroughly  with  MeOH; 
filtrate was concentrated in vacuo to give title compound as a clear gel (0.12 g, 0.27 
mmol, 82%). 
Rf 0.10 (9:1 CHCl3/MeOH); νmax (thin film, cm
-1) 3374, 3274, 2925, 1655, 1515, 
1311, 1143, 699; ʴH (CDCl 3, 500 MHz) 7.58 (2 H, br s, NH2), 7.39-7.42 (2 H, m, 
ArH), 7.27-7.31 (2 H, m, ArH), 7.02 (2 H, d, J = 7.8 Hz, ArH), 6.94 (2 H, d, J = 7.8 
Hz, ArH), 6.75 (1 H, br s, NH), 4.50 (1 H, d, J = 8.0 Hz, SCHCHH), 4.23 ( 1 H, d, J 
= 5.6 Hz, NCH), 4.17 (1 H, app. t, J = 8.0 Hz, SCHCHH), 4.02 (1 H, dd, J = 14.4, 
5.8 Hz, NCHHAr), 3.93 (1 H, dd, J = 14.1, 5.8 Hz, NCHHAr), 3.69-3.73 (1 H, m, 
SCH), 3.58-3.62 (1 H, m, NH2CH2CHH), 3.23-3.28 (1 H, m, NH2CH2CHH), 3.09-
3.19 (2 H, m, NH2CH2CH2), 2.22 (3 H, s, ArCH3); ʴC (CDCl3, 125 MHz) 162.7 (s), 
137.6 (s), 137.2 (s), 135.4 (s), 130.4 (d), 129.4 (d), 129.4 (d), 129.0 (d), 128.7 (d), 
128.2 (d), 72.7 (d), 71.2 (d), 67.6 (t), 51.5 (t), 46.8 (t), 39.7 (t), 21.2 (q);  LRMS 
(ES
+) 456 (M+H, 
81Br, 63), 454 (M+H, 
79Br, 60), 398 (98), 176 (100); HRMS (ES
+) 
calcd for C19H25BrN3O3S (M+H) 454.0800, observed 454.0809 
 
N-(2-(3S*,  4S*)-3-(2-fluorophenyl)-4-(N-(methylbenzyl)sulfamoyl)isoxazolidin-
2-yl)-5- (2-oxohexahydrothieno [3, 4-d]imidazole-4-yl) pentanamide (154a) 
 
To  a  stirred  solution  of  (3S*,  4S*)-2-(2-ethylamino)-3-(2-fluorophenyl)-
isoxazolidine- 4-sulfonic acid 4-methylbenzylamide 153a  (20  mg, 0.05  mmol)  in 
10:1 mixture CH2Cl 2/DMF (3.0 mL) was added D-biotin (14 mg, 0.05 mmol), HOBt 
(7.5  mg, 0.50  mmol, 10 eq.) and  N-methylmorpholine (5.6  mg, 0.05  mmol). The 
reaction was cooled to -10 °C before the addition of EDC.HCl (11 mg, 0.05 mmol) 
and was stirred at 0 °C for 1 h. The reaction mixture was allowed to warm slowly to 
RT and  left overnight  stirring. The  solvent was removed  in vacuo and  the crude 169 
 
residue was purified by flash chromatography (starting 5% MeOH/CH2Cl2) to give 
1:1 diastereo-mixture of the title compound as a clear gel (9.4 mg, 0.01 mmol, 30%). 
Rf 0.24 (9:1 CH2Cl2/MeOH);  νmax (thin film, cm
-1) 3405, 3312, 3283, 1699, 1609, 
1530, 1332, 1134, 788; ʴH (CDCl3, 600 MHz) 7.27-7.40 (4 H, m, ArH), 7.04-7.20 (4 
H, m, ArH), 7.02 (2 H, d, J = 7.2 Hz, ArH), 6.99 (2 H, d, J = 7.2 Hz, ArH), 6.95 (2 H, 
d, J = 8.0 Hz, ArH), 6.89 (2 H, d, J = 8.0 Hz, ArH), 6.42 (1 H, br s, NH), 6.20 (2 H, 
br s, NH), 6.16 (1 H, br s, NH), 5.69 (1 H, br s, NH), 5.46 (2 H, br s, NH),  5.20 (1 H, 
br s, NH), 4.49 (1 H, d, J = 12.1 Hz, NCHHAr), 4.44 (1 H, dd,  J = 9.9, 2.8 Hz, 
SCHCHH),  4.40  (1  H,  d,  J  =  10.3  Hz,  SCHCHH),  4.25-4.35  (3  H,  m,  SCH  & 
biotinyl-CH), 4.18-4.23 (2 H, m, SCHCHH), 4.09-4.15 (1 H, m, SCH), 4.10-4.14 (2 
H, m, NCH2Ar), 3.90-4.04 (3 H, m, NCH2CH2 & NCHHAr), 3.85-3.87 (1 H, br s, 
NCH), 3.79-3.83 (2 H, m, NCH2CH2), 3.65-3.70 (1 H, m, NCH), 3.26-3.53 (4 H, m, 
NCH2), 3.15-3.20 (3 H, m, biotinyl-CH), 2.91 (1 H, td, J = 12.6, 5.0 Hz, biotinyl-
CH), 2.78-2.86 (2 H, m, biotinyl-CH2), 2.71 (2 H, d, J = 13.5 Hz, biotinyl-CH2), 2.33 
(3 H, s, ArCH3), 2.29 (3 H, s, ArCH3), 2.00-2.24 (4 H, m, biotinyl-CH2), 1.56-1.80 (8 
H, m, biotinyl-CH2), 1.39-1.50 (4 H, m, biotinyl-CH2); ʴC (CDCl3, 150 MHz) 173.1 
(s), 164.0 (s), 161.5 (s, JCF = 256.3 Hz), 147.9 (s), (147.7 (s), 137.6 (d, JCF = 17.5 
Hz), 133.7 (s), 130.5 (d, JCF = 3.2 Hz), 129.3 (d), 127.9 (d), 127.9 (d), 124.8 (d, JCF = 
13.6 Hz), 123.6 (s, JCF = 9.2 Hz), 123.6 (s, JCF = 9.3 Hz), 116.3 (d, JCF = 22.1 Hz), 
116.1 (d, JCF = 22.2 Hz), 71.4 (d), 71.3 (d), 67.5 (t), 62.0 (d), 62.0 (d), 60.1 (d), 55.7 
(d), 55.0 (d), 47.0 (t), 46.9 (t), 40.8 (t), 40.6 (t), 38.3 (t), 38.0 (t), 36.1 (t), 29.7 (t), 
28.1 (t), 27.6 (t), 27.4 (t), 25.6 (t), 21.2 (q); LRMS (ES
-) 618 (M-H, 100), 325 (5); 
HRMS (ES
-) calcd for C29H37FN5O5S2 (M-H) 618.2220, observed 618.2215 
 
N-(2-(3S*,  4S*)-3-(2-bromophenyl)-4-(N-(methylbenzyl)sulfamoyl)isoxazolidin-
2-yl)-5- (2-oxohexahydrothieno [3, 4-d]imidazole-4-yl) pentanamide (154b) 
 
To  a  stirred  solution  of  (3S*,  4S*)-2-(2-ethylamino)-3-(2-bromophenyl)-
isoxazolidine- 4-sulfonic acid 4-methylbenzylamide 153b (13  mg, 0.03  mmol)  in 170 
 
DMF (2.0 mL) was added D-biotin (8.4 mg, 0.03 mmol) and DMAP (3.6 mg, 0.30 
mmol, 10 eq.). The reaction was cooled to -10 °C before the addition of EDC.HCl 
(5.9 mg, 0.03 mmol) and stirred at  RT overnight. The reaction mixture was diluted 
with water and extracted with chloroform. The organic layer was dried over MgSO4, 
filtered and solvent was removed in vacuo. The crude residue was purified by flash 
chromatography (starting 5% MeOH/CH2Cl2) to  give 1:1 diastereo-mixture of the 
title compound as a clear gel (17.6 mg, 0.025 mmol, 92%). 
Rf 0.26 (9:1 CH2Cl2/MeOH);  νmax (thin film, cm
-1) 3408, 3302, 3277, 1692, 1601, 
1536, 1323, 1133, 689; ʴH (CDCl3, 600 MHz) 7.34-7.43 (8 H, m, ArH), 7.02 (2 H, d, 
J = 8.0 Hz, ArH), 6.98 (2 H, d, J = 8.0 Hz, ArH), 6.85 (2 H, d, J = 7.8 Hz, ArH), 6.82 
(2 H, d, J = 7.7 Hz, ArH), 6.70-6.74 (2 H, br s, NH), 6.62 (1 H, br s, NH), 6.51 (2 H, 
br s, NH), 6.31 (1 H, br s, NH), 6.27 (1 H, br s, NH), 4.39-4.47 (4 H, m, NCHHAr & 
SCHCHH), 4.30-4.36 (1 H, m, SCH), 4.28 (1 H, t, J = 6.4 Hz, NH), 4.17-4.25 (1 H, 
m, SCH), 4.15 (1 H, d, J = 13.6 Hz, NCHHAr ), 4.03-4.12 (3 H, m, SCHCHH & 
biotinyl-CH), 3.92 (1 H, dd, J = 13.9, 5.1 Hz, NCHHAr), 3.76-3.90 (2 H, m, NCH), 
3.49-3.65 (6 H, m, NCH2 & biotinyl-CH), 3.17-3.30 (4 H, m, NCH2CH2), 2.78-2.92 
(6 H, m, biotinyl-CH & biotinyl-CH2), 2.69 (1 H, d, J = 11.6 Hz, biotinyl-CH), 2.29 
(3 H, s, ArCH3), 2.24 (3 H, s, ArCH3), 2.13-2.19 (4 H, m, biotinyl-CH2), 1.55-1.75 (8 
H, m, biotinyl-CH2), 1.36-1.46 (4 H, m, biotinyl-CH2); ʴC (CDCl3, 150 MHz) 173.1 
(s), 173.0 (s), 164.0 (s), 137.6 (s), 137.5 (s), 137.5 (s), 133.8 (s), 133.7 (s), 133.5 (s), 
133.4 (d), 129.4 (d), 129.3 (d), 129.0 (d), 129.0 (d), 128.8 (d), 128.8 (d), 128.2 (d), 
127.9 (d), 127.9 (d), 72.4 (d), 72.2 (d), 67.4 (t), 67.3 (t), 62.0 (d), 61.9 (d), 60.2 (d), 
60.1 (d), 55.7 (d), 55.2 (d), 55.1 (d), 53.5 (t), 46.7 (t), 46.6 (t), 40.7 (t),  40.6 (t), 38.3 
(t), 38.0 (t), 36.1 (t), 36.0 (t), 31.0 (t), 27.7 (t), 27.6 (t), 25.5 (t), 25.2 (t), 21.2 (q); 
LRMS (ES
-) 680 (M-H, 
81Br, 11), 678 (M-H, 
79Br, 10), 600 (100); HRMS (ES
-) 
calcd for C29H37BrN5O5S2 (M-H) 678.1419, observed 678.1426 
4.4  Miscellaneous compounds 
N-(p-Methoxybenzyl)-C-phenylnitrone (155)
113 
 
4-Methoxybenzyl hydroxylamine (2.1 g, 14 mmol), benzaldehyde (1.5 g, 14 mmol) 
and NaHCO3 (3.5 g, 42 mmol, 3 eq.) were mixed in dichloromethane and refluxed 171 
 
overnight. NaHCO3 was filtered off under gravity and  the solvent was removed in 
vacuo. The remaining solid was recrystallized in EtOAc and petroleum ether to give 
the title compound as a white solid and as a single diastereoisomer as judged by 
NMR (2.9 g, 12 mmol, 86%).  
mp 97-99 °C (lit.
113 mp 97 °C); νmax (thin film, cm
-1) 3053, 1612, 1514; ʴH (CDCl3, 
300 MHz) 8.19-8.24 (2 H, m, ArH and CHN), 7.33-7.41 (6 H, m, ArH), 7.93 (2 H, d, 
J = 6.8 Hz, ArH), 4.99 (2 H, s, CH2), 3.81 (3 H, s, OCH3); ʴC (CDCl3, 75 MHz) 
160.2 (s), 149.6 (s), 125.2 (s), 130.1 (d), 130.5 (d), 128.7 (d), 128.4 (d), 114.4 (d), 
114.1 (d), 70.6 (t), 55.3 (q);  LRMS (FAB
+) 241 (M
+, 36), 199 (51), 173 (100); 
HRMS (FAB
+) calcd for C15H15NO2(M+Na) 264.1000, observed 264.1006 
 
2-(p-Methoxybenzyl)-3-phenylisoxazole-4-pentafluorophenyl  ethenesulfonate 
(156)
113 
 
Pentafluorophenyl ethenesulfonate 110 (1.5 g, 5.5 mmol) and N-(p-methoxybenzyl)-
C-phenylnitrone 155 (1.99 g, 8.25 mmol, 1.5 eq.) were mixed in toluene (10 mL) and 
refluxed overnight. The solvent was removed in vacuo and the crude product was 
purified  by  flash  chromatography  (20%  EtOAc/petroleum  ether)  to  give  the  title 
compound as a white solid and as a single diastereoisomer as judged by NMR (1.51 
g, 2.93 mmol, 55%). 
Rf 0.69 (20% EtOAc/petroleum ether); mp 90-92 °C (lit.
113 mp 90 °C); νmax (thin 
film, cm
-1) 2950, 1505, 1367, 1162; ʴH (CDCl3, 300 MHz) 7.59 (2 H, dd, J = 7.7, 1.6 
Hz, ArH), 7.42 (3 H, d, J = 6.4 Hz, ArH), 7.28 (2 H, d, J = 6.0 Hz, ArH), 6.88 (2 H, 
d, J = 7.7 Hz, ArH), 4.62-4.66 (1 H, m, SCH), 4.50-4.62 (1 H, m, NCH), 4.46 (2 H, 
m, SCHCH2), 4.00 (1 H, d, J = 13.9 Hz, NCHHAr), 3.87 (1 H, d, J = 13.9 Hz, 
NCHHAr), 3.80 (3 H, s, OCH3); ʴC (CDCl3, 75 MHz) 159.1 (s), 136.2 (s), 130.2 (d), 
129.1 (d), 128.6 (d), 128.4 (s), 128.3 (d), 113.7 (d), 73.6 (d), 71.5 (d), 66.9 (t), 58.8 
(t), 55.2 (q); LRMS (FAB
+) 515 (M
+, 23), 333 (12), 154 (100); HRMS (FAB
+) calcd 
for C23H19F5NO5S (M+H) 516.0904, observed 516.0901 
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Preparation of ʱ-bromoethene phenylsulfone (157)
124 
 
Bromine (1  mL)  was dissolved  in CCl4 (15  mL), and was added dropwise  to a 
premixed solution of phenyl ethenesulfone (2.5 g, 15 mmol) and AIBN (0.10 g), in 
CCl4 (75 mL) under heating (70 °C). Additional AIBN was added after the addition 
of the bromine solution. The reaction was refluxed for 4 h followed by 24 h stirring 
at RT, and the solvent was removed in vacuo. The mixture was dissolved in benzene 
(75 mL) and a premixed solution of NEt3 (1.5 g, 15 mmol) in benzene (15 mL) was 
added and the reaction was stirred at RT for 3 h. The reaction mixture was washed 
with water and dried over MgSO4. The solvent was removed in vacuo and the crude 
product was purified by flash chromatography (10% Et2O/petroleum ether) to give 
the title compound as a white solid (2.9 g, 12 mmol, 80 %). 
Rf 0.14 (10% Et2O/petroleum ether); mp 46-48 °C (lit.
196 mp 44 °C); νmax (thin film, 
cm
-1) 3058, 1601, 1448, 1326, 1180; ʴH (CDCl3, 75 MHz) 7.91 (2 H, d, J = 7.1 Hz, 
ArH), 7.94 (1 H, t, J = 7.1 Hz, ArH), 7.52 (2 H, t, J = 7.2 Hz, ArH), 7.06 (1 H, d, J = 
3.2 Hz, CHH), 6.24 (1 H, d, J = 3.2 Hz, CHH); ʴC (CDCl3, 75 MHz) 136.4 (s), 134.4 
(d), 129.3 (d), 129.1 (d), 119.2 (s) 68.1 (t); LRMS (EI) 248 (M
+•, 
81Br, 6), 246 (M
+•, 
79Br, 6), 141 (18), 125 (52), 103 (100), 77 (54);  HRMS (EI) calcd for C8H7BrO2S 
(M
+•) 245.9344, observed 245.9341 
 
Preparation of 3-phenyl isoxazole-5-phenylsulfone (158)
124 
 
α-Chlorobenzoxime 116b (62 mg, 0.40 mmol, 1 eq.), α-bromoethene phenylsulfone 
157 (99 mg, 0.40 mmol, 1 eq.) and NEt3 (0.06 mL, 0.44 mmol, 1.1 eq.) were mixed 
in dichloromethane (5 mL) and stirred at RT for 72 h. The solvent removed in vacuo 
and crude residue was purified by flash chromatography (10% Et2O/petroleum ether) 
to give the title compound as a white solid and as a single regioisomer as judged by 
NMR (50 mg, 0.17 mmol, 44%). 173 
 
Rf 0.08 (10% Et2O/petroleum ether); mp 128-131 °C (lit.
124 mp 127 °C); νmax (thin 
film, cm
-1) 3055, 1596, 1166; ʴH (CDCl3, 300 MHz) 8.11 (2 H, d, J = 8.0 Hz, ArH), 
7.69-7.78 (3 H, m, ArH), 7.61 (2 H, t, J = 8.1 Hz, ArH), 7.45-7.48 (3 H, m, ArH), 
7.25 (1 H, s, IsoxH); ʴC (CDCl3, 75 MHz) 167.7 (s), 162.71 (s), 138.0 (s), 131.6 (s), 
135.0 (d), 131.0 (d), 129.7 (d), 129.2 (d), 128.6 (d), 127.3 (d), 106.6 (d); LRMS (EI) 
285 (M
+•, 43), 144 (41), 116 (24), 77 (100); HRMS (EI) calcd for C15H11NO3S (M
+•) 
285.0454, observed 285.0447 
 
ʱ-Bromoethenesulfonic acid 4-methylbenzylamide (159) 
 
To a stirred  solution of ethenesulfonic acid-4-methylbenzylamide 141  (1.1  g, 5.0 
mmol) in chloroform (15 mL), was slowly added pre-mixed solution of bromine (2.6 
mL, 50 mmol, 10 eq.) in chloroform (10 mL) and stirred at RT for 1 h. Solvent was 
removed in vacuo and the reaction mixture was then added toluene (10 mL) and NEt3 
(0.69  mL, 5.0  mmol, 1 eq.). The  reaction  was  further stirred  at  RT  for 3  h, and 
mixture was then washed with water. The organic layer was dried over MgSO4 and 
solvent  was  removed  in  vacuo.  The  crude  residue  was  purified  by  flash 
chromatography (starting 9:1 petroleum ether/Et2O) to give the title compound as a 
cream solid (1.0 g, 3.4 mmol, 68%). 
Rf 0.10 (9:1 petroleum ether/Et2O); mp 78-79 °C; νmax (thin film, cm
-1) 3304, 3107, 
1604, 1514, 1329, 1160, 940, 706; ʴH (CDCl3, 500 MHz) 7.22 (2 H, d, J = 7.7 Hz, 
ArH), 7.16 (2 H, d, J = 7.7 Hz, ArH), 6.84 (1 H, d, J = 3.1 Hz, CHCHH), 6.20 (1 H, 
d, J = 3.1 Hz, CHCHH), 4.89 (1 H, br s, NH), 4.17 (2 H, d, J = 5.8 Hz, NCH2), 2.34 
(3 H, s, CH3); ʴC (CDCl3, 125 MHz) 138.4 (s), 132.7 (s), 129.6 (d), 128.7 (t), 128.2 
(d), 127.0 (s), 47.6 (t), 21.2 (q); LRMS (EI) 291 (M
+•, 
81Br, 4), 289 (M
+•, 
79Br, 4), 
184 (7), 119 (100), 105 (42); HRMS (EI) calcd for C10H12BrNO2S (M
+•) 288.9766, 
observed 288.9750 
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(3S*,  4S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4-pentafluorophenyl 
sulfonate ester (160)
113 
 
To a stirred solution of pentafluorophenyl ethenesulfonate 110 (1.4 g, 5.0 mmol) in 
toluene  (20  mL)  was  added  N-methyl-C-(4-nitrophenyl)  nitrone  140j  (1.1  g,  6.0 
mmol, 1.2 eq.) and refluxed for 3 h. Solvent was removed in vacuo and the residue 
was purified by flash chromatography (starting 10:1 petroleum ether/Et2O) to give 
the title compound as a cream solid and as a single diastereoisomer as judged by 
NMR (1.3 g, 2.9 mmol, 58%). 
Rf 0.35 (2:1 petroleum ether/EtOAc); mp 125-127 °C (lit.
113 mp 128 °C); νmax (thin 
film, cm
-1) 3102, 2976, 1743, 1598, 1515, 1393, 1350, 992; ʴH (CDCl3, 500 MHz) 
8.25 (2 H, d, J = 8.8 Hz, ArH), 7.70 (2 H, d, J = 8.8 Hz, ArH), 4.62 (1 H, dd, J = 
10.2, 3.1 Hz, SCHCHH), 4.49 (1 H, dd, J = 10.2, 8.2 Hz, SCHCHH), 4.27 (1 H, td, J 
= 8.2, 7.5 Hz, SCH), 4.20 (1  H, d,  J = 7.5 Hz, NCH), 2.72 (3  H, s, NCH3); ʴC 
(CDCl3, 125 MHz) 148.5 (s), 143.2 (s), 129.1 (d), 124.4 (d), 73.8 (d), 73.0 (d), 66.9 
(t), 42.9 (q); LRMS (EI) 454 (M
+•, 65), 207 (19), 155 (34), 116 (100); HRMS (EI) 
calcd for C16H11F5N2O6S (M
+•) 454.0252, observed 454.0258 
 
(3S*,  4S*)-3-(5-Bromofuryl)-2-methylisoxazolidine-4-sulfonic  acid  4- 
methylbenzylamide (161)
113 
 
To  a  stirred  solution  of  (3S*,  4S*)-3-(5-bromofuryl)-2-methylisoxazolidine-  4-
pentafluorophenyl sulfonate ester 136 (0.47 g, 1.0 mmol) in dry THF (9 mL) was 
added 4-methylbenzylamine (0.36 mL, 3.0 mmol, 3 eq.) followed by DBU (0.17 mL, 
1.5 mmol, 1.5 eq.). The mixture was refluxed for 1 h. Reaction mixture was diluted 
with dichloromethane and washed with 2M HCl, saturated NaHCO3 and water. The 
organic layer was dried with MgSO4, filtered and solvent was removed in vacuo. The 175 
 
crude  residue  was  purified  by  flash  chromatography  (starting  10:1  petroleum 
ether/Et2O) to give title compound as a cream solid and as a single diastereoisomer 
as judged by NMR (0.23 g, 0.55 mmol, 56%). 
Rf 0.31 (1:2 petroleum ether/Et2O);  mp 122-125 °C (lit.
113 brown oil); νmax (thin 
film, cm
-1) 3280, 3141, 2853, 1736, 1504, 1320, 1141, 794; ʴH (CDCl3, 500 MHz) 
7.12 (2 H, d, J = 8.0 Hz, ArH), 7.08 (2 H, d, J = 8.0 Hz, ArH), 6.36 (1 H, d, J = 3.3 
Hz, furylH), 6.29 (1 H, d, J = 3.3 Hz, furylH), 5.01 (1 H, br s, NH), 4.30 (1 H, dd, J 
= 9.1, 6.8 Hz, SCHCHH), 4.19 (1 H, dd, J = 9.1, 3.1 Hz, SCHCHH), 4.16 (1 H, d, J 
= 13.7 Hz, NCHHAr), 4.11 (1 H, app td, J = 6.9, 3.1 Hz, SCH), 4.07 (1 H, d, J = 13.7 
Hz, NCHHAr), 3.87 (1 H, br s, NCH), 2.65 (3 H, s, NCH3), 2.33 (3 H, s, CH3); ʴC 
(CDCl3, 125 MHz) 150.7 (s), 138.1 (s), 133.3 (s), 129.6 (d), 128.1 (d), 123.0 (s), 
113.0 (d), 112.6 (d), 69.4 (d), 67.6 (d), 66.9 (t), 47.2 (t), 43.1 (q), 21.2 (q); LRMS 
(EI) 416 (M
+•, 
81Br, 2), 414 (M
+•, 
79Br, 2), 230 (
81Br, 100), 228 (
79Br, 98), 205 (
81Br, 
17), 203 (
79Br, 15), 187 (
81Br, 34), 185 (
79Br, 30), 120 (79), 105 (45); HRMS (EI) 
calcd for C16H19BrN2O4S (M
+•) 414.0243, observed 414.0250 
 
(3S*,  4S*)-2-Methyl-3-(4-Nitrophenyl)-isoxazolidine-4-sulfonic  acid  allylamide 
(162)
113 
 
To  a  stirred  solution  of  (3S*,  4S*)-2-methyl-3-(4-nitrophenyl)-isoxazolidine-  4-
pentafluorophenyl sulfonate ester 160 (0.45 g, 1.0 mmol) in dry THF (10 mL), was 
added allylamine (0.17 g, 3.0 mmol, 3 eq.) followed by DBU (0.22 g, 1.5 mmol, 1.5 
eq.)  The  mixture  was  refluxed  for  1  h.  The  reaction  was  diluted  with 
dichloromethane  and  washed  with  2M  HCl,  saturated  NaHCO3  and  water.  The 
organic layer was dried with MgSO4, filtered and solvent was removed in vacuo. The 
crude  residue  was  purified  by  flash  chromatography  (starting  10:1  petroleum 
ether/EtOAc)  to  give  the  title  compound  as  a  cream  solid  and  as  a  single 
diastereoisomer as judged by NMR (0.10 g, 0.31 mmol, 31%). 
Rf 0.21 (1:2 petroleum ether/EtOAc); mp 153-155 °C (lit.
113 mp 160 °C); νmax (thin 
film, cm
-1) 3264, 3117, 2984, 2888, 1650, 1608, 1519, 1339, 1149; ʴH (CDCl3, 300 176 
 
MHz) 8.23 (2 H, d, J = 8.8 Hz, ArH), 7.68 (2 H, d, J = 8.8 Hz, ArH), 5.68-5.75 (1 H, 
m, NHCH2CH), 5.26 (1 H, app.d, J = 9.7 Hz, NCH2CHCHH)5.14 (1 H, dd, J = 9.7, 
1.3 Hz, NCH2CHCHH), 4.61 (1 H, t, J = 5.9 Hz, NH), 4.36 (1 H, dd, J = 9.7, 7.0 Hz, 
SCHCHH), 4.29 (1 H, br d, J = 9.7 Hz, SCHCHH), 4.01 (1 H, d, J = 6.9 Hz, NCH), 
3.93-3.97  (1  H,  m,  SCH),  3.60-3.74  (2  H,  m,  NCH2),  2.68  (3  H,  s, NCH3);  ʴC 
(CDCl3, 75 MHz) 148.0 (s), 144.9 (s), 133.0 (d), 128.9 (d), 124.0 (d), 118.3 (t), 74.1 
(d), 72.9 (d), 67.1 (t), 46.0 (t), 43.0 (q); LRMS (EI) 327 (M
+•, 4), 211 (6), 205 (19), 
120 (100), 105 (15); HRMS (EI) calcd for C14H19N3O4S (M
+•) 327.0883, observed 
327.0888 
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5  Appendices 
5.1  Crystal Structure of 3-(4-chlorophenyl) isoxazole-5-PFP sulfonate (118c) 
 
Identification code     str0635 
Chemical formula     C15H5ClF5NO4S 
Formula weight     425.71 
Temperature       150(2) K 
Radiation, wavelength   MoKα, 0.71073 Å 
Crystal system, space group   orthorhombic, Pbca 
Unit cell parameters    a = 11.2886(14) Å  α = 90° 
        b = 12.1223(15) Å  β = 90° 
        c = 22.253(3) Å  γ = 90° 
Cell volume      3045.2(6) Å
3 
Z        8 
Calculated density     1.857 g/cm
3 
Absorption coefficient µ  0.471 mm
1 
F(000)       1696 
Crystal colour and size  colourless, 0.36  0.16  0.05 mm
3 
Data collection method  Bruker SMART APEX CCD diffractometer 
ω rotation with narrow frames 
θ range for data collection  2.63 to 28.35° 
Index ranges      h 15 to 14, k 16 to 15, l 29 to 29 
Completeness to θ = 26.00°  99.8 %  
Reflections collected    24452 
Independent reflections  3713 (Rint = 0.0540) 
Reflections with F
2>2σ  2979 178 
 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission  0.8488 and 0.9768 
Structure solution    direct methods 
Refinement method    Full-matrix least-squares on F
2 
Weighting parameters a, b  0.0694, 7.3487 
Data / restraints / parameters  3713 / 0 / 244 
Final R indices [F
2>2σ]  R1 = 0.0499, wR2 = 0.1158 
R indices (all data)    R1 = 0.0676, wR2 = 0.1283 
Goodness-of-fit on F
2   0.873 
Largest and mean shift/su  0.000 and 0.000 
Largest diff. peak and hole  0.680 and 0.442 e Å
3 
5.2  Crystal Structure of 3-(4-nitrophenyl) isoxazole-5-PFP sulfonate (118j) 
 
Identification code     str0639 
Chemical formula     C15H5F5N2O6S 
Formula weight     436.27 
Temperature       150(2) K 
Radiation, wavelength   MoKα, 0.71073 Å 
Crystal system, space group   orthorhombic, Pbca 
Unit cell parameters    a = 11.1025(10) Å  α = 90° 
        b = 12.8648(11) Å  β = 90° 
        c = 21.7271(19) Å  γ = 90° 
Cell volume      3103.3(5) Å
3 
Z        8 
Calculated density     1.868 g/cm
3 
Absorption coefficient µ  0.309 mm
1 
F(000)       1744 179 
 
Crystal colour and size  colourless, 0.35  0.32  0.16 mm
3 
Data collection method  Bruker SMART APEX CCD diffractometer 
ω rotation with narrow frames 
θ range for data collection  3.06 to 28.31° 
Index ranges      h 14 to 14, k 17 to 17, l 28 to 28 
Completeness to θ = 26.00°  99.8 %  
Reflections collected    25038 
Independent reflections  3791 (Rint = 0.0367) 
Reflections with F
2>2σ  3136 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission  0.8995 and 0.9522 
Structure solution    direct methods 
Refinement method    Full-matrix least-squares on F
2 
Weighting parameters a, b  0.0615, 1.1805 
Data / restraints / parameters  3791 / 0 / 262 
Final R indices [F
2>2σ]  R1 = 0.0371, wR2 = 0.0982 
R indices (all data)    R1 = 0.0474, wR2 = 0.1039 
Goodness-of-fit on F
2   0.988 
Largest and mean shift/su  0.001 and 0.000 
Largest diff. peak and hole  0.341 and 0.380 e Å
3 
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